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Infectious disease is one of the few genuine adventures left in the 
world. The dragons are all dead and the lance grows rusty in the 
chimney comer....... About the only sporting proposition that remains 
unimpaired by the relentless danestication of a once free-living human 
species is the war against those ferocious little fellow creatures, 
which lurk in the dark corners and stalk us in the bodies of rats, 
mice, and all kinds of domestic animals; which fly and crawl with the 
insects, and waylay us in our food and drink and even our love. 
Hans Zinsser, 1935 
racmnnnm 
Tick-borne encephalitis virus (TBEV) encodes a highly immunogenic ncn- 
structural glycoprotein, NS1. The proposed NS1 gene from the TE V 
strains Neudörfl and K23 was identified, cloned and sequenced. The 
NS1 gene from the Neudorfl strain of TBEV was then cloned under the 
powerful constitutive cytomegalovirus (CMV) major immediate-early 
promoter (IE) and the CMV IEP/NS1 fragment used as the basis of an 
adenovirus Eta deletion mutant. The novel combination of the 
cytomegalovirus immediate- early promoter and the adenovirus vector 
produced extremely high levels of NS1 expression in cells which do not 
support the replication of the adenovirus deletion mutant. The 
recombinant protein was shown to be indistinguishable from authentic 
TBEV NS1 in its (i) apparent molecular weight by polyacrylamide gel 
electrophoresis, (ii) glycosylation pattern, (iii) ability to form 
high molecular weight complexes, and (iv) ability to be secreted from 
cells. Furthermore, appropriate processing of NS1 expressed by the 
adenovirus recombinant occurred independently of any additional TBEV- 
encoded gene function. 
When inoculated directly into mice, the recombinant adenovirus 
RAd51 was shown to elicit an antibody response to the TBEV NS1 
antigen. Immunization of mice with RAd51 conferred both protection 
from disease and death when challenged with a lethal dose of TBEV. 
The capability of RAd51 to elicit an immune response following 
inoculation into mice was shown to result fron de novo synthesised NS1 
and not co-inoculated NS1. It has been proposed that protection 
elicited against TBEV challenge by NS1 is due to complement mediated 
cytolysis of infected cells. The ability of NS1 to protect mice 
deficient in the terminal lytic pathway of the complement cascade, 
implied that complement mediated cytolysis is not the major mechanism 
by which protection is elicited. 
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CHAPTER 1. INTRODUCTION. 
1.1 TICK-BORNE ENCEPHALITIS VIRUS 
1.1.1. Historical Perspective: 
Tick-borne encephalitis virus (TBEV) is classified as a member of 
the flavivirus genus within the virus family Flaviviridae (Westaway et 
al., 1985). Flavivirus research truly began with Major Walter Reed's 
experiments which described for the first time a filterable agent, 
yellow fever virus (YFV), capable of inducing disease in man, and 
demonstrated that transmission of YFV was via an arthropod vector 
(Reed et al., 1901; Reed and Call, 1902). Since the identification 
of YFV, a large ntmiber of arboviruses including Russian Spring Summer 
Encephalitis virus (RSSEV), louping Ill virus (LIV), dengue virus, 
Japanese encephalitis virus (JEV), West Nile virus (WNV), St. Louis 
encephalitis virus (SLEV), Murray Valley encephalitis virus (MVEV) and 
Kunjin virus have been isolated and classified within the 
Flaviviridae. 
Some of the earliest records of a tick-borne flavivirus infection 
were made in 19th century Scotland. These reports described the 
characteristic louping or leaping associated with LIV-infected sheep 
and hill cattle (Williams, 1897). LIV remained a veterinary problem, 
until an effective vaccine was developed in the 1930's (reviewed 
Edward, 1947). While LIV has never been considered clinically 
important (reviewed Davidson et al., 1991), the TBEV infections of the 
far eastern (FE) and central European (CE) virus subtypes are 
recognised as major public health problems within endemic regions. 
TBBEV has been recognised as a clinically important pathogen since 
the 1930's. TBEV was first isolated-during the early 1930's following 
an epidemic of neurological disorders amcngst forest workers from the 
eastern region of the Commonwealth of Independent States (CIS) 
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(Reviewed Silber and Soloviev, 1946; Smorodintseff, 1939). In 
searching for its causative agent, a team lead by Silber isolated a 
previously unknown tick borne virus which, because of it's seasonal 
incidence, was designated RSSEV. Responding to this outbreak of 
RSSEV, the Russians developed the first TBEV vaccine (reviewed 
Smorodintsev et al., 1940). 
Outside the CIS, the first epidemic for which TBEV was recognised as 
the causative agent was recorded during 1949 in Czechoslovakia 
(reviewed Blaskovic, 1958; Hloucal, 1960). As the virus responsible 
for this outbreak was very similar to that of FE TBEV and like LIV, it 
was designated Russian louping Ill Virus, later re- classified as CE 
TBEV. 
Until the 1950's only the four distinct virus types within the TBEV 
had been identified; LIV, QTsk haemorrhagic fever virus (OH V), the FE 
TBEVs, and CE TBEVs. OHFV stands out from the other three TBEV 
isolated because rather than inducing a encephalitic type pathology, 
CFV infecticris are of a ha rrhagic nature. It is interesting that 
two antigenicaly related viruses,. FE TBEV and OH FV isolated in areas 
of near geographical proximity and transmitted by similar mechanisms 
should cause such different diseases. Since 1950, the number of 
viruses identified as being antigenically related to the original TBEV 
isolates has risen to include viruses such as Kyasanur Forest disease 
virus (KFDV, Work, 1958), Langat virus (Gordon-Smith, 1956), Ibwassan 
virus (McLean and Donohue, 1959), Negishi virus (Ando et al., 1952), 
Karski virus (Lvov et al, 1976) and Royal Farm virus (Williams et al., 
1972). 
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Table 1.1. Flav1Vsidae (bwlexes and Fkwples of Viruses Contain 
Within Them (including the major human pathoqens): 
COMPLEX/ VIRUS DISEASE DISTRIBUTION 
Vector 
TBEV/ Louping Ill UK 
Tick CE Encephalitis Europe 
OHF Haemorrhage/fever USSR 
KFD Haemorrhage/Fever India 
FE Encephalitis USSR 
Langat Malaya 
Powassan Encephalitis Canada, USA 
Negishi Japan 
Modoc/ Modoc 
Unknown Others 
JE/ JE Encephalitis Japan, SE Asia 
Mosquito W Pacific 
SLE Encephalitis USA 
MVE Encephalitis Australia 
WN Encephalits/fever Africa, Asia, 
Europe 
Others 
Ntaya/ Ntaya 
Mosquito Others 
Uganda S/ Uganda S 
Mosquito others 
Dengue/ Dengue 1 Fever/Haemorrhage Asia, Caribbean, 
Unknown S. America 
Dengue 2 Fever/Haemorrhage Asia, Caribbean 
S. America 
Dengue 3 Fever/Haemorrhage Asia, Caribbean, 
S. America 
Dengue 4 Fever/Haemorrhage Asia, Caribbean, 
S. America 
Rio Bravo/ Rio Bravo 
Mosquito Others 
Tyuleniy/ Tyuleniy 
Tick Others 
Antigenically 
isolated Yellow Fever Fever Africa, Tropical includes America 
Based on Calisher et al., 1989. 
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1.1.2. Classification of TBEV: 
The Flaviviridae contains over 60 characterised viruses (Table 1.1) 
all classified within the genus Flavivirus. The presence of 
neutralizing, complement-fixing and haemagglutinating antigens on the 
surface of flavivirus particles has allowed their antigenic 
relationships to be examined. Classification of the flaviviruses 
began in 1944, when the complement fixation and neutralisation assays 
were used to established the antigenic relationship between two tick- 
borne flaviviruses, (LIV and RSSEV) and between both LIV and RSSEV and 
the three mosquito-borne flaviviruses (WNV, JEV and SLEV) (Casals, 
1944; Casals and Webster, 1944). 
The Flaviviruses as a group were first demonstrated in 1954 when a 
systematic study of arboviruses using the haemaglutination assay 
identified two distinct virus groups (Casals and Brown, 1954). 
Originally designated the Group A and Group B viruses, the two groups 
were later renamed the Alphaviruses and Flaviviruses. In 1974, cri the 
basis of their non-helical nuclear capsids, viral envelope and RNA 
genaue, the Alpha- and Flaviviruses were classified together in the 
new virus family, the Togaviridae (Fenner et al., 1974). Later two 
more genera, the Pestiviruses and Rubiviruses were added to the 
Togaviridae (Porterfield et al., 1978). 
A closer inspection of the Alpha- and Flavivixuses havever, revealed 
that although morphologically similar, significant differences in 
their genetic organisation and replicaticn strategy existed. In fact, 
the Flavivirus gencmic organisation was shown to be more like that of 
the picornaviruses than the alphaviruses with the mode and site of 
Flavivirus assembly having more in common with bunyaviruses than 
alphaviruses (Boulton and Westaway, 1972; Brawner et al., 1977). 
These differences persuaded the 1984 International Ccmnittee for the 
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Nomenclature of Viruses to vote the Flaviviruses into a separate 
family (reviewed Westaway et al., 1985). The application of new 
molecular biological technology has recently confirmed the 1984 
classification and highlighted sufficient similarities between the 
Flaviviruses and the Pestiviruses for inclusion of the Pestiviruses 
into the Flaviviridae as a second genus (Collett et al., 1988; 
Horzinek, 1991). 
Serological analysis of the Flavivirus genus by cross- 
neutralization, showed that the tick-borne flaviviruses formed 
antigenically distinct complexes distinct from those of the other 
flaviviruses (Madrid and Porterfield, 1974). Interestingly, each 
flavivirus antigenic complex identified by the 1974 study, reflected 
an ecological feature, such as their vector, ccaunon to the viruses 
within it. The tick-borne viruses comprising the newly identified 
complex, TBEV, had been shown in earlier studies using 
haemagglutination-inhibition and immun-diffusion techniques, to form 
seven closely related subgroups; the LIV, OHFV, KFDV, Langat virus, 
Powassan virus, Negishi virus and the TBEV CE and FE subtypes (Clark, 
1964). Initially, it was not clear whether the FE and CE subtypes 
were distinguishable but tryptic peptide mapping of the virus encoded 
proteins and, more recently, nucleotide sequencing has succeeded in 
differentiating the two subtypes at a molecular level (Heinz and Kunz, 
1981 & 1982; Mandl et al., 1988 & 1989a; Pletnev et al., 1990). In 
the most recent classification of the flaviviruses, the tick-borne 
strains of Karshi virus and Royal Fann virus along with the Rum Phnn 
bat virus and Carey Island virus were classified as additia al members 
of the previously defined TBEV canplex (Table 1.1) (Calisher et al., 
1989). 
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1.1.3. Transmission of TBEV: 
As arboviruses, (with the exception of milk-borne and transovarial 
transmission) the tick-borne flaviviruses require continuous cycling 
between their tick vectors and primary vertebrate hosts. The success 
of this transmission is directly dependent on a number of specific 
conditions being met which, by their very nature, define the 
geographical distribution of viruses. In order, therefore, to 
understand the epidemiology of TBEV, one must appreciate its natural 
history. 
Two types of vertebrate host have been identified for the tick-borne 
flaviviruses, the primary hosts and the dead-end hosts. Primary hosts 
of TBEV include a number of small mammals and birds which, when 
infected, are capable of supporting a viremia sufficient to infect 
feeding ticks (Cerny, 1975; review Chamberlain et al., 1954). Dead- 
end hosts, although susceptible to infection, are unable to support a 
level of viremia sufficient to ensure continued transmission of the 
virus. Dead-end hosts of viruses in the TBEV complex (except LIV) 
include the larger vertebrates such as goats, cows, sheep and man. 
In order to maintain the virus transmission cycle uninfected ticks 
and primary hosts must become infected. Irregular transmission of 
virus between ticks occurs transtadially and transovarially, with 
venereal transmission between the sexes having also been identified 
(Burgdorfer and Verma, 1967; Rao, 1963 Rehacek, 1962; Singh et al., 
1968). These modes of transmission have traditionally been considered 
of little significance to the maintenance of the viral reservoir. In 
general, transmissicn of TBEy to uninfected ticks is believed to occur 
while they feed on an infected primary host., For transmission to 
occur, the level of viremia in the host must be sufficient to infect 
the midgut cells of the feeding tick andýthe cells of the tick's 
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midgut must be susceptible to infection by the virus being transmitted 
(reviewed Casels and Reeves, 1959). Once an infection of the ticks 
midgut cells has been established, the virus spreads via the he ocoele 
to the ticks salivary glands. The virus can then be transmitted from 
ticks into the blood stream of a host during tick engorgement via its 
"saliva". Ticks are thought to remain infected for life with 
apparently little ill effect. 
Although members of the TBEV complex may be carried by a wide 
variety of tick vectors, they appear to be preferentially transmitted 
by specific tick species. While CE and LI viruses are usually 
transmitted by Ixodes ricinus, and FE TBEV by Ixodes persulcatus, 
isolation of these viruses from ticks of the genus Dermacentor and 
Haemophysalis collected in habitats unfavorable to the Ixodes has been 
recorded (reviewed Blaskovic, 1958). Powassan virus, OHFV and KFDV 
are most frequently isolated fron Ixodes cookei, Dermacentor pictus 
and Haemophysalis spinigera respectively. On rare occasions, TBEV has 
been isolated from the Aedes mosquito although the infrequency of 
these isolations implies that this form of transmission is of little 
epidemiological importance (Przesmycki et al., 1960). Because'of its 
ability to withstand low pH, TBEV can also transmitted via milk. 
Transmission to human populations via this route has posed a 
significant public health problem and been responsible for a number of 
TBEV outbreaks (Gresikova, 1958). 
1.1.4. Epidemiology of TBEV: 
Since arboviruses occur only where climate and conditions support 
sufficient numbers of closely associated primary hosts and suitable 
vectors, the epidemiology of mw infections is defined by the ecology 
of the virus-host relationship. While these factors restrict KDV in 
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India to Karnataka Provence and parts of the adjacent states, OHFV to 
Omsk and Novosibirsk and LIV mainly to upland sheep grazing areas of 
the UK (LIV having also been isolated in Norway and Spain), these 
factors have allowed the viruses of the CE and FE TBEV subtypes to 
spread across large areas of the temperate northern hemisphere. In 
reflecting the distribution of'their main tick-vector, the FE TBEVs 
have been identified throughout the CIS, while those of the CE subtype 
have been located in most countries of Europe and Scandinavia 
(Balaskovic, 1958). LIV is the only member of the TBEV canplex to be 
found in the UK; the geographical isolation of the UK has probably 
prevented infection of the native tick population by other viruses of 
the TBEV complex. 
As the natural habitat of the tick grows and recedes in response to 
changing climate and land use, the geographical limits of human 
infection alter. TBEV was initially limited to forest workers and 
hunters. Today, however, more extensive and frequent incursions by 
the public into forested and grassland areas and'the expansion of 
dcmestic animal production has meant that the incidence of both FE and 
CE TBE is on the increase. The influence of man over the spread of 
the TBEV foci has been apparent since the beginning of the 20th 
century when the development of sheep husbandry in the heather 
moorlands of Scotland resulted in an invasion of LIV infected Ixodes 
ricinus into the region. Reported cases of FE TBEV across the USSR 
have doubled between the years 1985 and 1990 (Dr. A. Karavanov, `IPEV 
CIS. personal carrnunication). In 1977, the Times newspaper reported 
that serological data collected in Austria, Czechoslovakia, Hungary 
and south-west Germany suggested that between 1000 and 1300 cases of 
TBEt1 were occuring annually, five years later this figure had doubled 
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(Times, November 14,1977). In recognising this increasing danger, 
the world Health Organisation (WHO) recently made TBEV a special, 
notifiable disease in 15 European states. 
The clinical reports of TBEV infection tend to be seasonal and 
climate dependent, with the designation of `Russian Spring-Summer 
encephalitis virus for viruses of the FE subtype reflects this. In 
Europe, tick activity occurs later and lasts longer than in the CIS, 
with outbreaks not being reported until the summer months and 
continuing into early autumn (reviewed Smorodintseff, 1939). The 
increased activity of questing ticks, stimulated by the wann months of 
summer, accounts for the increase in incidence of TBEV, while the 
reduction of incidences during winter months corresponds with the 
tick's diapause. 
Members of the TBEV are expressed in man as either encephalitis or 
haemorrhagic fever and they are responsible for a range of illnesses. 
The diversity of the clinical symptoms associated. with TBEV infections 
may be accounted for by the ability of the various TBEVs to operate 
through different vectors. Human TBEV infections are generally bi- 
phasic in nature and can be either so mild as to escape detection; 
moderately severe, with or without permanent residua; or fatal. The 
first phase of a TBEV infection, which frequently escapes diagnosis, 
is systemic and characterised by fever, headache and general malaise, 
often with gastrointestinal involvement. The second phase of the 
encephalitic disease is marked by the return of fever and involves the 
central nervous system (CNS). Haemorrhagic forms of TBEV lack a CNS 
involvement and are characterised by vomiting, diarrhoea and internal 
haemorrhage. The FE TI3EV's although antigenically and clinically very 
similar to those of the CE subtype, are associated with a more severe 
disease and a fatality rate as high as 20% canpared to that of between 
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1 and 5% for the CE TBEV's. Furthermore, survivors of FE TBEV 
infection, unlike those of the CE subtype, often experience a 
protracted convalescence which is frequently accompanied by residual 
paralysis of the upper limbs. 
1.1.5. Control of TBEV: 
Eradication of any arbovirus disease depends on the interruption of 
the virus transmission cycle. The cycle can be broken by removing 
either the tick or primary host. Although both these objectives are 
difficult to achieve, the control of vectors and host population 
numbers has been reasonably successful in limiting the incidence of 
disease. 
Methods available to reduce tick population in a circumscribed area 
are neither economical nor suitable for continual application. 
Temporary control of tick vectors following the predictions of 
epidemics by surveillance programmes which include vector trapping, 
antibody screening of primary hosts and monitoring of climatic 
conditions does, however, appear to be a more practicable solution. 
Prediction of epidemics allows for the limited use of effective but 
expensive and often environmentally damaging control measures such as 
the pasteurization of milk and spraying of uninhabited forest areas 
with DDT within endemic regions to be used (reviewed Blaskovic, 1959). 
These control measures, when canbined with public education and legal 
requirements, have proved to be of use in controlling TEEV outbreaks. 
Personal protection from tick bites by wearing suitable clothing and 
the use of insect repellants is only really practicable for the 
transient visitor. 
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While the temporary removal of ticks fron the transmission cycle is 
feasible, unless specific conditions apply the successful removal of 
the primary host is not. Vaccination of a primary host population 
which consists of small, wild m&rmals is clearly not feasible. The 
vaccination of a `captive' primary host population, such as the 
introduction of the human yellow fever vaccine 17D and the 
imrnunization of sheep against LIV has, however, been successful. The 
LIV vaccines have reduced the incidence of disease amongst grazing 
animal of the UK. The first LIV vaccine was a formalin-inactivated 
virus prepared from infected sheep brain, spinal cord and spleen 
(reviewed Gorden et al., 1962). Although successful, this vaccine 
was withdrawn because of the risk it posed to those involved in its 
manufacture and the possibility of its contamination with Scrapie. A 
second LIV vaccine, also a formalin-inactivated, was prepared in 
secondary sheep kidney cells (Brotherston and Boyce, 1970). A 
modified form of this cell grown vaccine is still available. 
Vaccination of domestic animals including cows, sheep and goats 
against both FE and CE TBEV has been attempted (Blaskovic et al., 
1960). Although these animals play little role in the transmission 
cycle of FE and CE TEEV, their vaccination is an important step in the 
prevention of human infection resulting from virus transmission via 
infected milk. The implication of primary host vaccination on the 
natural virus reservoir has yet to be examined. Since grouse and deer 
are being killed by LIV at this moment the overall effect of primary 
host vaccination on the natural reservoir may prove to be negligible 
and therefore be of little use in controlling the emergence of 
arboviruses. 
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1.1.6. Human TBEV Vaccines: 
TBEV vaccines, although able to reduce the incidence of infection, 
do not address the problem of virus transmission nor, presumably, 
affect the virus reservoir. Since both the economical impact and 
price in terms of human life and misery of =, especially in endemic 
regions, is so very high, the develcgnent of TBEV vaccines has been a 
priority. 
In addition to the LIV vaccines, a large number of candidate TBEV 
vaccines has been prepared, the success of which has been variable 
(reviewed Stephenson, 1988). The first flavivirus vaccine available 
for human use was a 1% formalin-inactivated suspension of infected 
mouse brain developed in Russia against the original RSSE TBEV isolate 
(Smorodintsev et al., 1940; Smorodintsev and Ilyenko, 1962). 
Unfortunately this vaccine contained myelin which produced an 
unacceptably high level of allergic reaction in vaccinees. Attempts 
to remove the contaminant resulted in a reduction in the antigenicity 
of the vaccine and consequently it was withdrawn. 
Development of cell culture systems for vaccine production initiated 
an extensive FE TBEV vaccine research programme in the CIS (Ilyenko, 
1959; Smorodinstev and Ilyenkov, 1960). An RSSEV based vaccine 
prepared in primary avian fibroblasts successfully protected in 
laboratory experiments, but when used to vaccinate populations in 
endemic regions failed to reduce the incidence of human disease and 
was withdrawn. More recently the programme has included the 
developnent of an FE TBEV candidate vaccine based on virus passaged in 
green monkey kidney cells (Chumakov et al., 1990; Grachev et al., 
1985) or the naturally occurring attenuated TBEV strain Yelantsev. In 
addition to the development of vaccines against the FE strains of 
TBEV, the CIS programme has made improvements in vaccine production 
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methods (Elbert et al., 1980,1981 & 1985). At the present time, the 
two FE TBEV vaccines available in the CIS are both based on 
inactivated virus prepared in chick cells (reviewed Chumakov et al., 
1990). An assessment of their efficacy however is difficult to obtain 
in the West. 
The first CE TBEV vaccine was based on infected, trypsinised chick 
embryo cultures inactivated with formaldehyde (Danes and Benda, 1960 & 
1960a). This inactivated vaccine was used in an immunization 
programme by the Czechoslovakians. Further epidemics of TBEV in 
eastern Europe during the 1960's, however, led to the production of a 
more efficient CE TBEV vaccine which is still in use today. A 
collaboration between the Centre for Applied Microbiology and Research 
(CANR) and the Institute of Virology, Vienna produced this formalin- 
inactivated vaccine based on the CE Neudörf1 strain of TBEV. Over 
several million doses of a highly effective, purified form of the 
Neudorfl vaccine have been administered, with only rare and temporary 
side effects being reported (Heinz et al., 1980; Kunz et al., 1980). 
Because of the growing concern surrounding CE TBEV and the commercial 
benefits to be gained fron it, a new CE TBEV vaccine based on the CE 
TBEV strain K23 is now under going trials (Bock et al., 1990; 
Klockmann et al., 1991). 
1.1.7. 'TBEV Vaccine Development: 
The current 'app roach to the develotxnent of flavivirus vaccines has 
been reviewed extensively (Brandt, 1988; Gibson et al., 1988; 
Stephenson, 1985 & 1988). A future generation TBEV vaccine should 
ideally be capable of protecting against viruses fron several of the 
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TBEV complexes, and if possible, it should protect against viruses 
fron other flavivirus antigenic complexes without presenting a risk to 
vaccinees. 
Immunization or prior infection with a flavivirus can afford a 
degree of protection against closely related viruses (Price, 1968; 
Price et al., 19631 1969; Sather and Ham cn, 1970; 
_Smithburn, 
1942). 
The precise immunological relationships between the flaviviruses 
appear to be important since monkeys were protected against 28 
different flaviviruses when immunized first against YFV, then Langat 
virus, dengue virus, and finally JEV but not when the vaccines were 
administered in a different order (Price et al., 1969). This cross- 
protection does, however, suggest that sequential immunization with 
several flavivirus vaccines may afford protection against a broad 
range of flaviviruses. 
An inherent risk in immunization against flaviviruses is the 
stimulation of antibody dependent enhancement (ADE) of subsequent 
infections (reviewed Halstead., 1982; Porterfield, 1986). The 
phenomenon of ADE in man is well documented for dengue virus. Four 
subtypes of dengue virus exist and exposure to each offers a 
reasonable level of protection against re-infection by the homologous 
serotype but only limited protection against the other three. 
Subsequent infection by a heterologous serotype can cause dengue 
haemorrhagic fever/shock syndrome (DHF/DSS) (reviewed Halstead, 1980; 
Halstead et al., 1973). Serological and epidemiological data suggest 
these more severe forms of dengue fever result from subneutralizing 
levels of circulating anti-dengue antibodies mediating the enhancement 
of subsequent dengue virus infections. 
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The mechanism of ADE may involve the infection of cell by virus 
complexed with an IgG or IgM antibody which binds to either the Fc 
receptor or complement receptor C3 of a cell (Cardosa et al., 1983; 
Daughaday et al., 1981; Halstead and 0' Rourke, 1977; Schlesinger and 
Brandriss, 1981). The cell is able to internalise the c mplexed virus 
more efficiently than non-complexed virus thus enhancing infection 
(Gollins and Porterfield, 1984). ADE has, however, only been 
demonstrated with other flaviviruses in experimental models and thus 
its importance to flavivirus vaccines in general is unclear (Barrett 
and Gould, 1986; Gould et al., 1987; Gould and Buckley, 1989., Hawkes, 
1964; Hawkes and Lafferty, 1967; Kayser et al., 1985; Phillpotts et 
al., 1985). 
The potentially dangerous implications of ADE have prompted 
investigations into the development of future flavivirus vaccines 
based on non-virion antigens. ' The use of non-virion antigens as 
flavivirus vaccines would remove the possibility of raising antibodies 
able to bind the virion and to mediate ADE. Identification of an 
extra-cellular, non-virion protein (NS1) encoded by flaviviruses, 
which has the potential to protect mice against homologous challenge 
has raised the prospect of its use in new vaccines (Cane and Gould, 
1988; Gould et' al., 1986; Henchal et al., 1988; Schlesinger et al., 
1985,1986 & 1987). Although B-cell epitopes between NS1 of the 
flaviviruses appear to be poorly conserved, a high degree of homology 
at the genetic and phenotypic level suggests that a broadly reactive 
vaccine based on the T-cell response against NS1 antigen may be 
possible (Mandl et al., 1989a; Pletnev et al., 1990; Iacono-Conners 
and Schmaljohn, 1992; Stephenson et al., 1984). Furthermore, the 
significance of a B-cell response to the NS1 antigen in vaccine 
mediated protection has yet to be investigated. 
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1.2. THE TBEV VIRION: 
1.2.1 The TBEV Genome: 
TBEV contains a single-stranded, positive-sense, RNA genome of 
approximately 10.5Kb. This RIB, molecule is infectious when inoculated 
intracerebrally into mice (Sokol et al., 1959) and since subgenomic 
flavivirus RNA has not been identified, is presumed to act, in a 
manner similar to that'of the picornaviruses, that is as the sole 
viral mRNA. 
The RNA molecule of TBEV encodes a single translated open reading 
frame (ORF), flanked by non coding regions which are presumed, to carry 
signals for RNA synthesis and translation (Fig. 1.1) (Mandl et al., 
1988 & 1989a). The 5' non-coding region of the TBEV genome is 
approximately 100 nucleotides, and computer analysis predicts the 
presence of a RNA stem-loop structure (Pletnev et al., 1990). Similar 
structures have been described for a number of other positive strand 
RNA viruses such as the mosquito-borne flaviviruses, picornaviruses 
and alphaviruses (Brintcn and Dispoto, 1988). Evidence from these RNA 
viruses and in particular YFV supports the involvement of the 
secondary structures in viral replication and translation of the 
flavivirus genome (Ruiz-Linares et al., 1989). The similarities 
between the tick-borne and mosquito-borne flaviviruses 5' non-coding 
regions imply a replication strategy common to the flaviviruses. 
Downstream of the 5' non-coding region is the major ORF which 
accounts for approximately 90% of the coding capacity of the gencme. 
In c nm n with the mosquito-borne flaviviruses and picornaviruses, the 
TBEV genaue encodes the TBEV structural proteins before the 'IBEV non- 
structural proteins. The TBEV gene order from the translation 
initiation colon is; the (anchored) core protein (C), the pre-membrane 
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Fig. 1.1 The TBEV genome 
The 3 and 5' non-coding regions are indicated by a red line at the 
ends of the open reading frame. 
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protein (PrM), the envelope protein (E), and the non-structural 
proteins (NS) NS1, NS2a, NS2b, NS3, NS4a, NS4b and NS5 respectively 
(Fig. 1.1). A second ORF, absent from the genome of the mosquito- 
borne viruses, is a feature of the TBEV 5' non-coding region. The 
significance of this small and apparently untranslated ORF is not 
known (Mandl et al., 1988; Pletnev et al., 1990). 
Following the long ORF of the TBEV gencme is a 3' non-coding region. 
This region has been found in at least two forms (Mandl et al., 1991). 
The first form, typical of the TBEV strain Neudörf1, contains 
approximately 100 nucleotides, and carries a 3' terminal 
polyadenylation signal preceded by the di-nucleotide AC. The 3' 
terminus of the TBEV strain Hypr, however, like those of the mosquito- 
borne flaviviruses, consists of over 450 nucleotides and terminates 
with the di nucleotide CU. The absence of a polyadenylation signal 
makes the genome'of the mosquito-borne flaviviruses and TBEV strain 
Hypr unusual amongst the positive-strand RNA animal viruses. Unlike 
the shorter form of the TBEV 3' non-coding regions the longer 
flavivirus 3' non-coding region has the potential to form a stem-loop 
structure which appears to protect the 3' terminus fron endonuclease 
digestion by hydrogen bonding the terminal nucleotide (Brinton et al., 
1986; Grange et al., 1985; Hahn et al., 1987; Wengler and Castle, 
1986). The stem loop structure(s) of the 3' non-coding regions of 
sane plant viruses have been s}y to be involved in the regulation -of 
RNA synthesis. This suggests a similar role for the equivalent region 
in TBEV (Strauss and Strauss, 1983). 
A degree of horology between the two forms of TBEV na-coding region 
has been demonstrated (Mandl et al., 1991). Fran the limited sequence 
data available for TBEV (both FE and CE subtypes), a high level of 
homology exists between nucleotides of the short form of 3' non-coding 
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region and the nucleotides immediately downstream of the large ORF in 
the longer forms. As with the alphaviruses, repeating sequence 
elements with serogroup specific patterns have been identified in the 
3' non-coding region of the mosquito-borne flaviviruses (reviewed 
Chambers et al., 1990a). In both forms of TBEV 3' non-coding region, 
however, these repeating sequence elements are absent. Alternatively, 
a sequence of approximately 20 nucleotides near the 3' end of the ZBEV 
NS5 gene is repeated immediately upstream of the polyadenylation 
signal in the shorter 3' non-coding region and a similar distance 
upstream of the translational stop codon in the larger 3' terminal 
region (Mandl et al., 1991). The importance of these elements has yet 
to be determined, although it has been suggested that they may be 
recognition sequences for RNA replicases. 
1.2.2. TBEV Virion Proteins: 
The three structural TBEV proteins form a spherical virion with a 
diameter of approximately 5OnM (Fig. 1.2) (Slavik et al., 1970). 
Although morphologically indistinguishable, two virion forms have been 
characterised, the intra-cellular form which contains PrM and the 
extra-cellular form which contains the mature membrane protein Mb 
(Guirakhoo et al., 1991). The TBEV genome is packaged within a 
nucleocapsid, composed of C, which exhibits cubic symmetry and which 
is surrounded by a bi-lipid envelope (Abdelwahab et al., 1964; Heinz 
and Kunz, 1979). The components of the TBEV and SLEV bi-lipid 
envelope are consistent with nascent virions budding through internal 
host cell membranes (Heinz and Kunz, 1979; Trent and Neaves, 1980). 
Anchored through the bi-lipid envelope by its hydrophobic C-terminus 
is E in association with PrM/M, both of which form spiked projections 
on the virion's surface (Heinz and Kunz, 1979a & 1980; Slavik et al., 
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Fig. 1.2 Schematic Representation of the TBEV Virion. 
Two forms of the virion are depicted: on the right is the 
extra-cellular virion; and on the left is the intra-cellular 
virion. 
NC Nucleocapsid 
G Genome 
LE Bi-lipid envelope 
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1970). The E-PrM association probably arises from interactions 
between their hydrophobic tails. The mechanism by which E is anchored 
may involve either a dual trap nbrane hook structure as depicted in 
Fig. 1.2, or a single transmembrane element. Evidence has been 
presented which suggests that there is no or little interaction 
between the capsid and the proteins of the lipid envelope (Heinz and 
Kunz, 1979a & 1980). 
The structural dents of the TEEV nucleocapsid are small (15KDa) 
basic (lysine rich) proteins (Heinz and Kunz, 1979 & 1979a, 
Krasilnikov et al., 1984). The positive charge carried by C may 
assist associations between C and the genomic RNA (Pletnev et al., 
1986; Rice et al., 1985). C is found in two forms, anchored C and C. 
As is characteristic for other flaviviruses, the TBEV encoded anchored 
C has a hydrophilic N-terminus and an internal hydrophilic domain 
separated by an internal hydrophobic region. However, TBEV C lacks 
both a hydrophobic region and second translational start colon located 
in the N-terminal hydrophobic region of the mosquito-borne viruses 
anchored C (Mandl et al., 1988). The C-terminus of anchored C 
consists of a hydrophobic 'domain, which has been shown to direct 
translocation of the &»instream protein, prM, in dengue virus and YFV 
(Markoff, 1989; Ruiz-Linares et al., 1989a). The C-terminal and 
internal hydrophobic domains may assist in the assembly of capsids by 
, anchoring' anchored C to cellular membranes, and stabilize 
interactions between aggregating Cs (Nowak et al., 1989; Rice et al., 
1985). The hydrophobic C-terminal or `anchor' of C encoded by WNV, 
Kunjin virus and YFV, is removed during maturation to generate C may 
account for the release of nascent nucleocapsids from membranes 
(Chambers et al., 1990; Nowak et al., 1989; Speight and Westaway, 
1989). Since the TBEV C gene product synthesised in a cell-free 
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translation system migrates more slowly on acrylamide gels than virion 
associated proteins and since sequence alignment with WNV has 
identified a conserved proteolytic cleavage site within TBEV anchored 
C, TBEV anchored C is probably also modified in this way (Mandl et 
al., 1988; Svitkin et al., 1984). The removal of this putative 
membrane anchor in TBEV, however, will remain speculative until the C- 
terminal of TBEV C has been determined directly. 
PrM (14.5KDa) is the glycosylated precursor of M (7.5KDa) and is 
produced-when proteolytic cleavage removes the glycosylated 
hydrophobic N-terminal domain from PrM (Nowak et al., 1989). This 
modification is necessary for the generation of fusion competent, 
infectious virions (Guirakhoo et al ., 1991; Randolf et al., 1990). 
Like C, PrM contains a hydrophobic C-terminus which, in YFV, has been 
shown to function as the translocation signal sequence for E and may 
anchor M into the bi-lipid envelope of the virion (Despres et al., 
1990; Ruiz-Linares et al. ', 1989). It has also been suggested that 
PrM/M plays a role in the protective humoral response (Heinz and Kunz, 
1977; Heinz et al., 1981; Kaufman et al., 1989). 
The TBEV surface protein E (55KDA) contains haemagglutination, 
complement fixation and neutralization antigenic determinants and 
directs the major humoral protective immunological response in a host 
(Heinz et al., 1981). Analysis of disulphide bonding within E of THEV 
has helped elucidate its secondary structure, while topographical 
epitope analysis has allowed the construction of an antigenic map 
(reviewed Heinz, 1986; Heinz et al., 1983 & 1983a). Three antigenic 
domains A, B and C within ZBEV E have been identified which correspond 
to the antigenic domains R1, R2 and R3 of WNV E and dc sins I, II and 
III of dengue virus E (reviewed Heinz, 1986 & 1990; Mandl et al:, 
1989; Mason et al., 1990; Megret et al., 1992; Nowak and Wengler, 
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1987). In addition to their antigenicity, the three domains of E have 
been linked with specific roles (Guirakhoo et al., 1989; reviewed 
Heinz, 1990; Heinz et al., 1983; Holzmann et al., 1990). A point 
mutation in domain B leads to virus attenuation, while domain A, both 
contains a tetra-peptide found in the fusion-active amino terminal of 
influenza virus HA2 and is able to undergo both antibody- and pH- 
mediated conformational changes. 
Of the three N-linked glycosylation motifs identified within TBEV E, 
only the N-terminal site appears to be available for modification 
(Winkler et al., 1987). While conserved amongst the characterised 
tick-borne flaviviruses, the position of the oligosaccharide in the 
mosquito-borne viruses is not conserved. Although encoding the 
glycosylation motifs, E encoded by Kunjin virus, WNV and at least one 
strain of YFV, is unglycosylated, the oligosaccharide side chain 
having been added appears to be removed during virion maturation 
(Deubel et al., 1987; Wengler et al., 1985; Wright, 1982). The 
importance of the glycan side chain has yet to be determined. 
1.2.3. TBEV Non-Structural Proteins (excluding NS1): 
NSS, the largest of the TBEV encoded processed proteins (91Kd), and 
NS3 are both positively charged and hydrophilic proteins. NS5 
contains the tri-peptide Gly-Asp-Asp of the RNA-dependent-RNA 
polymerase motif found in many plant and animal positive-stranded RNA 
viruses (Iacono-Connors and Schmaljohn, 1992; Kamer and Argos, 1984; 
Mandl et al., 1989a). This is, however, the only evidence for the 
flavivirus polymerase being provided by NS5 (Grun and Brinton, 1987). 
Amongst the positive-strand RNA animal viruses, . only picornaviruses 
and viruses of the Flaviviridae encode the RNase polymerase gene at 
the 3' end of their genome. 
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The consensus sequence of an RNA helicase motif and of a nucleotide 
triphosphate binding site have been identified in the C-terminus of 
TBEV NS3 (64KDa), implying a role in the viral replicase complex 
(Gorbalenya et al., 1989). The N-terminus region of NS3 exhibits 
homology with a functional trypsin-like serine protease (reviewed 
Bazan and Fletterick, 1990; Iacono-Conners and Schmaljohn, 1992; 
Timofeev et al., 1990). The protease domain is contained within the 
181 residues at the N-terminus of NS3 where three spatially conserved 
amino acids of the catalytic triad are located. In addition to the 
triad, a substrate binding pocket which interacts with the cleavage 
sites and on which efficient processing is dependent has also been 
identified in the N-terminal of NS3. Tb date, NS3 associated protease 
activity has been demonstrated for the mosquito-borne dengue virus, 
WNV and YFV (Cahour et al., 1992; Chambers et al., 1991; Falgout et 
al., 1991; Preugschat et al., 1990; Wengler et al., 1991). 
The small non-structural proteins, NS2a, NS2b, NS4a and NS4b have 
only recently been demonstrated for the mosquito-borne flaviviruses 
(Speight and Westaway, 1989a), while in TBEV their existence remains 
theoretical. These four small non-structural proteins of TBEV have 
been predicted from nucleotide sequence analysis and are apparently 
rich in hydrophobic residues (Mandl et al., 1989). If, as with other 
positive-strand RNA viruses such as the coronaviruses and 
alphaviruses, the flavivirus replication complex is membrane bound as 
suggested by Grun and Brinton (1988)-these hydrophobic, small non- 
structural proteins may direct the association between the viral 
replication complex or hydrophilic NS3 and NS5 and the cellular 
membranes (reviewed Chambers et al., 1990a). 
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Recent work with dengue virus has suggested a role for NS2a in 
mediating cleavage of the NS1: NS2a junction. The protease requirement 
is in the N-terminal 2/3 of NS2a which may either act directly or 
provide an obligatory sequence for a specific cellular protease 
(Falgout and Lai, 1990; Falgout et al., 1989). In the dengue and 
yellow fever viruses, NS2b has been shown to be a necessary component 
in the cleavage mechanism of the NS3 encoded protease (Cahour et al., 
1992; Chambers et al., 1991; Falgout et al., 1991). Little is known 
about NS4a and NS4b. 
1.2.4. TBEV RNA Synthesis: 
RNA synthesis of the tick-borne flaviviruses is believed to be 
associated with the exbplasnic reticulum in the perinuclear region of 
the infected cell (Lubiniecki and Henry, 1974). Although 
identification of the replicative forms of TBEV RNA has yet to be 
made, they have been demonstrated in cells infected with mosquito- 
borne flaviviruses (Chu and Westaway, 1985; Cleaves et al., 1981; 
Stollar et al., 1967). For dengue virus and Kunjin virus, two forms 
of the replicative complex have been identified: the replicative form 
(RF) and the replicative intermediate (RI). The RF is an RNA duplex 
consisting of positive and negative sense viral RNA copies, while the 
RIs appear to be semi-denatured RFS with the nascent RNA strands in 
the process of being transcribed. The relationship between the two 
types of replicative o lex is unclear. INA dependent RNA polymerase 
activity has been detected in cells infected with dengue virus, WNV 
and Ki nj in virus (Cardiff et al ., 1973; Chu and Westaway, 1987; Grun 
and Brintcn, 1986). This polymerase may be encoded by the NS5 gene. 
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On the basis of the data gathered so far, several strategies for 
flavivirus RNA synthesis have been proposed (reviewed Brinton, 1986; 
Chu and Westaway, 1985; Westarray, 1987). The basic strategy requires 
that the genomic RNA provides the template for negative strand 
synthesis which in turn becomes the template for progeny RNA. The 
resultant progeny RNA molecules then act as mRNA, as further templates 
for negative strand RNA synthesis, or are encapsulated into virions. 
Virus replication is however still poorly understood partly because of 
the lack of data on the mechanism regulating RNA synthesis. 
1.2.5. Processing of the TBEV Primary Translation Product: 
The TBEV genome is polycistronic, translation initiates at the N- 
terminal methionine of C, generation a single polyprotein precursor 
from which the viral proteins are co- and post-translationally 
processed (Fig. 1.3) (Lyapustin et al., 1986). A scheme involving 
multiple initiation of flaviviruses and similar to that of the 
alphaviruses, has been proposed (Westaway et al., 1977; reviewed 
Westaway, 1980; Westaway et al., 1984). The alternative and more 
convincing interpretation of current data which argues for the single 
initiation theory is now, however, generally accepted (reviewed 
Westaway, 1987; Rice, 1986). 
The mosquito-borne flaviviruses gene order has been identified by 
direct N- and C- terminal sequencing of the polyprotein cleavage 
products and by alignment the predicted cleavage sites on primary 
amino acid sequences fron the long cpF (Bell et al 1985, Biedrzycka et 
al 1987, Chambers et al 1989 & 1990, Coia et al., 1988; Nowak et al., 
1989; Speight et al., 1988; Speight and Westaway., 1989; Wengler et 
al., 1990; Wright et al., 1989). Analysis of these data has revealed 
the existence of logical and consistent processing signals and 
27 
ý1111111 ý1 
1 
'J 
O 
Cellular signalase located in the lumen of the ER. 
Viral protease located in the cytoplasm, which 
recognises di-basic amino acids. 
Unknown viral protease. 
I Possible cellular signalase located in the lumen of the RR. 
Cellular methionine amino pepsidase located in the 
.j cytoplasm. 
Protease recognising di-basic amino acids located 
i, in the cytoplasm. 
Protease recognising di-basic amino acids in 
Post-Golgi vesicles. 
1.3 Schematic Representation of the Predicted Event which 
cess the TBEV Translation Product. 
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cleavage sites (reviewed Chambers et al., 1990a; Rice and Strauss, 
1990). Direct N-terminal sequencing of the TBEV structural proteins 
and alignment of the TBEV amino acid sequence with that of the 
mosquito-borne viruses has confirmed the presence of the putative 
processing elements in the TBEV polyprotein (Boege et al., 1983; 
Iacono-Connors and Schmaljohn, 1992; Mandle et al., 1988,1989a & 
1991a; Pletnev et al., 1990). 
Processing of individual TBEV proteins from the nascent polyprotein 
precursor is presumed to be by cellular signalases and virus-encoded 
proteases. A signalase located within the lumen of the endoplasmic 
reticulum (ER) cleaves following a recognition signal defined by the 
-3-1 rule (Val-X-Ala where X is uncharged) (von Heijne, 1983). A 
potential -3, -1 site is located at the C-terminal of each of the TBEV 
structural proteins, and cleavage following these motifs liberates 
anchored C, PrM and E from the polyprotein precursor (Mandl et al ., 
1988 & 1991a; Pletnev et al., 1990). In addition to liberating the 
structural proteins from the polyprotein, this signalase cleavage 
also generates the N-terminal of PrM, E and NS1 and the C-terminal of 
anchored C, PrM and E. To permit access of the signalase to the 
cleavage sites, PrM, E and NS1 are translocated across the ER. 
The translocation signal sequences, located immediately upstream of 
the -3, -1 signalase recognition motif in anchored C, PrM and E, are 
comprised of three characteristic regions: a basic N-terminal domain; 
a central hydrophobic dcmain and a more polar C-terminal domain. The 
amino acid preceding each signal domain is charged, and probably acts 
as the translocation stop-transfer signal (Mandl et al., 1988 & 1991a; 
Pletnev et al., 1990; von Heijne 1983 & 1985). Following cleavage, 
PzM, E and NS1 are held in the lumen of the ER for a limited period to 
allow for virus assembly. The signalase responsible for generating 
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the structural proteins may also cleave the NS4a-NS4b junction, since 
the cleavage has no viral requirement and the amino acid sequence 
preceding the N-terminal of NS4b is consistent with a signalase 
cleavage site and translocation signal (Cahour et al., 1992; Mandl et 
al., 1989a). Furthermore, generation of the NS4b N-terminal in the 
ER is consistent with NS4a and NS4b containing membrane spanning 
domains. I 
The second type of cleavage event involves a virus encoded protease 
located in the cytoplasm, which cleaves between two basic amino acids 
(reviewed Krausslich and Wimmer, 1988; Wellink and von Kameen, 1988). 
Di-basic residues form the C-terminus of NS2a, NS2b, NS3 and NS4b, and 
cleavage between these residues generates the N-terminus of NS2b, NS3, 
NS4a, and NS5 (Ia mer and Schmaljchn , 1992; Mandl et al. , 1989a; 
Pletnev et al, 1990; reviewed Rice and Strauss, 1990). The trypsin- 
like serine protease of NS3, in association with NS2b, has been 
implicated in this processing (Cahour et al., 1992; Chambers et al., 
1991; Falgout et al., 1991; Preugschat et al., 1990; Wengler et al., 
1991). A second protease recognising di-basic amino acids may be 
responsible for the removal of the C-terminal hydrophobic domain of 
anchored C. 
'Three additional cleavage events, necessary for TBEV maturation, are 
the removal of a methionine residue from the N-terminus of the C 
protein (Boege et al ., 1983), the. maturation of PrM to M and cleavage 
between NS1 and NS2a. It has been proposed that a cellular protease 
with an acidic requirement and which recognises di-basic residues 
removes the hydrophobic N-portion domain from PrM since trimming of 
PrM occurs in the acidic post-Golgi vesicles (Pletnev et al., 1990; 
Randolf et al., 1990). Removal of the N-terminal methionine fron C, 
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is probably carried out by a cellular methicnine amino peptidase while 
the source and specificity of the cleavage between NS1 and NS2a region 
has yet to be determined. 
1.2.6. TBEV Virion Entry and Uncoating: 
Although specific host cell receptors have not yet been identified 
for any of the flaviviruses, there is considerable evidence to 
indicate that mosquito-borne viruses are taken into cells by receptor 
mediated endocytosis via coated pits which transport the virus to 
internal endoscmes (Gollins and Porterfield, 1985 & 1986; Ng and Lau, 
1988). Flaviviruses are also able to gain entry into a cell, via 
antibody bound to Fc or C3 cell receptors, (the mechanism of ADE). 
Fusion of TBEV with the endosanal membranes and the release of the 
viral gencme into the cytoplasm probably results fron pH dependent 
conformational changes. Consistent with this proposed mechanism of 
virus entry is the ability of weak bases to inhibit dengue virus, WNV, 
SLEV and YFV virus infections (Brandriss and Schlesinger, 1984; 
Randolf and Stollar, 1990) and to inhibit the release of WNV from the 
endosomes into the cytosol (Gollins and Porterfield, 1985). 
Observations that SLEV and JEV is maintained more successfully in an 
alkaline environment than an acidic one (Duffy and Stanley., 1945; 
Duffy, 1946) and that an acidic environment stimulates the uncoating 
of extra-cellular WW are also consistent with this mechanism of entry 
(Collins and Porterfield, 1986 & 1986a). pH dependent changes within 
antigenic domain A of TBEV E have been identified as possibly 
directing viricn-cell fusion (GJirakhoo et al., 1989). In the light 
of the work by C uirakhoo et al on TBEV, the ability of TBEV to remain 
31 
infectious at pH values below those required to inactivate other 
flaviviruses and the transmission of TBEV in the acidic environment of 
milk are unexpected (Gresikova, 1958 & 1959; Guirakhoo et al., 1989). 
1.2.7. TBEV Virion Maturation: 
TBEV assembly occurs in association with cell membranes (Lubiniecki 
and Henry, 1974). Once translated, PrM, E and NS1 are translocated 
through the ER, cleaved from the polyprotein translation product, 
glycosylated and oligcmerised, (where appropriate). The glycoproteins 
are then transported to the Golgi complex, where further modifications 
to their nascent oligosaccharide side chains take place. Virion 
assembly is presumed to be rapid, since the identification of 
intermediate steps including the mechanisms of nucleocapsid assembly 
and the characterisation of budding intermediates, has not been made 
(Demsey et al., 1974; Deubel et al., 1981; Filshie and Rehacek, 1968). 
It is proposed that the maturation of flavivirus virions consists of 
several, probably concurrent, events. Nucleocapsids are believed to 
assemble on the cytoplasmic face of cellular membranes, stabilized by 
the hydrophobic C-terminal anchor of C. The C anchor is cleaved to 
release nascent nucleocapsids, which are encapsulated by E and PrM 
budding through the internal cellular membranes into the post-Golgi 
vesicles. 
1.2.8. TBEV Virion Egress: 
The passage of virions out of the cell is through acidic post-Golgi 
vesicles. A mechanism by which nascent exiting TBEV virions are 
prevented from undergoing pH-mediated fusion with the intracellular 
membranes of these vesicle has been identified. The mechanism 
suggests that the PrM/E heterodimers identified in fusion incanpetent, 
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immature virions inhibit the conformational changes in E required for 
fusion (Wengler and Wengler, 1989). Immediately prior to egress, 
however, PrM and E are disassociated allowing generation of fusion 
competent virions by trimming of PrM to M (Randolf et al., 1990) and 
mature virions are released at the cell surface by vacuole discharge. 
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1.3. TBEV NON-STRUCTURAL PROTEIN NS1: 
Although little is known about the TBEV non-structural glycoprotein 
NS1 (47-51KDa), primary sequence canparisons with the mosquito-borne 
flaviviruses have identified several conserved features. These 
conserved features include the N- and C-terminal proteolytic cleavage 
motifs, potential N-linked glycosylation sites and the putative NS1 
translocation signal sequence located in the C-terminal of E. A high 
degree of structural conformity between the tick-borne and mosquito- 
borne flaviviruses is implied by 11 spatially conserved cysteine 
residues (Iacono-Connors and Schmaljohn, 1992; Mandl et al., 1989a; 
Pletnev et al., 1990). 
The 24 amino acid sequence preceding the N-terminus of NS1 in the 
TBEV translation product (between residues 752 and 77.6 for the 
Neudorfl strain of TBEV) are thought to direct translocation of NS1 
across the ER and are consistent with the amino acid composition of 
translocation signal sequences preceding the N-terminus of NS1 in the 
mosquito-borne flaviviruses (Putnak et al., 1988; Falgout et al., 
1989). Translocation of NS1 across the ER positions the E/NS1 
junction for cleavage by a cellular signalase located in the ER. At 
the N-terminal of the putative NS1 translocation signal in TBEV is an 
arginine residue with the potential to act as the stop-transfer signal 
for translocation, while an amino acid sequence, (Val-Gly-Ala), 
characteristic of the -3-1 signalase recognition motif forms the C- 
terminal of the translocation signal sequence (von Heijne, 1983 & 
1985; Mandl et al., 1989a & 1992a; Pletnev et al., 1990). 
The three amino acids forming the C-terminus of TBEV NS1 (Val Val- 
Ala) are also consistent with a -3-1 signalase motif, however, the 
signalase located in the ER and responsible for generating the C- 
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terminus of anchored C, PrM and E is not thought to mediate NS1: NS2a 
cleavage unless the translocation signal directing the E: NS1 junction 
into the ER, also directs translocaticn of NS2a. An indication as to 
the specificity of this novel enzyme cones from dengue virus for which 
the eight amino acids immediately preceding the C-terminal of NS1 have 
been implicated in the NS1: NS2a cleavage (Hora and Lai, 1990). The 
TBEV NS1 C-terminus octapeptide is consistent with signal sequence 
identified in dengue virus NS1 and may therefore provide a similar 
function. In addition to the octapeptide, deletion analysis has shown 
that efficient proteolytic cleavage at the NS1: NS2a junction of dengue 
virus also requires the presence of at least 70% of the NS2a protein 
(Falgout and Lai, 1990; Falgout et al., 1989). 
An alternative C-terminal NS1 cleavage product, a fusion protein of 
NS1 and a portion of the adjacent N terminus of NS2a, have been 
identified in YFV, JEV and possibly MVEV, but not in 'I'BEV- or dengue 
virus-infected cells (Chambers et al., 1990; Hall et al., 1990; Lee et 
al., 1989; Mason et al., 1987). The significance of this additional 
polyprotein cleavage product is unknown. 
The primary sequence of TBEV NS1 has revealed three potential N- 
linked glycosylation motifs (Asn-X-Thr/Ser) at amino acids 861-863, 
983-985 and 998-1000 of the Neudörfl strain (reviewed Kornfeld and 
Kornfeld , 1985; Mandl et al., 1989a). The position of the TBEV N- 
linked oligosaccharide side chain at amino acid 983-985 is conserved 
with one of the N-linked glycosylation sites found on the mosquito- 
borne flavivirus NS1. At least two oligosaccharide side-chains have 
been characterised for the NS1 protein of YFV, dengue virus and JEV 
while the'ability of TBEV NS1 to incorporate radiolabelled sugars is 
consistent with it being glycosylated (Mason, 1989; Past et al., 1990; 
Stephenson et al., 1987; Winkler et al., 1988). 
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A secreted, particulate, form of the TBEV NS1, which is 
approximately 4 kDa larger than the intra-cellular form, has been 
identified (Lee et al., 1989). The glycosylation studies of YFV, 
dengue virus and JEV suggest that the size increase associated with 
the extra-cellular form resulted from modification of the glycan side- 
chains during export of NS1 from the cell (Lee et al., 1989; Mason, 
1989; Post et al., 1990; Winkler et al., 1988). Both the intra- and 
extra-cellular forms of NS1 encoded by the tick-borne Powassan virus 
and several of the mosquito-borne viruses, have the ability to form 
heat labile dieters and possibly higher oligomers (Despres et al., 
1991; Parish et al., 1991; Putnak and Schlesinger, 1990; Winkler et 
al., 1988; Schlesinger et al., 1990). Bonds which stabilize dengue 
virus dimers are sensitive to both heat and acid pH but resistant to 
reduction by 2-mercaptoethanol (Winkler et al., 1988), but while the 
JEV intra-monomer bonds are also heat and acid labile they appear to 
be partially sensitive to reduction (Fan and Mason, 1990). The 
importance of NS1 dieters is unknown however, although dengue virus NS1 
dimers do appear to be more immunogenic' than the monomers (Falconer 
and Young, 1990). 
Antibodies raised to extra-cellular TBEV NS1 failed to neutralise 
viral plaque formation (Phillpotts et al., 1987). This result is 
consistent with biochemical data which indicate that in dengue virus 
NS1 does not form part of the virion (Brandt et al., 1970). NS1 of 
dengue virus, JEV, Kunjin virus and YFV has been detected on the 
surface of cells and shown to have properties consistent with cell 
association via hydrophobic domains even though the NS1 primary 
sequence contains no obvious hydrophobic regions (Cardiff and Lund, 
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1976; Despres et al., 1991; Fan and Mason, 1990; Mason, 1989; Putnak 
and Schlesinger, 1990; Schlesinger et al., 1990; Westaway and Goodman, 
1987; Winkler et al., 1989). 
During the course of natural infections, NS1 evokes a strong immune 
response. Experimental data from dengue virus- and YFV-infected mice 
and monkeys has shown that protection fron lethal challenge may be 
afforded by immunization with purified NS1 protein (Cane and Gould, 
1988; Schlesinger et al., 1986 &1987). Mice have also been protected 
from virus challenge by the passive transfer of anti-NS1 monoclonal 
antibodies (Gould et al., 1986; Henchal et al., 1986; Schlesinger et 
al., 1985). Although unable to neutralise virus infection, anti-NS1 
antibodies can direct complement mediated. lysis of virus-infected 
cells which has been proposed as a mechanism by which the protective 
immune response may arise (Schlesinger et al., 1985,1986,1987 & 
1990). Initial work with YFV suggested that a correlation existed 
between the ability of anti-NS1 monoclonal antibodies to elicit 
protection and to direct complement mediated cytolysis (CMC) of 
K infected cells. More recent studies involving other flaviviruses 
including TBEV have not supported this finding (Despres et al., 1991a; 
Henchal et al., 1988; Phillpotts et al., 1987; Putnak and Schlesinger, 
1990). The role and importance of the humoral protective humoral 
response has only been implied in, these protection studies, while the 
importance of an anti-NS1 MHC class I cytotoxic T lyphocyte (CTL) 
response is unknown. As new vaccines based on the TBEV NS1 protein 
are being considered the important implications of the immune response 
to NS1 merits further investigation. 
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1.4. AIMS: 
The main aims of this study are to firstly express recombinant TBEV 
NS1 in the absence of other TEEV encoded proteins using an adenovirus 
vector, and secondly to examine the potential of the recombinant NS1 
to protect mice against lethal TBEV challenge. In order to express 
TBEV NS1 gene it will be necessary to determine the factors encoded 
within the TBEV ORF which are required for synthesis of NS1. This 
will be achieved by examining the potential of several TBEV CDNA 
fragments when placed under the control of the powerful constitutive 
cytomegalovirus (CMN) major immediate-early IE promoter to express 
recombinant NS1 in transient expression experiments. Each cDNA 
fragment will contain a different form of the NS1 gene encoded by the 
Neudörf1 and K23 strains of TBEV and will be generated by PC R, using 
either reverse transcripts of the TBEV genome or large TBEV cDNA 
fragments as a template. A recombinant adenovirus based on a TBEV 
cDNA fragment with the potential to express high levels of NS1 will 
then be constructed to allow the possible bio-physical 
characterisation of the TBEV gene product can be undertaken. Since 
the role of NS1 in virus replication is unknown, expression of TBEV 
NS1 as described above should lead to a better understanding of its 
significance. Furthermore the expression system will be a suitable 
tool with which to investigate the immune response elicited by NS1 
from both an encephalitic and tick-borne flavivirus in vivo. 
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CHAPTER 2. Materials and Methods 
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2.1. Cell Culture: 
PS cells, a line derived fran pig kidneys, were used to propagate 
both the Neun, rfl and 1<23 strains of TBEV. 293 cell, an adenovizus- 
transformed human embryonic cell line constitutively expresses the 
adenovirus El gene product, supported efficient replication of E1a- 
recombinant adenovirus mutants (Graham et al., 1977). Efficient 
expression from the cytomegalovirus (CMV) immediate early (IE) 
promoter expression cassette in the adenovirus vector was obtained 
in the absence of adenovirus gene expression when propagated in 
human embryo lung fibroblasts, MRC5 cells (Wilkinson and Akrigg, 
1992). Since adenovirus gene expression was absent in MRCS cell 
infected with the adenovirus vector, adenovirus replication was also 
inhibited. 
Cell were passaged after being washed with pre-warmed phosphate 
buffered saline pH 7.5 (PBS: NaCl 8% (w/v); KCl 0.2% (w/v); 0.12%; 
KH 2PO4 0.12% (w/v); 0.19% (w/v) Na2HP04 (anhydrous)) and removed 
from the solid support with 1% trypsin/ethylenediaminetetraacetic 
acid, [di-sodium] salt solution (EDTA) (GibcoBRL, Paisley, 
Scotland). Further flasks (Nunc, GibcoBRL) were routinely seeded at 
a ratio of 1: 3 and, when required, cells were enumerated using a 
ha rccytcmeter (Weber Scientific, Lancing, UK) following dilution in 
tzypan blue vital stain (Flow, ICN, High Wycombe, Bucks) at a final 
concentration of 0.02%. 
Each cell line was propagated under specific conditions: PS 
mcnolayers were grown at 370C, in Leibovitz 15 media (L15; Imperial 
Laboratories, Andover, UK) supplemented with 5% (v/v) foetal calf 
serum (FCS, Imperial Laboratories), 0.1% tryptone phosphate broth 
(Difco, East Molesly, Surrey, UK) and appropriate antibiotics, while 
293 and MRC5 monolayer were grown in Glasgow Minimal Essential 
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Media (C M) (Imperial Laboratories) supplemented with 5% FCS and 
2mM glutamine under 5% 002/air at 370C. When infected with virus, 
cell monolayers were maintained under the appropriate conditions in 
media containing only 2% FCS (maintenance media). For stimulation 
of the 04V IE promoter, 0.01 mg/ml forskolin (Sigma, Poole, UK) was 
added to infected MRC5 cells. In one experiment the'culture medium 
was replaced with protein free medium (PAA, Linz, Austria). 
2.2. TBEV Strains: 
The two Central European TBEV virus strains used in this study 
were Neud8rf1 and K23. The Neud8rf1 strain of T BEV was originally 
isolated from an infected Ixodes ricinus tick collected in Austria 
(Heinz and Kunz, 1981). Plaque purified Neudörfl strain of TBEV was 
obtained from the progeny of a single viral plaque, following three 
sequential passages in chick embryo fibroblasts (CEF) grown in an 
agar suspension at the CANR, Fortan Down, UK. A further passage, in 
suckling mouse-brain (SMB), generated the seed stock from which 
working stocks were derived after a second SMB passage. The K23 
strain was isolated from an Ixodes ricinus tick collected in the 
Karlsruhr region of Germany (Rehse-Kupper et al., 1978). Following 
three passages in SMB, the virus was purified in tissue culture by 
limited end point dilution. A purified stock of this virus was 
kindly supplied by Dr Hilfenhous (Behringwerke AG, Marburg, Germany) 
and cn its receipt at CANIR, the virus was passaged once in S MB prior 
to use. - 
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2.3. Propagation of TBEV: 
High-titred stocks of both Neudörfl and K23 strains of TBEV were 
kindly provided by Mr J. Lee. For working purposes, 70% confluent PS 
cells monolayers (unless specified) were infected with virus at a 
multiplicity of infection (moi) of between 0.1 and 1 plaque forming 
units per cell (pfu/cell) in a minimal volume of PBS. After 4h 
incubation at 370C, the cells were washed with pre-warmed PBS and 
re-incubated in maintenance media until required (2 to 4 days). 
2.4. Titration of TBEV: 
'THEN strains were titrated in 24 multiwell plates (Nunc). TO each 
well, 0.5 ml PS cells at 3X105 cells/ml and 0.1 ml of virus diluted 
in PBS, from a series of 10-fold dilutions, were added. Following a 
4h incubation at 37°C, the infected cells were gently overlayed 
with 0.5 ml L15 carboxy methyl cellulose overlay (Meridick, 
Birmingham, UK) suspended in 2X L15 media supplemented with 3% (v/v) 
FCS. The cells were incubated at 37CC for 4 days before being fixed 
in formal saline (10% formalin in PBS) and stained with 0.1% crystal 
violet (Meridick) in 20% industrial methylated spirit (Merick). 
2.5. TBEV Plaque Reduction Neutralization Assay: 
TBEV plaque reduction neutralization assays were performed as 
titraticns (section 2.4) with 100 4 aliquots of 2-fold dilutions of 
antisera in PBS being reacted with an equal volume of PBS containing 
20 virus pfu for 4h at 370C prior to being mixed with the cells. 
The neutralisation titre was calculated as being the reciprocal of 
the antisera dilution which produced a 50% reduction in the number 
of plaques, in comparison with the control sample of virus reacted 
with PBS. 
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2.6. Production of Recombinant Adenovirus Stocks: 
In addition to those El a- recombinant adenoviruses constructed in 
this study, a defective adenovirus expressing 13-gal (RAd35) kindly 
supplied by Dr (V13 Wilkinson of CAMR, was used as a control virus. 
Recombinant adenovirus stocks were prepared from 293 cells which had 
been infected with an moi of 0.1 pfu/cell when 80% confluent. The 
virus, diluted in a minimal volume of media, was left to adsorb to 
the cells overnight at 370C. Next day, the cells were washed with 
pre-warmed PBS and returned to the incubator in maintenance media 
until the cytopathic effect (cpe) was seen in 100% of the monolayer. 
Virus was harvested from the infected cells that had been washed in 
PBS and recovered by a5 min centrifugation in a MSE minstral 
(Fisons, Loughborough, Leics) at 2000 rpm. The cells were 
resuspended in PBS (2 ml per 2X106 cell) and the virus extracted by 
mixing the cells vigorously with an equal volume of Arklone P (ICI, 
Runcorn, Cheshire, UK). The virus containing aqueous phase was 
separated by centrifugation at 2,000 rpm in an MSE minstral, 
harvested, aliquoted and stored at -70°C. 
2.7. Titration and Plaque Purification of Recombinant Adenavirus 
Stocks: 
Recombinant adenoviruses were titrated in 293 cells grown in flat 
bottomed, 96 well, microtitre plates, (Nunc). Monolayers (80% 
confluent) were infected with 0.1 ml fron a 10-fold serial dilution 
of the virus in culture medium and incubated overnight at 370C. 
Next day, the inoculum was replaced with 0.1 ml of fresh medium and 
the plates were returned to the incubator for 8 days. Media was 
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replaced after 4 days and again if acidic. Cells were examined for 
the presence of a cpe and viral titre was calculated by the 
Spearman-Karber endpoint determination (Finney, 1971). 
Plaque-purified recombinant adenoviruses were obtained from wells 
containing virus diluted to the end-point. The media from an 
appropriate well was harvested, diluted and re-plated. This 
procedure was repeated twice before the virus was deemed to be 
plaque purified. 
2.8. Purification of Adenovirus by Gradient Centrifugation: 
The aqueous phase of the Arklone P extracted virus (section 2.6) 
was carefully pipetted on top of a CsC1 solution (1.6 ml of density 
1.45 g/ml and 3.0 ml of density 1.33 g/ml in 5mM Tris/HC1,1 mM 
EarA, pH 7.8) in a 15 ml Beckman (Beckman Instnanents, High Wycombe, 
Bucks) centrifuge tubes and centrifuged at 90,0002 in a Beckman L5- 
6513 Ultracentrifuge, for 2 h. The opalescent virus layer, located 
at the interface between the higher and lower density solutions, was 
removed by aspiration and diluted 1: 2 with the Tris/EDTA buffer 
before being layered onto a second CsCl gradient of 3 ml of density 
1.33 g/ml and 2.0 ml of density 1.45 g/ml. This gradient was 
centrifuged overnight (16 hrs) at 100,0002, and a band of opalescent 
virus forced at a density of 1.34-1.35 g/ml. After harvesting, the 
virus was dialysed overnight against 10% glycerol in the buffer used 
to make up the gradients. 
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2.9. Infection of PS Cell 1Konolayers With Infected Mause Brain 
Homogenate and Sera: 
Sera was harvested from Balb/C mice as described in section 2.38, 
while brains were removed fron the decapitated heads of anesthetised 
mice and placed into universal tubes containing 1 ml ice cold 
sterile PBS. The brains were chopped up, rinsed in fresh, ice cold 
PBS and placed into a second sterile glass universal containing 1 
ml/brain of ice cold PBS and 1/2 inch depth of sterile 0.3 cm 
sterile glass spheres (Sigma). The brains were vortexed for 1 min 
and stored at -700C. When required, both the brains and sera 
were rapidly thawed at 37 QC and placed on ice. 50 }. 4l sera and 0.5 
ml brain homogenate aliquots were incubated at 370C for 4h on PBS 
washed cells growing on glass coverslips. The inoculum was removed, 
the cells rinsed with PBS and reincubated at 370C in maintenance 
media for a further 7 days. The presence of infectious virus was 
assessed by an immunofluorescence antibody test (section 2.28). 
Work TBEV took place in category '3 facilities under the 
appropriate regulations. All recombinant adenoviruses were worked 
with in category 2S containment in accordance with the Advisory 
Committee on Genetic Manipulations (ACGM) recommendations. 
2.10. Plasmids Strains: 
Plasmid pMI'L23 (Fig. 3.1) was kindly given by S. Chambers of CPMR 
(Chambers et al., 1989), while the transfection vector, pW100 (Fig. 
3.2), and the recombinant adenovirus transfer vector pMV60 (Fig. 
3.20) were kind gifts from Dr. Wilkinson of CAM2 (Wilkinson and 
Al rigg, 1992). Plasmid pJM17 (Fig. 3.21), containing the genaue of 
adenovirus type 5 d1309 with the prokaryotic vector pBRX inserted 
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into the Eta gene and a deletion in the E3 gene, was a gift from 
Professor Frank Graham at McMaster University Canada (McGrory et 
al., 1988). 
2.11. Bacterial Strains: 
The two bacterial strains used in this study were obtained from 
either GibcoBRL or the Promega Corporation (Southampton, UK. ). 
The E. cola K12 JM109 endAl, recAl, gyrA96, thi, hasR17, (r-k, 
m+k), re]A1, supE44, (lac-proAB), [F', traD36, prom, lacIgZ M15] 
was preferentially used to propagate plasmids. JM109 contains an F' 
episome carrying the laclq mutation responsible for the over 
production of the lac repressor which allows expression of the lac 
operon to be regulated by the lac inducer IPTG. 
E. coli MAX efficiency DH5 competent cells F-, 0 80d lacZ M15, 
(lacZYA-argF), U169, recA1, endA1, hsdR17 (r-k, M+k), su2E44, -, thi- 
1, MA, relA1, were used only for high efficiency transformations. 
This strain is F-, the F' episare being replaced with the 80d lac Z 
M15 marker which provides QC complementation of the B-gal gene 
provided by the plasmid. Induction of the ß-gal gene permitted 
positive identification of recombinant colonies. 
2.12. Propagation of Bacterial Strains: 
Bacterial strains were grown in sterile L-broth (10 g bacto- 
tryptcne, 5g bacto-yeast extract and 10 g NaCl per litre, pH 7.5), 
or on L-agar (15 g sterile bacto-agar/Ltr L-broth). In antibiotic 
selection experiments, ampicillin (Sigma) was used at a final 
concentration of 50 pg/ml and the chrcmogenic substrate 5-bromo-4- 
chloro-3-indoyl-3-galactosidase (x-gal), which turns blue when 
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hydrolysed by ß-galactosidase, was used at a final concentration of 
0.02% (w/v) together with 50 y. M iso-propyl-3-D-thio- 
galactopyranoside (IPTG). 
Lcng term storage of transformed bacterial colonies was achieved at 
-80°C, when bacterial cultures, grown overnight at 37°C in L-broth 
supplemented with 50ug/ml ampicillin, were mixed with an equal 
volume of sterile glycerol and frozen in 1 ml aliquots. To recover 
the bacteria from -80°C, a loopful of the thawed suspension was 
streaked out onto L-agar, or inoculated directly into nutrient broth 
and incubated overnight at 370C. 
2.13. RNA Extraction From TBEV-Infected PS Cells: 
Zbtal cellular RNA was extracted from t'. o 225 cm2 flasks of TBEV- 
infected PS cells. At 48 h post infection (hpi), cell monolayers 
were washed twice in PBS at roan targperature and detached fron their 
solid support using 0.3 an diameter sterile glass spheres (Sigma). 
The cells were recovered by 10 min centrifugation in an MSE minstral 
centrifuge at 3000 rpm, resuspended in 0.9 ml of 0.15 M Nacl; 0.1 M 
Tris/HC1 pH 7.5; and 1 mM PI rA containing 25 U/ml placental RNase 
inhibitor (Sigma) and allowed to swell. After 10 min, the cells 
were lysed by the addition of Nonidet P40 (NP40: 10% (v/v) stock 
solution) to a final concentration of 1%, and vigorously vortexed 
for 30 sec. The cell nuclei and debris were removed by a2 min 
centrifugation (12,5009) using an MSE micro-centrifuge and the RNA 
extracted from the supernatant 3 times with, phenol, and twice with 
chloroform. The RNA was recovered by ethanol precipitaticn, washed, 
and dissolved in TE buffer (TE Buffer: 0.01 M Tris/HC1 pH 8.0; 1 mM 
EDTA) containing 25 U/ml placental RNase inhibitor. The 
concentration of RNA was assessed by spectrophotcmetry (Pye Unican 
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SP 6-550 spectrophotometer) at 260 nm where an optical density of 
1.0 is equivalent to RNA at 40 }, g/ml. During this procedure certain 
precautions were taken to minimise the risk of contamination by 
ribonucleases, these involved; good'aseptic technique; the use of 
double distilled or a similar high quality water; heat sterilisation 
of glass wear and autoclaving of buffers and reagents where 
practicable. 
2.14. Denaturing Formaldehyde Gel Electrophoresis of RNA: 
Samples were prepared by mixing 4.5 pl of RNA in a MSE micro- 
centrifuge tube with 2.0 4 1X MOPS buffer (10X MDPS buffer: 0.2 M 
3-N-Morpholino-propane-sulphonic acid, pH 7.0; 0.05 mM sodium 
acetate; 0.01 mM EDTA); 3.5 pl 40% formaldehyde; 10 ul re- 
crystalised formamide (Casey and Davidson, 1977) and denaturing at 
55° for 15 min. After chilling on ice, the samples were mixed at a 
ratio of 5: 1 with sample buffer (50% (w/v) ficol; 1 mM EDTA; 0.25% 
(w/v) bromophenol blue) and applied to a pre-run horizontal 
denaturing formaldehyde agarose gel formed in the BRL mini gel 
apparatus (Lehrich et al., 1977). The 1% high melting point agarose 
gel was prepared in water by cooling a melted agarose solution to 
6000 before adding 5X MOPS buffer and formaldehyde to give a final 
concentration of 1X and 2.2 M, respectively. Electrophoresis was 
carried out in 1X MOPS buffer, ' at 50 V for 4h, after which the 
nucleic acids were stained by immersing the gel for 1h in 1 jig/ml 
ethidium bromide diluted in the tank buffer, and destained in fresh 
tank buffer for a further hour. The stained bands were visualised 
by transillumination with longwave UV light (365 nm) and 
photographed (polaroid film 667) using a red filter. E. coli 16S 
and 23S r RNA molecular weight markers were included on the gel. 
48 
2.15. Reverse Transcription of Purified RNA: 
cDNA copies of total infected cell RNA were prepared in 20 µl 
volume reverse transcription reactions. RNA (5 )1g) and (0.5pg) 
random hexonucleotide primers (Boehringer Mannheim, Lewes, UK) were 
incubated in the presence of 0.1 % dimethyl sulphaxide (EMSO) at room 
temperature for 3 min, before being added to pre-warmed reverse 
transcription mix containing 1X PCR buffer (Promega Corporation), 
(10X PCR buffer: 100 rrM Tris/HC1 pH 8.3; 15 rrM EC1,500 mM MOC12; 1% 
Triton X100: gelatin 0.1% (w/v)); 20 U placental RNase inhibitor 
(Sigma); 500 pM of each of dATP, drip, da and dGIP (Perkin-Elmer, 
Beaconsfield, Bucks. ); and 2.5 mM MgC12.20U of Moloney murine 
luekaemia virus reverse transcriptase (Pharmacia Biosystem Ltd, 
Milton Keynes, UK) was added and the reaction was incubated at 370C 
for 40 min. 
2.16. Polymerase Chain Reaction: 
The polymerase chain reaction was, used to amplify specific regions 
of cDNA containing the NS1 gene generated by reverse transcription 
(section 2.15). The limits of the amplified fragments were defined 
by 2 oligonucleotides which hybridised to opposite strands of the 
target sequence so that their 3' ends were towards each other. The 
20 pl PCR mix contained 44 of the reverse transcription product; 
1X TM buffer (Pranega Corporation) ;1 pM of each of both primer; 1 
U Tag DNA polymerase (Prcmega Corporation) and was overlayed with 
white paraffin oil (Sigma). When the cDNA template was provided 
from the reverse transcription reaction, the WIP mix present in 
that volume was sufficient for the PQR, however, when the template 
was provided from an alternative source, a 0.2 mM dNI'P mix (Prcmega 
Corporation) was supplied. During each PCR cycle, the cDNA template 
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was denatured at 9400 for 45sec, and primers allowed to anneal for 2 
min at a temperature calculate by assigning each A and T base of the 
primer 20C and each G and C base 4°C and subtracting 10°C from the 
sun. Once annealed, extension from the primers was performed for 4 
min at 720C. This three step cycle was repeated 30 times, after 
which the oil overlay was removed by chloroform extraction, and the 
DNA recovered by ethanol precipitation. PCR primers, sequencing 
primers and single stranded adaptors were kindly synthesised by 
J. M. Chamberlain using an Automatic DNA Synthesiser BT8500, (Biotech 
Instrumentation Ltd, Luton, Beds, UK). 
2.17. Restriction Endonuclease Digestion: 
Restriction endonucleases and their buffers were supplied by the 
Promega Corporation and used according to the manufacturer's 
instructions. 
2.18. Agarose Gel Electrophoresis: 
High melting point agarose (0.8% (w/v)) was melted in 1X Tris- 
borate-E[YTA (TBE) buffer (TBE buffer 10X: 90 mm Tris; 90 mM boric 
acid; 2.5 mM EDTA pH8.3) and poured in a horizontal mini gel 
apparatus (BRL) at a temperature of between 50°C and 60°C. DNA 
samples were mixed with 1/10 volume loading buffer. (10% ficol (v/v); 
0.05% brcmophenol blue (w/v)) prior to electrophoresis. Following 
electrophoresis at 80 V for 1 h, the nucleic acids were stained with 
ethidiun branide staining and visualised under a UV light source as 
described in section 2.14. 
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2.19. Elution of DNA fragments from Agarose gels: 
cDNA was recovered from agarose gels by electroeluticn. Following 
ethidium bromide staining, the required DNA fragments were excised 
precisely fron the gel and placed into a dialysis bag with 1/2X THE 
buffer. The bag was immersed in 1/2X TEE buffer so that it was 
perpendicular to the electrodes. Electroelution was achieved 
following the application of 50 V for 30 min, with the current's 
polarity being reversed for the last 30 sec to detach any cDNA 
adhering to the inner wall of the bag. The buffer and eluted cDNA 
were removed from the bag and the DNA recovered by ethanol 
precipitation. 
2.20. Ligation of DNA Molecules: 
Following the linearisation of plasmid vectors, they were treated 
with bacterial alkaline phosphatase (GibcoBRL) according to the 
manufacturer's instructions to prevent self-ligation. The cDNA 
inserts and linearised vectors were then mixed at a concentration of 
5: 50 pg/ml, respectively, in 25 pl volume of ligase buffer (Promega 
Corporation) (10X ligase buffer: 300 mM Tris/HCl pH 7.8; 100 mM 
MgC12; 100 mM DTT; 10 mM ATP) and using two units T4 DNA Ligase 
(GibcoBRL). The ligation reaction was allowed to proceed at 150C 
temperature overnight. 
2.21. Preparation of Adaptors: 
Adaptors were supplied as single-stranded DNA molecules. The 
palindremic nature of these oligonuceotides allowed molecules to 
self-anneal to form double-stranded molecules. In a two step 
reaction, 1 dug of adaptor in 1X kinase buffer (kinase buffer 1OX: 
500 mm Tris/HC1 pH 9.0; 100 mM MgC12; 50 mM Drr; 1 mM spermidine) 
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containing 1 mM ATP and 200 U T4 polynucleotide kinase were first 
phosphorylated when the reaction was incubated at 370C for 30min. 
Followed 5 min in a water bath at 950C, the water bath was turned 
off and the oligonucleotides allowed to anneal overnight. 
2.22. Transformation of Competent Cells: 
Circular recombinant plasmid DNA was used to transform competent 
E. coli, according to instruction supplied by the appropriate 
manufacturer (GibcoBRL or Prcmega Corporation). Briefly, 54 of 
the ligation reaction, diluted 5-fold in TE buffer, was mixed with 
100 p1 of competent cells and placed on ice for 30 min. Following 
heat shock at 420C for 45 sec, the cells were returned to ice and 
after 2 min the cells were gently added to 0.9 mls warmed L broth 
which was shaken at 37cC for 1 h. 'Ihe cells were then plated onto L 
agar containing 50 µg/m1 ampicillin to select for colonies 
containing plasmids. 
2.23. Small Scale Plasmid Preparation: 
Rapid, small scale plasmid preparations were obtained from a 
single host bacterial colony based on the method of Birnboim and 
Doly (1979). Single colonies were picked and overnight cultures 
grown in L broth ccntaining 100 pg/ml ampicillin. Cells fran 1.5 ml 
of each culture were recovered by centrifugation in a MSE micro- 
centrifuge (12,000 rpm), resuspended in 100 p1 25 mM Tris/HC1 pH 
8.0; 500 mM ESA; 50mM glucose and placed on ice. After 5 min, 200 
p1 1% SDS (w/v) in 0.2 M NaOH was added, followed by 150 p1 3M 
Sodium acetate pH 4,. 8,5 min later. After 10 min the supernatant 
was clarified by centrifugation (121000 rpm, 5 min), and harvested. 
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The DNA was recovered from the clarified supernatant by ethanol 
precipitation and the resulting DNA resuspended in TE buffer for 
analysis. 
2.24. Large Scale Plasmid Preparation: 
Large amounts of purified plasmid DNA were prepared using a 
protocol which followed that of Chewell and Helinski (1969). 
Individual cloned bacterial colonies were picked and grown overnight 
in 3 ml L. broth (containing 100 pg/ml ampicillin) in a shaking 
incubator at 37CC. Next day, each overnight culture was made up to 
500 ml with L. broth (plus ampicillin) and further incubated with 
shaking until the OD 650 reached 0.9, when chloroamphenicol (Sigma) 
(75 mg/ml in ethanol) was added to a final concentration of 75 
pg/ml. The cultures were incubated for another 12 h before being 
harvested by centrifugation at 8000 rpm, 4CC for 15 min in a Sorval 
GSA rotor (Durctit, Stevenage, Herts) and resuspended in 2 ml of 25% 
(W/v) sucrose and 50 mM Tris/i-C1 (pH 8.0). After 5 min 0.3 ml of 20 
Mg/ml lysozyme (Sigma) in 0.25 MEA was added. The suspension was 
intermittently agitated an ice over a period of 5 min after which 2 
ml of 0.25 M IDTA was added. Cells were lysed after 5 min by the 
addition of 3 ml lysis solution (1% Brij 58 (w/v); 0.4% Na 
deoxycholate (w/v): 10 mM Tris; 1 mM EDTA), followed'by vigorous 
mixing and incubated cri ice for 20 min. Cell debris was removed by 
centrifugation at 15,000 rpm at 40C for 45 min (Sorval SM24 rotor) 
and the clarified lysate decanted. Solid CsC12, to a final 
concentration of 0.95 g/ml was added together with 100 ul of 
ethidium bromide (200 pg/ml) to the lysates. Samples were then 
transferred to Ti56 polymer tube (Beckman, High Wycc e, Bucks, UK). 
The tubes were heat sealed and centrifuged at 38000 rpm for 60 h. 
53 
Following centrifugation, the tubes were examined under aW light 
(366 nm wavelength) and the plasmid containing lower, fluorescent 
band aspirated. 
Plasmid DNA was extracted 3 times with propan-2-ol (Meridick) 
saturated with CsC12 from this band and dialysed 3X against 200 
volumes of TE buffer. To determine DNA concentration the absorbance 
of the plasmid preparation was measured at 260 nm and 280 nm. 
2.25. DNA Sequencing: 
TBEV cDNA within plasmids were sequenced by overlapping primer 
extension reactions which between them spanned the entire length of 
the CDNA insert (Fig. 3.11). Apart fron the primers, reagents were 
supplied in the United States Biochemical Corporation's (Cleveland, 
Ohio, USA) Sequenase version 2.0 kit. For each template reaction, 
3-5 jig of the plasmid DNA was denatured by incubation in 0.2 M NaOH 
at 37 CC for 30min. The reaction was neutralised by a 0.1 volume of 
2M ammonium acetate pH 4.5 and the denatured DNA recovered by 
ethanol precipitation. After washing with ethanol, the DNA was 
redissolved in 74 water to which 24 5X Sequenase reaction buffer 
(5x Sequenase reaction buffer: 200 mm Tris/HC1 pH 7.5; 100 mM MMCl 2; 
250 mM NaCl) and 14 sequencing primer (0.5 pM) were added. The 
primer annealed to the denatured plasmid during a2 min incubation 
at 65 CO. The reaction was then allowed to cool before 1 pl of 0.1 M 
DTT; 2 }ll of 1X labelling mix (labelling mix: 7.5 pM dATP; 7.5 PM 
dCIP; 7.5 pM drrP; 7.5 pM d MP); 0.5 yl [35S ]-dATP (5 pCi) (Mersham 
international PLC, Aylesbury, Bucks) and 24 Sequenase diluted 1/8 
with enzyme buffer (Enzyme buffer: 10 mM Tris/HCl pH 7.5; 5 MM DTT; 
0.5 4/ml BSA) were added. The concentration of labelling mix was 
varied to allow sequencing near to the primer (0.05-0.1X) or further 
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fron it M). Primer extension proceeded at roan temperature for 3- 
5 min, before 2.5 ul of the reaction was added to each of 4 
prewarmed tubes containing 80 pM of 1 of the 4 termination mixes 
(ddATP, ddCTP, ddGTP, ddTTP). The termination reactions were 
incubated for 5 min at 3700 and were stopped with 4 }il of stop 
solution (95% formamide; 20 mm EDTA; 0.05% bromophenol blue; 0.05% 
xylene cyanol FF). 
Prior to analysis on a pre-heated sequencing gel each sample was 
boiled for 2 min. Electrophoresis of the sequencing reactions was 
carried cut in a 376 an X 17 an X 0.2 an vertical polyacrylamide gel 
apparatus (Raven). Gels were prepared from 50 ml of a 6% (w/v) 
acrylamide/bis acrylamide stock solution containing 8M urea and 
TEE buffer, and polymerised by the addition of 150 j il of 10% (w/v) 
ammonium persulphate and 50 ßi1 N, N, N', N'-tetramethylethylenediamine 
(7 D) (Sigma). An inverted sharks tooth comb was inserted into 
the top of the gel. Once set, electrophoresis took place in TEE 
buffer at 1100 V for 4-6 h (Pharmacia 3000/150 power supply). The 
electrophoresed sequencing gels were fixed in methanol 10% (v/v); 
acetic acid (10% v/v) solution for 10 min, before being placed onto 
3MM paper (Whatmann, Maidstone, Kent) covered with Saran Wrap 
(Genetic Research Instrumentation, Dunmow, Essex) and dried under 
vac u ni at 80cc. The dried gels were compressed and sealed in a film 
cassette holder, which immobilised them under X-ray film (Amersham 
International PLC). Autoradiographs were developed using Kodak DX80 
developer and FX40 fixer. 
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2.26. DNA Transfection of Eukayotic Cells: 
The calcium phosphate DNA transfection methodology was developed 
by Graham and Van der Eb (1973). 10 pg of plasmid DNA was dissolved 
in 210 4 0.5 mM EDTA; 1 mM This pH 7.5 and pipetted into a 10 ml 
polypropylene tube (Falcon). The tube was gently vortexed as 30 p1 
of 2M CaC12 was added drepwise to the DNA solution. This mixture 
was in turn, added dropwise to a tube containing 240 )jl of 2X HBS 
buffer (280 mM NaC1; 50 mm Hepes: 1.5 mM Na2HP04 pH 7.12) during 
vigorous vortexing. A precipitate was allowed to form at room 
temperature and after 30min the transfection mixture was added 
directly to the culture media of cells which had been seeded onto a 
50 mm Petri dish 24 h before to produce an 80% confluent monolayer. 
The transfection mixture was removed following an overnight 
incubation at 37CC and the cells washed once with PBS, and once with 
caiplete media. Fresh media was then added and the cells incubated 
a further 24 h before being analysed for expression. 
I- I 
2.27. Production of Infected Cell Lysates: 
Cells were washed with PBS before being removed from their solid 
support with a rubber policanan into PBS. The suspended cells were 
recovered from PBS by a2 min gentle centrifuged in an MSE Micro- 
centrifuge at 65002 and resuspended in 100 }. l1 of buffer (0.15 mM 
NaCl; 0.1 M Tris pH 7.5; 1 mM EDTA) to which 20 ug/ml of the 
protease inhibitor phenylmethylsulphonylfluoride (PMSF) and NP40 
(final concentration of 1% (w/v)) had been added. The cells were 
lysed by vigorous vortexing for 30sec, the debris removed by 
centrifugation, and supernatant stored at -20°C. 
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2.28. Indirect Immunofluorescence: 
Cells grown on glass coverslip were washed once in PBS and fixed 
by immersion in acetone for 30 sec. Fixed cells were first 
incubated for 1h with the appropriate anti-NS1 monoclonal 
antibodies prepared fron tissue culture supernatant (diluted 1: 50 in 
PBS), before being washed in PBS (30 min) and then incubated for 1h 
with fluorochrome-conjugated goat anti-mouse IgG (Sigma) diluted 
1: 500 in PBS. The cells were washed once more and the coverslips 
mounted in 95% glycerol. All incubations and washes were performed 
at 37°C in a moist chamber. The cells were examined by UV light 
microscopy. Photographs were taken using Leitz Dialux 20EB 
microscope with appropriate filters and attachments. 
Imnunofluorescence was also used to demonstrate the presence of 
antigens on the cell suface. PBS washed cells were fixed for 15-30 
min with freshly prepared 2% solution of fixative (10% (w/v) 
methanol free paraformaldehyde solution made up in a corning plastic 
tube was gently heated in a water bath, NaOH was added until the 
paraformaldehyde dissolved after which 10 ml of the paraformaldehyde 
was added to 9.7 ml of water and 30.3 ml of PBS and keeped on ice 
until required). The fixed cells were rinsed well with PBS and 
covered with 1% BSA in PBS for 15 min (blocking buffer). The 
blocking buffer was gently aspirated and antibody (1: 50 in PBS) 
added to the cells for 45 min. The cells were again washed in PBS 
and 1% BSA in PBS before being incubated for 45 min in fluorothrcn--- 
oonjugated goat anti-mouse Ig3 diluted 1: 500 in PBS. The conjugate 
was then rinsed off and the cells washed well in PBS before being 
mounted in 95% glycerol and examined by UV microscopy. 
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2.29. Radio-Labeling of Virus-Infected Cells: 
Uninfected and RAd51-infected cells were grown in methionine-free 
a i. i (Imperial Laboratories) supplemented with 2% FCS, and 2 mm 
glutamine, under 5% C02/air prior to the addition 250 pCi of [35S] 
methicnine (Amersham International PLC) in a minima]. amount of fresh 
methionine free medium. After the pulse, cells were rewashed'and 
returned to the incubator in fresh maintenance media. 
2.30. Immunoprecipitation of NS1 From Radiolablled Cells: 
Im ur precipitaticn experiments were performed on [35s] methionine 
radiolabelled infected-cell lysates (section 2.29) and directly on 
labelled cell culture supernatants. Cell lysates (100 ul) or 
supernatants (0.5 ml) are reacted for 1h on ice with an anti-NS1 
monoclonal antibody pool containing the monoclonal antibodies; T12, 
T33/1, and T33/3 (Stephenson et al., 1984). The antibody: antigen 
ca plexes were captured on protein A- and protein G- Sepharose beads 
(Phannacia) during a1h incubation at 4°C. The beads were then 
washed three times with PBS, and recovered by 5 min centrifugation 
in an MSE micro-centrifuge (12,000 g) before being resuspended in 
PAM sample buffer (section 2.23) containing 0.5% 2-mercaptoethanol. 
The protein were released fron the beads by boiling for 10 min prior 
to SDS PAGE (section 2.33). Following electrophoresis, the gel was 
dried down under vacuum and subjected to autoradiography (section 
2.25). 
2.31. Endoglycosidase Treatment of PS1: 
Glycosidase F (glyorF; end*F (EC 3.2.1.96] and -9lycosidase F [EC 
3.2.2.18) and endoglycosidase H (enäd-I; [EC 3.2.1.96] reactions were 
carried out according to the manufacturer's instructions 
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(Boehringer). Briefly, immunoprecipitated radiolabelled NS1 (100 
p1) released and separated from the Sepharose beads by boiling 
samples for 10 min in '400 }il of SDS (0.1% (w/v)) followed by 
centrifugation in an MSE micro-centrifuge. 100 p1 of the recovered 
protein was treated with 0.1 U of glycoF in 0.25 M sodium acetate; 
20 mM EDrA, 1WM 2-mercaptoethanol, (pH 6.7) or with 0.03 U of endcH 
in 50 mM sodium acetate (pH 5.5); 1 mg/ml of BSA, (pH 5.5), 20 pg/ml 
PMFS and 25 Ug/ml aproteinine were added and the reaction incubated 
for 24 h at 370C before analysis by SDS PAGE (section 2.35). 
2.32. Ultra-Violet Light Treatment of Virus Stocks: 
tN irradiation of RAd51 stocks was performed using a purpose built 
apparatus. 10 ml of virus was pipetted into a 100 an diameter petri 
dish which was placed on a rocking table situated 30 an from the W 
light source. The gentle rocking motion of the table ensured that 
the virus suspension was evenly irradiated. The W light source 
delivered 1.5 mW/cm2 which is equal to 1.5 pJ/nmq2 per sec. Samples 
from the same RAd51 stock (titrated at 107 pfu/ml) was irradiated 
for Os, 60 sec (0.9 m7/mn 2) , 120sec (1.8 m7/mn2), 5min (4.5 m7/mm2), 
10min (9.0 m7/m2) and 15min (13.5 m7/mn2). 2 ml of each radiated 
sample was inoculated into 293 cells grown on glass coverslip and 
test by immunofluorescence for expression of the NS1 antigen or 
titrated in 293 cells as a test of virus infectivity. 
2.33. Poly-Acrylamide Gel Electrophoresis (PAGE): 
A SDS polyacrylamide resolving gel (10% (w/v); acrylamide; 0.3% 
(w/v) bis acrylamide; 375 rim Tris/HC1 pH 8.8; 0.1% (w/v) SDS) was 
polymerised by the addition of 0.1% (w/v) ammonium persulphate and 
0.0445% (v/v) ZEMED, and poured into the required size mould. The 
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gel was carefully overlayed with isobutanol (Meridick) to ensure a 
level surface and allowed to set. The isobutanol was then poured 
off and a stacking gel (5% (w/v) acrylamide; 0.15% (w/v) bis 
acrylamide; 130 nm Tris/HC1 pH 6.8; 0.1% (w/v) SDS) polymerised by 
the addition of 0.1% (w/v) ammonium persulphate and 0.01% (v/v) 
m ED, added. The gels were run in buffer contained Tris-glycine 
buffer (25 mM Tris pH 8.3; 250 mM glycine; 0.1% SDS) and the samples 
prepared in 1X sample buffer (10X sample buffer: 1% (w/v) SDS; 50% 
(v/v) glycerol; 0.15% (w/v) bromophenol blue). Samples were not 
boiled in reducing agent prior to electrophoresis, since this 
treatment destroys epitopes recognised by the anti-NS1 monoclonal 
antibodies T12, T33/1 and T33/3 and suggesting that these antibodies 
recognise conformational dependent epitopes. The apparent molecular 
weights of the sample proteins was established relative to 
prestained markers proteins (BioRad, Hemal Hempsted, Herts). 
A gradient SDS PACE czmprising of an acrylamide gradient from 5% to 
15% was prepared using a Buchler gradient maker (Buchler Industrial 
Inc, Fort Lee, New Jersey, USA). A 5% gel (5% (w/v) acrylamide; 
0.15% (w/v) bis acrylamide; 375 nti Tris/Hcl pH 8.8; 0.1% SDS) and a 
15% gel (15% (w/v) acylamide; 0.45% (w/v) bis acrylamide; 375 mM 
Tris/Hcl pH 8.8; 0.1% SDS) were mixed in the gradient maker 
immediately following polymerisation with 0.1% (w/v) ammonium 
persulphate and 0.008% or 0.004% TFiMED respectively, and pumped into 
the gel former. The gel was overlayed with isobutanol and a 
stacking gel added as described above. 
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2.34. Coomassie staining of SDS Poly-Acrylamide Gels: 
When required the presence of proteins on SDS polyacylamide gel 
was demonstrated by stained with coomassie blue R-250 (Sigma). 
Following electrophoresis the stacking gel was removed and the 
resolving gel fixed and stained by immersicn in 0.25% cocmassie blue 
R-250 in methanol, acetic acid and water (3: 1: 6) for 2h at room 
temperature. After overnight destaining in the stain solution 
without cocmaassie blue, the gel was dried under vacui n for storage. 
2.35. Western Transfer Experiments: 
Proteins separated by SAS PAGE were electrophoreticallY transferred 
to a nitrocellulose membrane (Hybcnd C plus, Amersham International 
PLC) essentially according to Burnette and Dunn (Burnette and Dunn 
1986). The nitrocellulose filter was immersed in transfer buffer 
(25 mM Tris; 190 mM glycine; 20% methanol (v/v)) for 2 min before 
construction of a 'sandwich' of scotchbrite pad; filter paper (2 
sheets); gel; nitrocellulose filter; filter paper (2 sheets); 
scotchbrite pad. The 'sandwhich' was placed into a BicRad Transblot 
apparatus with the nitrocellulose filter between the gel and anode 
and immersed ccnpletely in transfer buffer. Transfer was achieved 
by the applicaticn of 30 V (0.12 amp) overnight at roan temperature. 
Western blots were washed in washing buffer (PBS containing 0.3% 
(v/v) Tween 20; 3% (w/v) and solid milk powder (Cadbury's) at roan 
temperature for 1 h., The blots were immersed for a second h in 
washing buffer containing 10 pg/mi of the appropriate antibody after 
which they were washed 3 times in blocking buffer, and incubated for 
1h in washing buffer containing anti-mouse IgG horseradish 
peroxidase conjugate (Amersham International PLC). Finally, the 
filter was washed once in washing buffer and 4 times in PBS, and 
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drained well. Equal volumes of the Chemiluminescent detection 
agents A and B (Amersham International PLC) were mixed and applied 
to the nitrocellulose. After 1 min agitation, the agents were 
poured off and the filter wrapped in Saran Wrap before exposure to 
X-ray film which was developed as in section 2.25. 
2.36. Nice Strains: 
Female Balb/C mice were obtained from Harlan Olac, (Bicester, 
Oxon. ) and used at 4-6 weeks old. Haemolytic complement positive 
mice (sufficient) and mice lacking the complement C5 receptor 
therefore devoid of haemolytic complement activity (deficient) 
(reviewed in Rosenberg and Tichibana, 1986) were provided as the 
congenic mouse pair B10 D2 sufficient (NSN) and B10 D2 deficient 
(OSN) by Jackson's Laboratory, Bar Harbour, Maine, USA. 
2.37. In Vivo LDS0 Assay of TBEV: 
A group of 10 mice was injected subcutaneously with 200 Al of 
virus from a single dilution in a 10-fold series. The mice were 
maintained until a hind leg paralysis occurred and death was 
imminent, when they were sacrificed. Cne LD50 dose was calculated 
using a modification of Reed and Meunch method (Reed and Meunch, 
1938). 
2.38. Recombinant Adenvirus Immunization Schedule: 
Mice were immunised with recombinant adenoviruses by inoculating 
107 pfu of virus diluted to 100 }il with PBS into the intra- 
peritoneal cavity (IP). This inoculation protocol was repeated 
after 1 and 3 weeks. Serum was obtained from blood samples 
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collected from terminally anesthetised mice by cardiac puncture. 
The serum was separated by centrifugation (3000 rpm) in serum 
separation tube (Becton Dickinson). 
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CHAPTER 3. Results 
64 
3.1. Cloning, Sequencing and Transient Expression of the TEEV NS1 
gene: 
3.1.1 Overview: 
In order to identify the TBEV NS1 it was necessary to generate a 
cDNA construct containing the NS1 gene. Total cytoplasmic RNA was 
purified from TBEV-infected cells, and reverse transcribed using 
random primers. From the TBEV gencmic RNA, a cDNA fragment of 1,891 
bp, containing the canplete NS1 gene together with part of the E and 
NS2a genes (F NS12a) was generated by PCR. Initially, PCR generated a 
truncated fragment with a 858 bp deletion which mapped to a region 
with potential to encode a hairpin loop in the corresponding RNA 
molecule. The treatment of RNA with DMSO in the presence of random 
primers prior to the reverse transcription reaction was found to be 
necessary for efficient generation of the full-size cDNA fragment. 
Restriction endonuclease cleavage sites within the PCR primers 
facilitated cloning of the PCR-amplified fragment into the vector 
pMIZ23 (Fig. 3.1). pMIL23 is based on the p(X series of vectors, but 
contains a different polylinker region providing alternative cloning 
sites (Chambers et al., 1988). The fragment FENS12a was cloned into 
pMrL23 generating plasmid pMV40. The sequence of the cloned TBEV 
fragment was determined and found to be in agreement with the 
published results (Mandl et al., 1989), except for a translationally 
silent change from T to A as base 3265. 
To ensure that the NS1 coding sequence was correctly identified five 
additional viral DNA constructs in which the putative NS1 ORF was 
presented in a different context were generated by PCR using FENS12a 
as the template, including; the NS1 gene embedded within a long ORF, 
the gene without additional 31 coding sequence, the gene without 
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additional 51 coding sequence, the gene without a translocation signal 
sequence, and the predicted coding region. The inclusion of 
appropriate translational start and stop codcns on each NS1 construct 
to be expressed was achieved by encoding them within the PCR primers 
or by addition of the adaptor L1. The generation of these various 
constructs permitted the identification of elements required for 
appropriate expression of NS1 in a transient expression system before 
going on to construct a recombinant adenovirus. Each fragment was 
checked by DNA sequencing to ensure PCR had not generated a mutant 
before being cloned under the control of the C1KV major IE promoter in 
the transient-expression vector pvV100 (Wilkinson and Akrigg, 1992) 
(Fig. 3.2). In pMV100, the polylinker of pUC19 has been replaced by a 
fragment containing the CMV major IE promoter (-299 to +69) and its 
associated polyadenylation signal (+2757 to +3053). Nucleotide 
sequence numbering of the QW major IE gene is as described by Akrigg 
et al ., (1985). Two BamHI sites and an >baI site are situated between 
the IE promoter and polyadenylation signal to facilitate cloning into 
the expression vector. Each TBEV cDNA fragment was cloned into i. W100 
at the xbaI restriction site and the resultant plasmids transfected 
into 239 cells. Expression of the NS1 gene product was assayed by 
immunofluorescence. 
The CMV major IE prCmoter was chosen to drive expression for it is 
an extremely powerful constitutive promoter. The strength of the 
promoter lies in its enhancer element which contains an array of 
imperfect 16,18,19 and 21 imperfect bp repeats (Reviewed in 
Wilkinson and Akrigg, 1991). The 18 and 19 bp repeats bind 
transcription factors, this binding can be stimulated by various 
agents including forskolin and significantly enhances yields of 
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proteins under its control (Wilkinson and Akrigg, 1992). Furthermore 
the CMV IE promoter can function in a wide range of cell types, 
although the host range of CMV is extremely limited. 
3.1.2. Extraction of Total RNA From TBEV-Infected Cells: 
PS cells were infected with the TBEV Neudörfl strain at 0.1 
pfu/cell. Total cytoplasmic RNA purified from infected PS cells as 
described in section 2.13, and was examined by formaldehyde gel 
electrophoresis (Fig. 3.3). The presence of discrete bands 
corresponding to 28S and 18S cellular ribosomal (r)RNA purified from 
mock-infected PS cells, suggested that the viral RNA in the sample may 
also be intact. 
3.1.3. Production of TBEV cDNA: 
First strand synthesis of cDNA was generated by a reverse 
transcription reaction in which total cytoplasmic RNA was treated with 
DMSO as described in 2.15. It was not necessary to directly assess 
the efficiency of this reaction as a successful PCR would imply a 
efficent reverse transcription reaction. 
3.1.4. PCR Amplification of the TBEV NS1 Gene: 
Since the PCR primers used in this study were annealed at 
temperatures higher than the annealing temperature required by randcm 
primers, it was not necessary to remove the random primers fron the 
reverse transcription reaction, before it was used in PCR. Using the 
DIA sequence data (and the co-ordinates) of the Neud6rfl strain genome 
given by Mandl and o>-workers (Mandl et al., 1988 & 1989), a 1,891 bp 
cDI frag ent ocntaining 33% of the 3' end of the E gene, the cxnplete 
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2W, 
18S 
6S 
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Fia. 3.3. Formaldehyde Gel Electrophoresis of Total Cytoplasmic RNA: 
RNA purified fron TBEV-infected PS cells was subjected to formaldehyde 
gel electrophoresis (Lane 2). 28S and 18S rRNA markers obtained from 
mock infected PS cells are shown on the right (Lane 3) and E soli 23S 
and 16S rRNAs are shown on the left (Lane 1). 
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NS1 gene, and 79% of the NS2a gene (FENS12a) was identified as 
encoding all the elements required for efficient expression of NS1 
(Fig. 3.4). Fragment FENS12a was amplified by PCR using primers P1 
and P2 (Fig. 3.4) and conditicns described in section 2.16. Primer P1 
is homologous to the 26 bases downstream of the nucleotide 2096 cn the 
positive cDNA strand of the E gene, while primer P2 is complementary 
to 25 bases on the positive cDNA strand ending at nucleotide 3987 in 
the NS2a gene. Primers P1 and P2 also certain additional 5' sequence 
elements designed to provide the PCR-generated DNA fragment FENS12A 
with flanking MllII restriction endonuclease cleavage sites. To 
assess the product from each PCR reaction a2 pl aliquot was examined 
by electrophoresis on a 1% agarose gel (Fig. 3.5, Lane 6). 
3.1.5. Cloning of FENS12a into pMTL23: 
The 1,891 bp DNA PCR fragment generated using primers P1 or P2 
lacked translational signals and the XbaI restriction endonuclease 
sites necessary for cloning into pMI'L23. This deficiency was remedied 
by the ligation of the palindremic adaptor L1 to FENS12a (Fig. 3.4). 
The adaptor L1 contained pre--fanned BBlII restriction site at each end 
and an XbaI site at the centre. Upstream of the XbaI site was a 
nucleotide sequence encoding a translational stop codon (TAA) and 3' 
to the XbaI restriction site was a translational start codon (ATG). 
Following PCR amplification the TBEV cDNA fragment generated, FENS12a, 
was recovered from PCR by ethanol precipitation. The dried 
precipitates were resuspended. in &glII digestion buffer and treated 
with the endonuclease Bg1II. The digested cDNA fragments were 
purified by agarose gel electrophoresis and electro-elution. Double 
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E Nst NS2a I 
953 2441 3497 4187 
FENS I 2a 
FENS1 
FNSI2a 
FNS1 
FSNS12a 
FSNS1 
2096 Lt/P1 
2096 L1/Pi P4 
2441 P3 
2441 P3 P4 
P2/L1 3987 
3496 
P2/Lt 3987 
3496 
2366 P5 P2/L1 3987 
2366 P5 P4 3496 
oligonucleotides used: 
P1 GGGCC(AGATCT)?. TCATCTATGTTGGGGAACTGAGTCA 
P2 GCGCGC{AGATCT)GCTGTGTCATGAGAGCCATGAGCA 
P3 GGCC(TCTAGA]ATGGATCTTGGTTGCGCTGTCG 
P4 GCGCC(TCTAGA]TTACGCAACCACCATTGAGCGAAC 
P5 GGGCAGA(TCTAGA]ATGAGAAACCCTACAATGTCC 
L1 GATCT)CATAA(TCTAGA]TTATG(A 
[J XbaI endonuclease cleavage site. 
{I BglII endonuclease cleavage site, in L1 sticky end only. 
ATG/TAA Initiation/ termination codons, TTA is the complementary 
form of the termination codon. 
TBEV nucleotide sequence. 
Fig. 3.4. Mao of the TEE; NS1 cDNA Fracments Generated by PCR: At 
the top of the figure is sown the location of the TEE, V gene products 
encoded by this portion of the gencme (E, NS1 and NS2a). Vertica 
lines der to putative cleavage sites, pile numbers below indicate t: e 
first nucleotide of each gE e. The batched region represents the 2 
amino acid translocaticn signal sequence. PCR DNA fragment 
designatirns are listed on the left and on the right are maps of the 
sequence encoded by the fragment. The numbers adjacent to the 
fragments irxiicate its first and last nucleotide. The DNA fragments 
FENS12a, FENS1, FNS1, FRYS12a and FSNS1 were generated using the 
"oligonucleotide primers P1 to P5, as it cated" The adaptor L1 was 
self-annealed and ligated to the PCR-ger'. erated fragments as indicated 
to provide either a trans. larrrnal start cr stcP ox1n, as appropriate. 
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Fiq. 3.5. Assessment u red TBEV cDNA by Agarose Cz_. 
electrophoresis: Following amplification, DNA was separated on a 1% 
agarose gel and strained with ethidium bromide. A control DNA 
template from dengue virus gencmic cDNA and appropriate primers is 
shc)wn in Lane 2. An approximately 1.0 kb DNA fragment (Lane 3) was 
generated by PCR in which the template was provided from a reverse 
transcription reaction primed by the primer P2. No DNA fragment was 
generated by PCR when the reverse transcription reaction providing the 
PCR template was primed with P2 but not treated with DMSO (Lane 5). 
When the TBEV-infected cell RNA was treated with 0.1% DMSO for 5 min 
at roan temperature prior to the reverse transcription reaction, and 
random primers were included in the reaction, the full 1.891 bp viral 
DNA, fragments (Lane 6) was generated by £(R with this template. When 
in addition to the condition used to generate the cDNA fragment in 
Lane 6, P2 had been added to the reverse transcription reaction 
generating a 1.0 kb and 1891 bp fragment (Lane 4). Molecular weight 
markers are shown on the left (Lane 1) and all sizes are in kb. 
73 
123456 
stranded, phosphorylated L1 adaptors, prepared as described in 2.21, 
were ligated to the viral cDNN at a ratio of 2 pg of adaptor per 2 pg 
of viral cDNA in order to generated the following DNA molecule: 
5' 3' 
BS]I - A-RbaI-A`I - 1II L1 /FENS12a/L1 P91II-TAA-XbaI-ATG-B, S1II 
L1 I TBEV DNA I L1 I 
The viral cDNA ligated to the adaptor was recovered from the 
ligation reaction by ethanol precipitation, and digested with XbaI. 
Digestion with XbaI removed the translational stop codon from the 5' 
of L1 /F NS12a/L1 and the translational start codon from the 3' end of 
L1/FENS12a/L1, and facilitated cloning of the fragment into the 
plasmid vector pMI'L23 at the plasmids unique XbaI restriction site 
(Fig. 3.6). 
Competent E. coli cells, transformed with 1v! IL23 containing the TBEV 
cDNA fragment L1/FENS12a/L1, grew as white colonies when plated onto 
L-agar containing 5-gal and IPTG. White colonies resulted from 
disruption of the lac Z gene by the insertion of the viral construct 
and permitted positive selection of recombinant plasmids. Individual 
white colonies were harvested and amplified. A plasmid, pMV40, was 
recovered from the transformed cells in a small scale plasmid DNA 
preparation and the presence of L1/FENS12a/L1 insert in pMV40 was 
demonstrated by examination of XbaI digested FW40 on a 1% agarose gel 
(Fig. 3.7, Lane 1). 
In addition to cloning the NS1 gene of the Neudorf1 strain, a 
similar DNA fragment FiMiS12a, containing the NS1 gene from the TBEV 
K23 strain was also generated. FKENS12a was. generated by reverse 
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E AM NSI NS2a 
FENS 12a 
/ 
E NSl ý NS2a 
0 FKENS 12a 
On 
FENS 12a 
pMV40 
\ 
APR 
ý/ / FKENS12a 
pMV56C 
Ori 
AmpR. 
Fig. 3.6. Schematic Re presentation of the Cloning of L1/FENS12a/L1 
and L1 /FKENS12a/L1 into t1ITL23: Cloning of L1 /FENS12a into the XbaI 
site of pMV23 generating p W40, is indicated by the continuous line cn 
the left. Cloning of L1/FKENS12a/L1 into pMTL23 at the XbaI 
restriction site, generating p1V56C, is indicated by the broken line 
on the right. 
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4.0 
3.0 
2.0 
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Fia. 3.7. XbaI Digest of ýMV40 and pMV56C: XbaI-digested pMV40 and 
pMV56C electrophoresed through a 1% agarose gel demonstrated the 
presence of the 1891 bp DNA fragment FENS12a in pMV40 (Lane 1) and the 
1891 bp fragment FKENS12a in pW56C (Lane 2). Molecular weight markers 
show in the left hand lane. The size of several markers, in kb, is 
indicated by numbers to the left of the figure. 
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1z 
transcription and PCR fron TBEV strain K23-infected cell RNA using the 
same primers P1 and'P2. Adaptors L1 were ligated to FKENS12a as 
described for the fragment FENSS12a allowing L1/KFENS12a/L1 to also be 
cloned into pMTL23 at its unique XbaI restriction endonuclease 
cleavage site, generating p4V56C (Fig. 3.6, Fig. 3.7, Lane 2). The 
nucleotide sequence of the K23 cDNA fragment in pMV56C was then 
determined. 
3.1.6. Nucleotide Sequence Analysis of the Ns1 Gene Fron the &"3i rf1 
and K23 TBEV Strains: 
pMV40 was denatured with NaOH prior to sequencing to allow the 
sequencing primer access to its complementary sequence. After the 
primer had annealed and the sequencing reaction had been completed, 
samples were boiled and subjected to electrophoresis. The gels were 
then dried down and visualised by autoradiography. Reading of the 
sequence was performed manually. The nucleotide sequence of viral 
fragment cloned into pMV40 was obtained from a number of primer 
extension reactions, the strategy for which is illustrated in Fig. 3.8 
and Fig. 3.9. Since the nucleotide sequence of the Neud6rfl strain 
had been published previously, only one strand of FENS12a was 
sequenced. The nucleotide sequence of both the positive and negative 
strand of the K23 strain NS1 gene in FKENS12a was determined as the 
1<23 sequence had not been determined previously. The strategy used to 
sequence the MS1 gene frvn the 123 strain was the, same as that for the 
Neudorfl strain. 
The nucleotide sequence of the cloned Neudorfl cDNA fragment FENS12a 
in pMV40 was found to be in agreement with the published results 
(Mandl et al., 1988 & 1989a), except for a translationally silent 
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Univ > -Strl-> -Inv6 > 
E> -Str3-> -Inv7 > 
-Str2-> -Inv5-> 
E Gene I NS1 I NS2a 
2096 2296 2496 2696 2896 3096 3296 3496 3696 3896 3987 
<Invl- 
<-Inv4 < Univ 
<-Inv2 - <-Rev1 
<-Inv3b -< Rev2 
Fig. 3.8. Strategy for Sequencing NS1: All sequencing primers were 
complementary to both the Neudbrfl and K23 strains. Individual 
primers are denoted by the lettering shown over the arrows while the 
length of each arrow indicates the region of sequence obtained by 
primer extension fron that primer. The sequence of each primer is 
shown in Fig. 3 . 9. The flavivirus genome is depicted by the 
continuous line. The location of the gene products encoded by this 
portion of the genome (E, NS1 and NS2a) are shown, while the vertical 
line (I ) denotes putative cleavage sites. The numbering below the 
gencme is that of the nucleotide sequence fron the Neud6rf1 strain of 
TBEV. 
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E 5'- AcCAAA -3' 2323 
Str1 CATCAGCCATAAAGGAG 2584 
Str2 , CTTCATGGTGGGCACGGAAG 
2858 
Str3 AATGACACAGGCAC 3072 
Inv5 CGATAATGCTGACG 3149 
Inv6 CCAGAATGGTGCTG 3381 
Inv? GATAGAGAGCCTGGT 3667 
Rev1 GACGGTGAGGCTTCTG 3790 
Rev2 GTAATTCACCGTTGTCC 3496 
Inv4 GATCTGTGTGGATTGC 3017 
Inv3b GAATGGCCCCAGC 2793 
Inv2 CCATTCTGAGACCTC 2510 
Inv1 CAGAAAGCCTCCAGC 2227 
Sequencing Primer, M13 reverse 5' -AACAGCTATGACCATG- 3' 
Sequencing Primer, M13 universal 5' -TTTTCCCAGTCACGAC- 3' 
Fig. 3.9. The sequencing Primers: The number to the right of each 
primer sequence is the position of that primers 5' nucleotide within 
the Neu& rfl strain gencme (Mandl et al., 1989a). The M13 sequencing 
primers were supplied by United States Biochemical Corporation, and 
are complementary to sequences adjacent to the cloning site in pMIL23 
permitting primer extension into the cloned DNA fragment. 
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change fr T to A at base 3265 (Fig. 3.10) . The nucleotide sequence 
obtained for the NS1 gene of K23 strain encoded by FKENS1 2a is also 
shown in Fig. 3.10. 
The amino acid sequence of NS1 encoded by the Neudörfl strain of 
TEEV and by the K23 strain frarnent cloned into pMV56C was derived by 
the `TRANS' subroutine in 'DNASTAR' software from the nucleotide 
sequence Fig. 3.11. Despite 37 nucleotide substitutions, the amino 
acid sequence of K23 strain NS1 encoded by pM156C differed from that 
of the NS1 encoded by the TEV Neudärfl strain by cnly eight residues. 
The NS1 nucleotide sequence of these two CE TBEV strains show a lower 
degree of ha ology with the published sequence of the FE Sofin strain 
of TBEV and Langat strain of TBEV. The position of the N-linked 
glycosylation motifs within the primary sequence of all four TBEV NS1 
genes so far sequenced are absolutely ccnserved, one of which is also 
spatially conserved with one of the motifs identified within the 
primary sequence of the mosquito-bcrne viruses. The homology profiles 
of TEEV NS1, as determined by 'Dot-plot' analysis, between K23 strain 
and the other TBEV NS1 sequences available revealed two specific 
patterns (Fig. 3.12), one common to oc parisc* s between the K23 strain 
and the viruses of the CE subtypes represented by Neucbrfl strain of 
TBEV; the other pattern cammn to comparisons between K23 strain and 
the viruses of the FE subtypes represented by the Sofin strain and 205 
strain of TBEV. This horology pattern may represent a means of typing 
the FE and CE isolates 
in addition to the general sequence hanology observed between the 
NS1 primary sequence of tick-borne viruses, 11 cysteine residues were 
identified as being conserved between the tick-borne and mosquito- 
borne viruses so far sequenced (Fig. 3.11). The conservation of the 
cysteine residues implies a common protein structure. 
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2410 
IQ3 AGB APC CGT ACA ATG Ur, A'IG ACS TIT CIC CIG GX GG% OT CTG 
N.... ... ... ... ... ... ... ... ... ... T.. .. T ... ... ... 
* 2455 
K23 GM TIG GM AM ACC CIT OSN GIG GM GX GAT Grr C' GCT 
N ... ... ... ... ... ... ... ... ... ... ... ... .. T ... ... 
2500 
IM GIG GACACA GAA CA AM CIGCICCM ZýTC GG 03C CIGGTT 
N ... ... .. G ... ... ... ... ... ... ... ... ... ... ... .. C 
2545 
K23 GIG 'ICS AGB GAG GIC ZCA GAA 'ICS TAT CC ATC TAT Gar M TAC 
N ... ... ... ... ... ... ... ... ... ... .. T ... ... ... ... 
2590 
IM OMGpOAAACMG3J=__ GM 9r OM ATAAPGGAG NA TTT 
N ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 
2635 
FQ3 GAA GAG GOA AGr AMT G3T GI'A GIC COü C? f APC X33 CIC GAG ATG 
N .. G ... ... ... ... .. C ... ... ... ... ... ... ... ... ... 
2680 
IM CA TG ACS 'ICA GIC ACA GIG CIG AAT 'Its CET CIG GCG 
N ... ... ... 6 ..... .. G ... ... A. ... ... T. ... ... ... 
2725 
1Q3 CAA CM GAG GM AAT CIC X41 GIG GIG GIG (? C AAG MT GAC CCC 
N ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 
2770 
}23 ACr C TAC C31 Wr GGr GIC - cx, r TIA CIG ACA AAA OHA AAG 
N ... ... ... ... ... ... ... C. U ... ... ... A. ... ... ... 
2815 
1Q3 GAC ATA AAA GOC 'IOC TOG AAA AGC '103 01r CAT 'ICS A'IC AM TGG 
N ... ... ... .U.... ... ... ... ... ... ... ... .. G ... ... 
2860 
K23 AGT ACT CCI' GAG 0T OM CM CX TIC A'TG GIG (X P GAA GGA 
N .. C T. ... ... ... ... ... ... ... ... ... ... ... ... 
2905 
1Q3 CAA PL3P GAG TM Ox CIA CPG AGN C3G APG ? CA 032 GIT TIC ACG 
N ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 
2950 
IQ3 GIG X7 GAA TIC CM GIT CX CIG NIA ACA AAG GIT TIC TIG GAT 
N ... ... ... ... ... ... ... ... ... ... ... .. C ... ... ... 
2995 
1Q3 TIC AGA M GAA Q^A ACA CAT GAG ZGT GPC ACA 03A GIG AZT GGA 
N ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 
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3040 
IQ3 CXT GM GIC AAG AAT C A'IG CAA AC CAC ACA GAT CAA AGT CTC 
N ... .. A ... ... .. C ... ... ... ... ... ... ... ... ... ... 
3085 
IM 'RD A'IG PG TM AM AAA AAT GAC ACA C ALT TPC ATA Grr GAA 
N ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 
3130 
IM CIT TIG GIC ACT (? C CIG PG3 APC 'ICA Ta; OCP (EI lE CAC 
N ... ... ... ... ... ..... ... ... ... ... ... ... ... ... 
3175 
P23 ACr AM GAT AAT CEP GAC GIG GIG GW- TCG GAG TI'A TIG CIT CCG 
N ... ... ... ... ... ... ... ... ... .. A ... ... C.. ... ... 
3220 
P23 GCs AC. CIG GM G3k CCE ACA TCr TM TIC APC NE AMA CCr GGT 
N ... ... ... ... ... ... ... ... ... ... ... . ... . T. C. 
3265 
3 TAT TM GAA GG GIG AAA G3J CC71 TGG AAG TAC Ate; 02r A'IC CGA 
N ... ... ... ... ... ... ... ... `... ... ... ... ... ... ... 
3310 
1Q3 GIC MC AGA GAG GAG ZGT Qý Gl' AE ACC GIT ALT MC AAC GCC 
N .. T ... ... ... .. C ... ... ... ... ... ... .. C ... ... ... 
3355 
JQ3 AFG BUT GC AAA ACA CAA COCA 'ICI' GIG AGG ACS ACC ACA GAG AGT 
N ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... 
3400 
10 O3 APG GIT A'IG 4^A GAA TCX ¶I 'ILS CM (XE 7M ACA ATG CCA 
N ... ... .. A ... ... ... ... ... ... ... ... .. G ... ... 
3445 
I23 am GIG AI TIC CCM AM 071 Or GAT ICI' T( TAT GM MG GAA 
N ... ... ... ... ... ... .. T ... A.. ... .. C ... ... ... ... 
3491 
im ATA COG TA GIC CAT GC CAG G GI GM CIT GIT (XC '1 MG GTG 
N ... ... ... ... ... ... ... ... .. G ... ... ... ... ... ... 
3497 
E23 GIT GCG 
N ... ... 
Fig. 3.10. Nucliotide sequence of K23 and Netx3 rfl strain of M3EV in 
cDNA fragments FENS1 2a: The translocation signal coding sequence is 
underlines and the N- terminus of the putative NS1 gene is indicated 
by *. Nunbers cn the right and above each row indicates the number of 
the last nucleotide in each row as determined by Mandl et al 1988, 
1989a). 
82 
N RVIM SMSFL LAG GL VLAMT LGVGA DVG A VDI'ER ME EM Gomv VWREV 801 
K ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... S ..... ..... .. ..... ..... ..... ..... ..... ..... ..... L .... L .. G.. S ... ..... ..... ..... ..... ..... ..... ..... 
N SEWYD NYAYY PErr AI SA IKEIF E B= GWPQ NRIE M AMWRS SVI'EL 851 
K ..... ..... ..... ..... ..... ..... ... ..... ..... .. 
V. 
S ..... ..... .... L ..... ..... ... T. 
I... ..... ..... . A... 
L ..... ... FH .... A V.... VOAY .. EI. 
I ... ..... ..... . VL.. 
# ## 
N NW A D E1 N L'IVW DKFDP TDYRG GVPGL LKKGK DIKVS WKSW, 7 HSMIW 9 01 
K ..... ..... ..... ..... ... .. S.. . R... .. A.. ..... .. 
I.. 
S .... V .. D.. ..... .. L.. ... I. S . ..... ..... ..... ..... 
L ..... ..... ..... .. A.. S.... ..... N... ..... . R... R. . 
L. 
N SIPFA PRRFM VGIEG QSDC: P IERPIC rGVFT VAEEG VGI RT KVFZD MEP 9 51 
K . T... ... ..... ..... ..... ..... ..... ..... ..... ... S . V... .. L.. ..... S .... ..... ..... ..... ..... ..... .... 
S 
L . V... ..... I. V.. GR... FA... ... M. .... I.... ... M. L ... 
L 
N MIED TG'V! AAVKN G`IAM TDQSL WN RSM IOM TYIVE LLVID LRNCS 1001 
S ..... ..... ..... ... V. ..... .. K. V R.... .... .... ..... L T ... ..... ..... ... V. ..... .. K. I .... T Vr... . I... .... 
T 
N WASH TIDIA DVVDS E FLP ASLAG PRSWY NRIPG YSEQV KGE'4QK YTPIR 1051 
K ..... ..... ..... .. L.. ..... ..... ..... ..... ..... ..... S ..... ..... E .... ..... ..... ..... ..... ..... ..... . S... L ..... ..... G.. N. K.... ..... ... T. . V... . A... R... A HT. V. 
N VIREE C PGIT VTINA KCDKR GASVR SM G(VIP EW CR ACIN P PA'T'ER 1 101 
K ..... ..... ..... ..... ..... ..... ..... ..... ..... ..... S . T... .... R ..... D .... ..... ..... ..... ..... T.. L. ..... L IK... .... R ... DK A .... ..... ..... ..... ..... T. EL. ... Y. 
N IGIt C WYAME IRPVH DX L VRSNN VA 1128 
K ..... ..... ..... ..... ..... .. S ..... ..... ..... ..... ..... .. L ..... ..... ..... T.... ..... .. 
Fig. 3.11. Amino acid sequence Comparisons of NS1 from the TBEV 
Strains (N) neud r-f1, (K) K23, (S) Sofin and (L) Lanqat: Three 
potential N-linked glycosylation sites are indicated by ###, and the 
potential translocation signal sequence is overlined. The number to 
the right of each line identifies the left hand amino acid of that 
line with respect to the Neudörfl sequence as reported by Mandl et 
al., (1988,1989a & 1991a). The sequence of the strain Sofin is fran 
Pletnev et al., (1990), and the Langat strain is from Iacono-Connors 
and Schmaljohn, (1992). 
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Fig. 3.12. Dot Matrix Analysis of the Hanoi gy Between NS1 of the TBEV 
K23 (K) Strain and the Neudörfl (N), Sofin (S) or 205 Strains: The 
matrices were created by the DNASTAR programme, 'DOTPLOT' using 90% 
match with 30 nucleotide segments. The numbers to the left and above 
each plot indicates the nucleotide number when the first base of NS1 
is 1. 
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3.1.7. Characterisation of the Truncated 1 kb PCR Fragment: 
In the initial reverse transcription reactions carried out using 
primer P2 and not treating the RNA template with DMSO, a truncated 
fragment of approximately 1 kb was amplified by the PCR (Fig. 3.5, 
Lane 3). Restriction cleavage of the aberrant 1Kb fragment indicated 
that it contained the first 1kb (approximately) of the 1891bp viral 
DNA fragment with 0.9kb of the 3' end having been deleted. Analysis 
of the TBEV Neudorfl strain nucleotide sequence between the region 
described by the primers P1 and P2 revealed a near perfect inverted 
repeat of the 25 nucleotide sequence between bases 3157 and 3181 (IR1) 
occurring between nucleotides 3930 and 3954 (IR2) (Fig. 3.13). This 
inverted repeat conferred the potential for a stem-loop structure 
within the gencmic RNA which would involve approximately 0.9 kb fron 
the 3' of the region defined by the PC R primers P1 and P2 ie 3' of 
fragment FENS12a. The reverse transcriptase was therefore assumed to 
have `jumped' the stem-loop structure during the reverse 
transcription, generating a truncated cDNA copy of the genaue which, 
in turn, was used as the PCR template, and passing the eirar on to the 
amplified fragments. 
To test whether the proposed stem-loop structure was responsible for 
the amplification, by PCR, of the truncated DNA fragment, the 
truncated fragment was sequenced. Following its amplification by PCR 
the truncated fragment was purified and the adaptor L1 ligated to 
allow insertion of the fragnent into pmrL23. Nucleotide sequencing of 
the truncated fragment revealed it to contain the region between 
nucleotide 2096 to 3119 of the genarge from the TBEV Neudörf1 strain. 
This region formed the 5' 1033 bp of the fragment FENS12a stretching 
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Fia. 3.13. The Nucleotide Sequences Involved in the Generaticn of the 
Truncated PCR Product: The primer p2 was complementary to the 
sequence between nucleotides 3110-3119 (R2) and to the sequence 
between 3963-3972 (Ri). ¶fl nucleotides between 3157-3181 (IR1) and 
between 3930-3954 (IR2) form the putative stem-loop structure. 
indicates mismatched base pairs in the putative stem-loop structure. 
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from the 5' of primer P1 to a position 38 nucleotides upstream from 
the first nucleotide of the inverted repeat (IR1) sequence at position 
3157 (Fig. 3.13). 
The 10 nucleotides forming the 3' end of the truncated fragment 
(between bases 3110-3119) were found to be complementary to the 10 
nucleotides of the 3' end of the primer P2 and therefore represented a 
second region of homology (R2) in PEAS12a to the primer P2 (Fig. 3.13). 
It was concluded that the primer P2 had preferentially recognised the 
10 bases of R2, possibly because the secondary structure had made R1 
inaccessible to P2. In an attempt to denature this stricture prior to 
reverse transcription the RNA template was treated with DM50 in the 
presence of random primers (2.15). This method resulted in the 
successful generation of the full 1891 bp PCR DNA fragment FENS12a 
(Fig. 3.5, Lane 6). it was surprising that treatment of the genome 
with DMSO allowed binding of P2 to 3963-3972, as when RNA templates 
were treated with DM50 in the presence of P2 prior to the reverse 
transcription reaction the resultant cDNA template could only generate 
a truncated fragment in PCR (not shown). When random primers were 
included in the reverse transcription but the RN was not treated with 
DMSO however, no PCR product could be detected (Fig. 3.5, Lane 5). 
The need to treat genanic RNA with DMSO prior to its inclusion in 
the reverse transcription reaction in order to generate the complete 
fragment FTM12a provides evidence that sectary structure may impede 
the reaction. A comparison identified a repeat and inverted repeat 
sequence to be present in the gencmes of the CE TBEV strains of Langat 
(Iacono-Connors et al., 1992) and K23 (this Thesis), and the Far 
Eastern strains Sofin (Pletnev et al., 1990) and 205 (Safrrn v et al., 
1991), but not in the available sequences of the mosquito-borne 
viruses. 
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3.1.8. G iezatian of Additional Constructs Containing the INS1 Cage: 
Five additional DNA fragments in which the NS1 gene of the Neud6rf1 
strain was presented in a different context were amplified by PCR in 
which the template was provided by the sequenced fragment FENS12a 
excised from pN1V40 on a XbaI fragment. Three additional PCR primers 
P3, P4 and P5 were designed to be used in conjunction with P1 and P2 
in PCR to generate the additional viral cDNA fragments (Fig. 3.4). 
Primers P3 and P5 are homologous to 18 bp on the positive strand 
from nucleotide 2441 and 2366 respectively. Primer P3'defines the 
putative 5' terminal of the NS1 gene, while P5 defines the 5' end of 
the putative translocation signal sequence 78 nucleotides upstream 
from the putative 5' terminal of the NS1 gene. These primers were 
also designed to generate an upstream XbaI site to facilitate cloning 
and an inframe translation initiation codon (AUG). Primer P4, is 
complementary to 21 bp on the positive strand ending at nucleotide 
3496 and defines the putative 3' terminus of the NS1 gene, and also 
contains both an additional upstream element that generates a 
translation termination colon (TAA) and an XbaI site during PQ2. The 
five additional Neudörfl strain DNA fragments containing the NS1 gene 
generated and described in Fig. 3.4, were designated: FENS1 containing 
the 33% of E gene and the putative NS1 gene in FENS1 2a but not the 
NS2a sequence; FNS12a containing the putative NS1 gene and NS2a 
sequence of FENS1 2a but not the E gene portion; FNS1 containing only 
the putative NS1 gene from FENS12a; and FSNS1 and FSNS12a which were 
identical to FNS1 and FNS12a but with the addition of the 78 
nucleotides located immediately upstream from the putative 5' terminal 
of NS1 at the 3' terminal of the 'E gene expected to encode the 
translocation signal. Since the fragments PENS1, FNS12a, and FSNS12a 
were generated using primers P1 or P2, the adaptor L1 was ligated as 
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for fragment FENS12a, to facilitate cloning and translation. As only 
one terminal of the fragment required this modification, only 1 lag of 
adaptor was reacted with 2 pg of fragment in the ligation reaction. 
The remaining fragments, FNS1 and FSNS1, which did not require the 
addition of adaptors were inserted directly into the p ! TL23 following 
digestion with I. Each additional cloned viral fragment was 
sequenced using the primers described in Fig 3.8 and Fig. 3.9. The 
sequences of the additional fragments were found to agree with the 
nucleotide sequence of the template FENS12a. Each construct contained 
an in-frame translation initiation codon derived fiat either the PC2 
primers or, in the case of fragment FENS1 2a and FE[SS1, by the addition 
of the adaptor L1. An inframe stop codcn, present in either primer P4 
or the adaptor L1, was also incorporated into all the fragments. 
3.1.9. Cloning of TBEV NS1 cDNA Constructs into the Transient 
Eukaryotic Expression Vector: 
Following sequencing of the TBEV cDNA fragments, the fragments were 
excised from pNM23 using XbaI and isolated by electrophoresis and 
electro-elution before being inserted into pMV100 at a unique XbaI 
restriction site of pMV100. The resultant plasmids were used to 
transform competent E. coll. The plasmids were recovered from the 
cells of a single colony generated and their cDNA inserts examined. 
plasmids were designated; pMV39 containing FENS12a, p1V43 containing 
FENS1, pMV41 containing FNS1, pMV53 containing FNS12a, pMV45 
containing FSNS1 and pMV54 containing FSNS12a (Fig. 3.14). 
Restriction digestion of the plasmid with AI caifirmed the insertion 
of the TBEV cDNA fragments at the appropriate site (Fig. 3.15), while 
HindIII digestion demonstrated that the IEP/TBEV cDNA expression 
cassettes could be excised from the plasmid (Fig. 3.15). SacI 
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Fragment Plasmid 
FENS12a L1/P1 E NS1 NS2a P2/L1 pMV39 
FENS1 L1/P1 P4 PMV43 
FNS12a P3 P2/L1 pMV53 
FNS1 P3 P4 pf1V41 
FSNS12a PS P2/L1 pNVS4 
FSNS1 PS p4 pMV45 
Xba IX bai 
E Promoter N S1 poly A 
Fig. 3.14. Cloning of the NS1 Gene Under the Control of the IE 
pr roter: Insertion of the 39baI-digested PCR fragments ocntaining the 
TBEV NS1 gene into the xbaI site of p W100 placed the gene under the 
control of the Gf1 major IE pe ter. pW100 ocntains the CMV major 
iE prcm ter (-299 to +69) upstream of a multiple cloning site in a pUC 
base plasmid. Downstream of the multiple cloning site in pMV100 is 
located the polyadenylation signal sequence derived from the a4V major 
IE gene (+2757 to +3053). The name given to each plasmid generated in 
the cloning experiment is indicated on the right hand side. 
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FiQ. 3.15. XbaI Digest of pMV39, pMV43, pMV53, pMV41, pMV54, and 
pDV45: XbaI digested plasmids were electrophoresed through a 1% 
agarose gel and stained with ethidium bromide. XbaI digestion 
demonstrates the presence of FENS12a in pMV39 (Lane 2); of FENS1 in 
p 1V43 (Lane 3) ; of FNS 12a in pMV53 (Lane 4) ; of FNS1 in p v1V41 (Lane 
5); of FSNS12a in pNV54 (Lane 6); and of FSNS1 in pMV45 (Lane 7). The 
size (in kb) of several molecular weight markers (lane 1) are 
indicated on the left. 
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1234567 
restriction digestion cleaves pMV100 and the NS1 gene asymmetrically 
which allowed the orientation of the TBEV cDNA fragment to be 
ascertained with respect to the CMV IE promoter (Fig. 3.17). 
3.1.10. Transient Expression of NS1: 
Using the transfecticn technique described in section 2.26, plasmids 
containing the CMV IE promoter/NS1 expression cassettes were 
introduced into 293 cells and expression of the NS1 gene product was 
assayed by immunofluorescence (Fig. 3.18). NS1 expression was 
detected in transfected cell using the anti-NS1 monoclonal antibodies, 
as the first antibody and fluorescein-conjugated goat anti-mouse IgG 
as the second antibody. A strong green cytoplasmic inrrnmofluorescence 
was observed only in cells infected with TBEV or transfected with 
plasmids containing the translocation signal sequence immediately 
upstream of the NS1 gene, i. e., with pvW45 (fragment FSNS1) and pMV54 
(fragment FSNS12A) (Fig. 3.18,2 and 3). The expressed protein was 
recognised by three different monoclonal antibodies (T12, T33/1 and 
T33/3) raised against the NS1 protein, with the cytoplasmic pattern of 
fluorescence produced being identical to that observed in TBEV- 
infected cell. Significant levels of expression could not be detected 
in cells transfected with constructs containing the additional 
upstream E gene sequences, plasmids pMV39 (fragment FENSI2A) (Fig. 
3.18,4) and pMV43 (fragment FENS1), or those lacking the signal 
sequence altogether, pMV41 (fragment FNS1) and pMV53 (fragment 
FNS12A). No significant levels of fluorescence could be detected in 
mock-transfected or mock-infected cells. 
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FiQ. 3.16. HindIII Digest of pMV39, pMV43, pMV53, pMV41, pMV54, and 
p45_ Hindill digested plasmids were electrophoresed through a 1% 
agarose gel and stained with ethidium bromide. Hindill digestion 
demonstrates the presence of FENS12a in pMV39 (Lane 2); of FENS1 in 
pMV43 (Lane 3) ; of FNS 12a in pMV53 (Lane 4) ; of FNS1 in pMV41 (Lane 
5); of FSNS12a in pMV54 (Lane 6); of FSNS1 in pMV45 (Lane 7). The 
size (in kb) of several m,, lecular weight markers (lane 1) are 
indicated on the left. 
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Fiq. 3.17. Orientation of FSNS1 in pMV100 by SacI Digestion: Sacl 
cleaves at the 5' end of the IE promoter in pMV100 and 38 bp into the 
5' end of FSNS1. Following cloning of FSNS1 into pMV100, the 
orientation of FSNS1 with respect to the IE promoter in pMV100 was 
determined by Sacl digestion. The FSNS1 is correctly orientated in 
pMV100 with respect to the IE promoter as SacI digestion produces one 
fragment of approximately 3200 bp and one fragment of approximately 
500 bp (not visible) (Lane 1). Saci digestion of a plasmid in which 
FSNS1 is incorrectly orientated with respect to the IE promoter in 
pMV100 generates a fragment of approximately 1500 bp and one of 
approximately 2200 hp (Lane 2). The size, in kb, of several molecular 
weight markers in the left hand lane are indicated on the left of the 
figure. 
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Appropriate presentation of the translocation signal sequence and 
therefore translocation of NS1 to the ER, appears to be critical for 
efficient expression of the NS1 antigen. What is not clear, however, 
is why the internal translocaticn signal of fragment FENS1 and FENS12a 
was unable to permit expression of a protein recognised by anti-NS1 
monoclonal antibodies, it is possible that the signal was masked by 
chain folding rendering it non-functional. 
The proteins expressed by pMV45 and pMV54 and recognised by the 
anti-NS1 monoclonal antibodies were examined further by Western-blot 
(Fig. 3.19). Lysates of cells harvested 48 h post-transfection with 
pMV45, pMV54, and cells infected with TBEV, were prepared for 
separation by SDS PACE in a ncn-reducing SDS loading buffer. Reducing 
conditions were not used and samples were not boiled prior to 
electrophoresis. Following electrophoresis, the separated viral 
proteins were transferred from the gel to Hybond membranes and probed 
with an anti-NS1 monoclonal antibody pool (T12, T33/1, T33/3). 
Fig. 3.18. Detection of NS1 Expressed in Cells by ? mrnmofluorescence" 
Expression of TBEV NS1 detected by ilrmunofluorescence with the anti- 
NS1 monoclonal antibody pool (T12, T33/1, T33/3) in TBEV-infected 293 
cells (1); pMV45-transfected 293 cells (2); pMV54-transfected 293 
cells (3); pMV39-transfected 293 cells (4); TBEV-infected MRCS cells 
(5); RAd51-infected MRCS cells (6) and mock-infected NRC5 cells (7). 
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FiQ 3.19. Detection of NS1 by Western Blot: Lysates prepared from 
293 cells were separated on a 10% SDS-PAGE before being 
electrophoretically transferred to a nitrocellulose filter. The 
proteins transferred to the membrane were probed with the anti-NS1 
lcal antibody pool (T12, T33/1, T33/3). NS1 (Mr of 47 kDa) was 
only detected in TEEV-infected 293 cell monolayers (Lane 5). A larger 
NS1 complex of approximately 92 kDa was detected in TBEV-infected 
cells (Lane 5), RAd51 infected 293 cells (Lane 4), pMV45 tranfected 
293 cells (Lane 2) and pMV54 transfected 293 cells (Lane 1). NS1 
specific proteins were not detected in the mock transfected (Lane 3) 
or mock infected 293 cells (Lane 6). Sizes in kDa are indicated on 
the left. 
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The location of NS1 bound antibody was visualised by 
chemiluminescence reagents which recognised the anti-mouse antibody 
and recorded on radiographic film. The maxaneric form of the NS1 (47 
kDa) could readily be demonstrated in TBEV-infected (Fig. 3.19, Lane 
5) but not in pW45- or p N54-transfected (Fig. 3.19, Lane 2 and Lane 
1) 293 cell extracts. A diffuse, slower-migrating band corresponding 
to a protein with an apparent molecular mass of approximately 92KDa, 
however, gave a positive signal with the infected cell extract and the 
pW45- and pt4V54-transfected cell extracts. Neither the NS1 specific 
47 kDa or 92KDa band were seen in mock-transfected or mock-infected 
samples (Fig. 3.19, Lane 3 and Lane 6). 
This result demonstrated that TBEV and plasmids pMV45 and pMV54 
encode a protein which participates in high molecular weight complexes 
of approximately 92 kDa. The 92 kDa protein may be hcwdimers of NS1 
or NS1 complexed with cellular encoded components. 
The co-migration of the NS1 specific product detected in cells 
transfected with pMV54 with cells transfected with pW45, implies that 
the fragment FSNS12a contained sufficient information to permit the 
removal of the NS2a-encoded peptide from the FENS12a translation 
product. If the NS2a portion had not been reproved the protein encoded 
by the fragment in pW54 (FSNS12a) was expected to migrate more slowly 
than that encoded by pMV45, on SDS PAGE. 
It was found that the 75 nucleotides from the C-terminal of the E 
gene needed to be retained immediately upstream of the NS1 gene within 
the ORF in order to generate a protein recognised by anti-NS1 
monoclonal antibodies. The requirement for appropriate processing of 
the C-terminus of NS1 was circumvented in the constrict FSNS1 by the 
insertion of a translational stop codon at the predicted cleavage 
site. 
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3.2. Expression of TBEV NS1 Encoded by a Defective Adenvirus 
Expression Vector: 
3.2.1. Overview: 
Plasmids pMV45 and pMV54 were identified in transient DNA 
transfection experiments as being able to induce the expression of 
TBEV NS1 antigens. There was no obvious difference in the level of 
expression of NS1, distribution of immunofluorescence, apparent 
molecular weight or their ability to form large molecular weight 
complexes between the pMV45- and pMV54-encoded NS1. Since it was 
envisaged that co-expression of NS2a would complicate the analysis of 
animal protection experiments, plasmid pMV45, which contained only the 
NS1 coding sequence, was used as the basis for expression in the 
adenovirus vector. 
The expression cassette was excised from FW45 on a Hindill fragment 
and inserted into the adenovirus transfer vector pMV60 generating 
pMV51.1V60 is identical to pXOC2 (Spessot et Al., 1989) except that 
a linker (containing the Hindill cloning site) has been inserted at 
the unique XbaI cleavage site (Wilkinson and Akrigg, 1992) (Fig. 
3.20). The HindIII linker in pMV60 is located between regions with 
homology from either side of the Eta gene which map to the region 
between nucleotide 30 and 420, and between 3328 and 5788 of the human 
adenovirus type 5 genome and are able to direct homologous 
recombination with the adenovirus genaue provided by pJM17. p. M17 
antains the entire human adenovinis type 5 (Ad5dl309) gencme with the 
prokayotic vector pBRX inserted into the Eta gene (McCrory et al., 
1987) (Fig. 3.21). The prokaryotic vector insertion in pJM17 makes 
the adenovirus genome too large to package into the adenovirus 
nucleocapsid. Furthermore the adenovirus genome contained within 
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piM17 has a deletion in the E3 gene region. The products encoded by 
the E3 gene are not essential for virus replication in tissue culture 
but is potentially important in in vivo study since it is thought to 
protect adenovirus-infected cells against lysis by adenovirus-specific 
cytotoxic-T lymphocytes (CTL) (reviewed Wold and Gooding, 1991). 
Following co-transfection of pMV51 and pJM17 into 293 cells, a 
reccnbinaticn event led to the generation of the defective recombinant 
adenovirus RAd51. During the recombination event, the IEP/NS1 
expression cassette replaced both the prokaryotic vector and Ad Eta 
gene region. Replacement of this region by the CMV IE/NS1 expression 
cassette reduced the size of the adenovirus genome (pJM17) 
sufficiently to enable viral packaging of the viral genaue generating 
the recombinant adenovirus RAd51. RAd51 was harvested by Arklone P 
extraction and plaque purified by limiting end point dilution 
titration. 
A significant feature of the Ad vector is that it is defective in 
its Eta function. Eta is a trans-activator of early gene expression 
and like other adenovirus El deletion mutants, RAd51 can only 
replicate in a helper cell line, i. e. a cell line providing the Eta 
function such as 293 cells. Infection of cells lacking the El helper 
function results in constitutive expression from the CMV major IE 
proter without activation of adenovirus early phase gene expression. 
Infection of non-permissive cells with recombinant defective 
adenoviruses at a high moi can be accomplished without inducing 
detrimental effects (e. g., cpe), and allows the detection of the 
expressed protein without any de novo synthesised adenovirus-encoded 
proteins being present. 
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Since recombinant TBEV NS1 was to be used in examining the 
protection elicited in mice by the protein it was necessary to 
investigate whether the recombinant proteins were processed by the 
infected cell in a manner similar to that of the TBEV-encoded protein. 
During its synthesis TBEV NS1 is translated to the lumen of the ER, 
where it is folded and glycosylated. Further modification occurs 
within the Golgi complex before NS1 is secreted from the infected 
cell. Detailed carparisons were made between NS1 produced by TBEV and 
RAd51-infected cells to demonstrate the ability of the NS1, 
synthesised from the recombinant adenovirus, to canplete these post 
translational modifications. 
3.2.2. Construction of Recombinant Adenovirus: 
The CMV IEP/NS1 expression cassette was excised from pMV45 on a 
HindIII fragment (Fig. 3.16, Lane 7), and inserted into pMV60 at a 
unique Hindill restriction site located between the two regions of 
adenovirus sequence. The resultant plasnid was designated pMV51 (Fig. 
3.22). The presence of the CMV IE/NS1 expression cassette was 
confirmed by xbaI digestion and its orientation in relation to the 
flanking sequences established by digestion with Sacl which cleaves 
the plasmid and CMV IE/NS1 expression cassette asymmetrically. 
plasmids pº7M17 (5 pg) and p 1V51 (5 . g) were co-transfected into a 
monolayer of 293 cells (Fig. 3.23). The cells were incubated for 
seven days at which time the formation of viral plaques in the 
monolayer was observed. Co-transfection had enabled homologous 
recombination between pMV51 and pMJ17 to occur resulting in the 
incorporation of the expression cassette CMV IE/NS1 into the 
adenovirus gename, replacing both the adenovirus El gene region from 
nucleotide 402 to 
3328 and the intervening prokaryotic vector. 
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Fig.. 3 22 Cloning of the IEP/NS1 Expression Cassette into the 
de., Qvirus Transfer vector PMv60: The IE/NS1 expression cassette was 
excised from pMV45 on a 
Hindlil fragment and inserted into the 
transfer vector pMV60 to generate p4V51. DNA sequence numbers shown 
on the plasmids correspond 
to the adenotype 5 genome. 
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Fiq. 3.23 Generation of Adenovirus Recombinant RAd51: Plasntds piMi 7 
and pMV51 were co-transfected into 293 cells. Homologous 
reoanbinaticn between the two plasnids results in the EI gene (bp 452- 
3328) and the prokaryotic vector pBRX in pMJ17 being replace with the 
j prcrroter/NS1 expression cassette. Harologous recombination reduced 
the overall size of the adenovirus gencme in pKJ17, and the resultant 
recombinant adenovirus RAd51 was package within an adenovirus 
particle. 
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Following recombination the size of the genome was decreased 
sufficiently to enable packaging of the recombinant genome into an 
adenovirus particle. The recombinant virus, designated RAd51, was 
harvested by Arklone P extraction. The purified RAd51 was used to 
infect a 175 ant flask of 80% fluent 293 cells. When the monolayer 
had been destroyed, the virus was harvested with Arklone P and plaque 
purified by limiting end point dilution titration. 
3.2.3. EXPRESSION NS1 FROM RAd51: 
Expression of NS1 in RAd51-infected cells was initially investigated 
by immunofluorescence. Monolayers of both permissive 293 cells and 
ten-permissive MRC5 cells were infected with RAd51 at 30 pfu/cell as 
determined on 293 cells. 293 and MRC5 monolayers were also infected 
with TBEV at 1 pfu/ml or PBS. Two days past infection the monolayers 
were examined for the expression of NS1 by immunofluorescence 
(Fig. 
3.18). The cytoplasmic pattern of fluorescence observed following 
RAd51 infection of MRC5 cells (Fig. 1.18,6) was similar to that 
observed with TBEV-infected cells (Fig. 1.18,5), while no 
fluorescence was detected in mock-infected cells (Fig. 1.18,7). 
Expression of NS1 in MRCS cells with RAd51 at a moi of up to 30 
pfu/cell produced no obvious cytopathic effect 
in the monolayer. 
3.2.4. Analysis of NS1 Expressed From RAd51: 
The formation of larger molecular weight forms of NS1 in RAd51- 
infected cells lysates was derer strated by Western blot analysis (Fig. 
3.19). Cell lysates prepared 24 hpi from RAd51- and TrEV- infected 
293 cells were separated by SDS PAGE and electrophoretically 
transferred to Hybond membranes. The membranes were probed with the 
anti-NS1 monoclonal antibody pool 
(T12, T33/1, T33/3) and the 
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antibodies detected by chemiluminescent reagents. The samples were not 
boiled or reduced prior to electrophoresis, since the large molecular 
weight forms of NS1 were believed to be heat labile and because 
reduction prevents recognition by the anti-NS1 monoclonal antibodies 
used in this study. A diffuse protein band of 94 kDa, which co- 
mi, grated with a NS1 specific protein fron both pW45- (Fig. 3.19, Lane 
2) and p W54- (Fig. 3.19, Lane 1) transfected cell lysates and from 
v-infected (Fig 3.19, Lane 5) cell lysates, was detected in RAd51- 
infected cells (Fig. 3.19, Lane 4). The inability to detect monomeric 
NS1 encoded by the DNA fragment FSNS1 has been discussed in section 
3.1.9. 
The monomeric form of R M51-encoded NS1 was, however, demonstrated 
when RAd51-infected MRC5 cell lysates were subjected to SDS PAGE 
stained with coanassie blue (Fig. 3.26). Both the recombinant and the 
wild type TBEV extra-cellular forms of NS1 were consistently found to 
co-migrate on polyacylamide gels and to be of a higher apparent 
molecular weight than their intracellular counterparts. 
3.2.5. Glycosylation of NS1. 
During its synthesis in infected cells, NS1 of TBEV is translocated 
to the lumen of the ER, where it is glycosylated and then transported 
to the Golgi complex where there is further modification of its 
oligosaccharide side chains. The ability of recombinant NS1 to 
complete these post-translational modifications was examined by 
riparing the susceptibility of the recombinant and the TBEV-encoded 
NS1 to glycosidase digestion with erdii and glyooF (Fig. 3.24). F, rc; 
removes N-linked 
high mannose or hybrid oligosaccharide side chains 
but is ineffective against complex glycans, whereas endoF cleaves all 
three type of N-linked glycan. 
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Eq3.214. Effect of Glycosidase Treatment on NS1: Radiolabelled NS1 
from RAd51 and TBEV infected 293 cells was immunoprecipitated with 
anti-NS1 monoclonal antibody pool (T12, T33/1, T33/3) and examined by 
SDS-PA( on a 10% gel and detected by autoradiography. TBEV-encoded 
NS1 is shown in (a) Lanes 2,4,6,8,10,12 and (b) Lanes 1 and 3, 
Rad51-encoded NS1 is shown in (a) Lanes 3,5,7,9,11 and (b) Lanes 2 
and 4, following treatment with glycoF (F) or endoH (H) or no 
treatment (U). (a) Lane 1 containes mock infected, intra-cellular 
1es not subjected to glycosidase treatment. Sizes cn the left are 
shown in kDa. 
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80% confluent, 293 cells were infected with RAd51 at a moi of 10 
pfu/cell. The infected cells were pulse labelled 24 pi with 
35S 
methionine for one hour. Cell lysates and culture supernatant from 
the infected cells were obtained three or four h following the pulse 
label and NS1 immunoprecipitated by an anti-NS1 monoclonal antibody 
pool (T12, T33/1, T33/3). NS1 was released from the imnune complex by 
boiling for ten minutes and the sepharose beads were removed by 
centrifugation. Aliquots of the released antigen were then treated 
with either endoH or glycoF as described in section 2.31. The 
digested NS1 samples were boiled before being subjected to 
electrophoresis on a 10% SDS PAGE followed by autoradiography. 
Treatment with both glycosidases was shown to have a similar effect 
on the recombinant and TBEV-encoded NS1 protein as analysed by SDS 
PAGE. The presence of N-linked high mannose or hybrid 
oligosaccharides side chains on the intracellular forms of the NS1 
protein was revealed by endoH digestion, which reduced the apparent 
size of NS1 by 8 kDa from 47 to 39 kDa (FIG. 3.24(a), lane 12; Fig. 
3.24(b), Lanes 1 and 2). Treatment of intracellular TBEV and RAd51 
NS1 with glycoF produced a band which co-migrated with the endoH 
treated form indicating that no complex or biantennary side chains 
were present on 
the intracellular form of the protein (Fig. 3.24(a), 
Lanes 8 and 9). The molecular mass of the de-glycosylated form of 
NS11 39 kDa, is in agreement with the value for the primary amino acid 
sequence of 39,162 Da predicted from DNA sequence analysis. (Pletnev et 
al., 1989). 
Unlike the+intracellular form of NS1, treatment of extra-cellular 
NS1 ('IBEV or RAd51-encoded) with endoll did not generate protein of 
similar apparent molecular weight to 
that generated by glycoF 
digestion (Fig. 3.24(a), Lanes 2,3,6 and7). Untreated extra-cellular 
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NS1 (Fig. 3.24(a), Lane 4 and 5) migrates more slowly than the 
corresponding intracellular form on SDS PAGE (Fig. 3.24(a), Lanes 10 
and 11; Fig. 3.24(b), lanes 3 and 4), with an apparent molecular mass 
of 51KDa. Following treatment of extra-cellular NS1 with glycoF, 
however, the protein co-migrated with the treated intracellular form 
described above. EndoH treatment of extra-cellular NS1 generated a 
protein which migrated with an apparent molecular mass of 47 kDa, not 
39 kDa, implying that in going fron the intra-cellular form, both the 
recanbinant and the wild type NS1 proteins acquired additional complex 
or biantennary oligosaccharide side chains. 
3.2.6. Kinetics of NS1 Expression and Secretion: 
The study of the kinetics of NS1 synthesis and secretion from 
infected cells was also investigated by immunoprecipitation of pulse 
labelled infected cell monolayers (Fig. 3.25). At 80% confluence, 
45 mcnolayers were infected with an moi of 30 pfu/cell of RAd51 and 
treated with the CMV IE praioter stimulant forskolin. Following 24 h 
incubation the infected cells were labelled with 35S methionine for 
ow hour. Cytoplasmic lysates and culture supernatant were obtained 0 
h (Fig. 3.25, Lanes 1& 2), 1h (3 & 4), 2h (5 & 6), 3 haus (7 & 8), 
4h (9 & 10), and 5h (11 & 12) after the addition of the pulse. 
Samples 13 and 14 are cell lysates and tissue culture supernatant 
respectively, from mock-infected cells pulse-labelled and then 
incubated for 4 h. All samples were immunoprecipitated with the 
nr=lcnal, antibody T12 and subjected to electrophoresis on a 10% SDS 
polyacrylamide gel, followed by autoradiography. 
The autoradiograph was overexposed to show the temporal expression 
of intracellular NS1 (Fig. 3.25); in shorter exposures the difference 
in migration of the intra- and extra- cellular forms of NS1 could be 
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Fig. 3.25. Time Course of NS1 Secretion From RAd51 Infected MRC5 
Cells: Cell lysates (Lanes 1,3,5,7,9,11 and 13) and culture 
supernatants (Lanes 2,4,6,8,10,12 and 14) were obtained at 0 
(Lane 1 and 2), 1h (3 and 4), 2h (5 and 6), 3h (7 and 8), 4h (9 
and 10) and 5h (11 and 12) following the addition of a1h pulse with 
35s methionine. Lanes 13 and 14 are cell lysates and tissue culture 
supernatants, respectivly, from mock infected cells pulsed for 1h with 
35s methionine and then incubated for 5 h. All samples were 
immunoprecipitated with the monoclonal antibody T12 and subjected to 
SDS-PAGE, followed by autoradiography. Sizes are shown in kDa. 
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seen (data not shown). The intracellular forms of NS1 was detectable 
one hour after addition of the isotope, reaching a maximum by 3 h, 
after which its level declined. Extra-cellular NS1 protein was 
detected in RAd51-infected tissue culture supernatant at high levels 
from three hours onward. Detection of intra-cellular prior to the 
extra-cellular NS1 is consistent with there being a product precursor 
relationship between the two forms of the protein. 
3.2.7. Level of NS1 Expressed in RAD51-Infected Cells: 
Experiments performed using the expression vector based on a 
combination of the CMV major IE promoter and the adenovirus vector 
indicated that the system was capable of producing surprisingly high 
levels of expression (Wilkinson and Akrigg, 1992). To assess the 
level of expression of NS1 from RAd51-infected cell lysates and 
culture supernatants were separated by SDS PAGE and visualised using 
the protein stain coomassie blue (Fig. 3.26). 
In order to maximise expression levels, MRC5 cells grown in 175 cn2 
flasks were infected with RAd51 or the control adenovirus El- deletion 
mutant expressing 13-galactosidase, RAd35, at a very high moi of 100 
pug/cell and incubated for six days in protein free medium containing 
forskolin. The protein free media was obtained from PAA, Linz, 
Austria. Tissue culture supernatant (1/125 of total sample) and 
cytoplasmic cell lysates (1/50 of the total sample) were subjected to 
SDS PAGE on a 5%-15% polyacrylamide gradient gel (Fig. 3.26). In 
samples heat treated prior to electrophoresis, the presence of an 
infected-cell specific protein (ICSP) was clearly shown. The ICSP had 
an apparent molecular mass of 47 kDa in cell extracts (Fig. 3.26, Lan&-. 
5), and co-migrated with a less abundant cellular protein and a 
slightly bigger ICSP of approximately 51 kDa present in the 
ill 
ýý' ý 'ý ' jý 
ý 
ý'?, ýý i 
x' ̀, ý ý' "ý y1 f 1 
5 
ý 
i1 F 
yb ý 
ýý, 
ýý 
ý. ýý:: 
12345678 
'4110 ~-". r 
ý,,. ,.,.. '"'ýº 484 
na 
-C 
1 
447 
. t, . 433 
Fig 3.26. Detection of Recombinant NS1 on a Coomassie Stained 
ýnl yacrylamide Gel: RAd51-infected MRC5 culture supernatants and MRC5 
cell lysates were subjected to SDS-PAGE on a5 to 15% gradient 
polyacrylamide gel. Lanes 1 and 8 show E1- adenovirus-infected cell 
lysates; 2 and 7 show El- adenavirus-infected cell supernatants; 3 and 
6 show RAd51-infected cell supernatants; and 4 and 5 show RAd51 
erected cell lysates. Only Lanes 5 to 8 were heat denatured prior to 
electrophoresis. Bands attributed to recombinant NS1 are indicated 
with arrowheads. Sizes are shown in 
kDa. 
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supernatant (Fig. 3.26, Lane 6). These ICSPs are interpreted as 
representing the intra- and extra-cellular forms of NS1. In intra- 
and extra- cellular samples that were not boiled prior to 
electrophoresis, neither protein band was visible, but additional 
slower migrating bands are apparent, which presumably correspond to 
NS1 protein ocmplexes (Fig. 3.26, Lane 3 and 4). Absence of the high 
molecular weight complex in the boiled samples implies that they are 
heat sensitive. Surprisingly, in the unboiled samples, the extra- 
cellular protein complex migrated faster than the intracellular 
protein complex. This anomaly may be due to some conformational 
property of the oligomerised protein. 
The NS1 protein was identified as the predominant cytoplasmic 
protein in RAd51-infected cells, whereas NS1 can not be visualised on 
similarly stained gels in extracts of TBEV-infected cells. The very 
high levels of NS1 expression observed by using the adenovirus 
recombinant clearly exceeded the yield obtained from TBEV-infected 
cultures. 
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3.3. In Vivo Studies of NS1: 
3.3.1. Overview: 
It has been established that, in mice, an imm ne response to NS1 of 
the mosquito-borne flaviviruses YF and dengue, both causative agents 
of haemorrhagic diseases, confers a degree of protection against 
lethal challenge with hcmlcgous virus (Gould et al., 1986; Henchal et 
aý_, 1988; Schlesinger et al., 1985,1986 & 1987). To investigate the 
possibility of a similar role for the NS1 antigen of an encephalitic 
and of a tick-borne flavivirus, vaccination with the recombinant 
adenovirus RAd51 was assessed in a mouse protection model. 
Preliminary experiments had demonstrated that the adenovirus 
recombinant RAd35 could express ßß-galactosidase, under the control of 
the CMV IE promoter, when infected into primary murine macrophage 
culture. It was therefore decided to attempt to inoculate mice 
directly with RAd51 rather than to try and purify the recombinant NS1 
protein. Once it 
had been established that mice could raise anti-NS1 
antibodies when 
immunized with RAd51, experiments were undertaken to 
examine the potential of this response to protect mice against both 
death and disease caused by TBEV. 
Further experiments were carried out to demonstrate the importance 
of the terminal 
lytic pathway of the complement cascade. Since the 
level of lyS1 expressed in vitro was so very high it could not be ruled 
cut that small amounts of NS1 onntaminating the RAd51 inoculum opposed 
to de novo synthesised protein were responsible for the protection 
reported. An experiment in which mice were immunized with RAd51 
treated with UV radiation and/or purified RAd51 was undertaken in 
order to demonstrate 
that protection was elicited by de novo 
synthesised protein. 
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3.3.2. Serological analysis of NS1 expressed From RAd51: 
Four Balb/C mice were inoculated with RAd51 according to the set 
schedule (section 2.38). One week following the third inoculation 
with RAd51, sera were obtained from blood collected from the Jxrrn nized 
mice by terminal cardiac puncture. The presence of anti-NS1 
antibodies in the pooled RAd51 antisera from the mice was determined 
by analysis of the ability of the sera to recognise NS1 on western 
transfers (Fig. 3.27). 
293 cells were infected with RAd51 and TBEV at a moi of 1.0 
pfu/cell. Cell lysates were prepared from the infected cell 48 hpi 
and a parallel lysate of mock infected-cells. Duplicate samples of 
each cell lysate were subjected to SDS PAGE on a 10% polyacrylamide 
gel. Samples were not boiled or treated with reducing agent prior to 
electrophoresis. Following electrophoresis the proteins were 
electrophoretically transferred to Hybond membranes. One sample of 
each lysate was probed with anti-NS1 monoclonal antibody T12 (Fig 
3.27(a)). This demonstrated the presence of the 94 kDa "dimer" in 
samples fron TBEV - and NS1-infected cells (Fig. 3.27(a) Lane 2 and 
3). The 47 kDa NS1 band was demonstrated in the TBEV-infected cell 
sample (Fig. 3.27(a) Lane 2), as expected, but was not detected in the 
RAd51-infected cell sample (Fig. 3.27(a) Lane 3). The second sample 
fron each lysate was probed with RAd51 antisera (Fig. 3.27(b)). The 
presence of anti-NS1 antibody in the RAd51 antisera that recognised 
the "dimeric" complexes in TBEV- and RAd51-infected cells was 
demonstrated (Fig. 3.27(b)., Lanes 2 and 3). The 47 kDa protein in 
the TBEV-infected sample appeared to be absent, probably as a result 
of there being no anti-47 kDa specific antibodies in the anti-RAd51 
antisera (previously demonstrated in section 3.2.4). The 
concentration of recombinant adenovirus inoculated into the mice 
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Fia 3.27. Demonstration of the Reactivity of anti sera raised to 
Cytoplasmic extracts fron 293 cells that were uninfected (Lane 
1) my infected (Lane 2) and RAd51 infected (Lane 3) were subjected 
to SDS-PAGE on a 10% polyacrylamide gel. Samples were not denatured 
or treated with reducing agents prior to electrophoresis. Proteins 
were electrophoretically transferred to a nitrocellulose membrane and 
probed with 
(a) anti-NS1 monoclonal antibody T12 and (b) serum from 
RAd51 vaccinated mice. The 62KDa and >11 OKDa bands specific to lane 
3b can be attributed to adenovirus fibre and capsid proteins 
respectively. 
Sizes are shown in kDa. 
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during the study was high enough to elicit an anti-adenovirus immune 
response as the 62 kDa and >110 kDa bands specific to Fig. 3.27(b), 
Lane 3, can be attributed to the adenovirus fibre and capsid proteins 
respectively. 
The ability of the RAD51 antisera to neutralise homologous virus 
infections was tested by plaque reduction neutralisation assay. Five 
duplicate volumes of PS cells were infected with 20 pfu of Neudörfl 
strain of TBEV that had been reacted with RAd51 antisera at dilutions 
of either 1/2, or 1/4, or 1/8, or 1/16 or 1/32 in PBS. No reduction 
in the number of plaque was seen in monolayer infected with virus 
previously treated with RAd51 antisera when compare to the number of 
plaques in the m=layers infected with virus reacted with PBS. This 
indicated that anti-RAD51 antisera did not contain antibodies capable 
of neutralising TBEV infections. The anti-NS1 recombinant antibodies 
in the RAd51 antisera were also found to fix complement (not shown). 
Localisation of NS1 on the surface of paraformaldehyde fixed PS 
cells expressing NS1 was demonstrated by iRmunofluorescence using the 
method in section 2.28 (Fig. 3.28). The ability of NS1 to localise to 
the infected cell surface is eccnsistent with a mechanism of protection 
involving complement mediated lysis of infected cells. 
3.3.3. Protection Elicited Against Lethal TBEV Challenge by 
immunization with by RAd51: 
The dose of the Neudorfl strain of TBEV required to kill 50% of 
Balb/C mice (1 LD50 dose) when introduced subcutaneously was 
calculated prior to the protecticn study as described in section 2.37. 
RAd51 was inoculated as prescribed by the immunization schedule 
(section 2.38) into 22 Balb/C mice. At the same time 16 mice were 
inoculated with the El- recombinant adenovirus expressing 3-gal 
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Fig. 3.28. Location of RAd51 Encoded NS1 on the Cell Surface: The 
presence of RAd51 encoded NS1 was demonstrated on the suface of PS 
cells infected with RAD51 and fixed with paraformaldehyde fixed (c) by 
indirect immunofluorescence with monoclonal antibodies T12, T33/1 and 
T33/3, but not on the surface of similarly fixed RAd35-infected PS 
cell (b) or mock-infected PS cells (a). 
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(RAd35) and 12 mice were inoculated with PBS. One week following the 
third inoculation of the immunization schedule, sixteen of the RAd51 
inoculated mice were challenged subcutaneously with the Neudörfl 
strain of TBEV; eight of the mice received 100 LD 50 and eight received 
1000 LD50. The remaining six RAd51 inoculated mice were challenged 
with PBS. At the same time eight of the RAd35 inoculated mice and six 
of the PBS inoculated mice were challenged with 100 LD 50 of TBEV, the 
remaining mice received 1000 LD50" 
No mouse challenged with a lethal dose of TBEV following vaccination 
with PBS or RAd35 survived longer than 15 days post challenge, the 
majority dying at, or around, day 10 (Table 3.1). Eleven out of 16 
animals vaccinated with RAd51, however, not only survived severe virus 
challenge, but also failed to exhibited any symptoms of disease. The 
five mice vaccinated with RAd51 which did die, although exhibited 
symptoms of disease similar to the control group, still survived, on 
average, six days longer than their RAd35 and PBS counterparts. There 
was no significant difference in survival time between the controls 
inoculated with PBS or RAd35. The size of the MW challenge dose did 
not significantly affect survival time of the mice which died or the 
survival rate of the protected mice. 
3.3.4. Pmtectiai Against Disease Fb7 Dw i ng ToW C haUalge in Mice by 
Immunized With RAd51: 
In an attempt to understand the mechanism by which NS1 protects mice 
fron TBEV an experiment was performed to identify at which point NS1 
interrupts TBEV spread following infection. To examine the potential 
of the immune response to NS1 to inhibit the spread of a productive 
TBEV infection in mice it was necessary to established the pattern of 
virus spread in the absence of immunizing NS1. 
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TABLE 3.1. Protection of RAd51 Vaccinated Mice Against TBEV Challenge: 
imrnmizatim TBEV Challenge 
Dose (LD50) 
100 
1000 
0 (PBS) 
100 
1000 
100 
1000 
Mice Survived/ Average Survival 
'Ibtal NO (%) Time (days) 
RAd51 
RAd51 
RAd51 
RAd35 
RAd35 
PBS 
PBS 
5/8 (62.5) 
6/8 (75) 
6/6 (100) 
0/8 (0) 
0/8 
0/6 
0/6 
18 
15 
10 
11 
10 
9 
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Thirty Balb/C mice were inoculated subcutaneously with 10 LD50 of 
the Neu&rfl strain of zsEV. A challenge dose of 10 ID50 was used, as 
in the previous protection experiment RAd51 immunization failed to 
protect 100% of the mice which may have been due to the high TBEV 
challenge dose overwhelming the protective immunity in a proportion of 
the mice (section 3.15). Each day post challenge serum samples were 
obtained from two mice by terminal cardiac puncture (section 2.38) and 
the brain was removed frcin each grouse, washed in ice cold PBS before 
being pooled, homogenised (section 2.9) and stored with the sera at 
-7000. Sample collection ceased 10 days post challenge when all of 
the remaining mice had died. When all samples had been collected they 
were used to infect mcnolayers of PS cells. Seven days pi the cells 
were examined for the presence of a productive TBEV infection by 
imnunofluorescence using the TBEV anti-E monoclonal antibodies (T7, 
Zg, S8 and S12) at 5 }, g/30 ml blocking buffer (Table 3.2). The TBEV E 
antigen was detected in cells inoculated with serum harvested from 
mice on days 3,4 and 5 post challenge. TBEV E antigen was only 
detected in the cells inoculated with brain samples taken after day 5 
following challenge and persisted until death. 
Following this study, a further 54 mice were immunized according to 
the prescribed schedule with RAd51-infected cell lysates while 30 mice 
were infected with RAd51 and 30 with PBS. One week following the 
third inoculation of the immunization schedule, all the mice were 
challenged with TBEV Neudörfl strain at 10 LD50" 
Fran the PBS and RAd35 vaccinated groups, two mice were sacrificed 
each day post challenge and serum and brain samples were obtained. 
The samples frcm the RAd35 immunized mice were pooled each day as were 
those fron the PBS immunized mice. on day one post challenge, and 
fnxn day 14 to the end of the experiment at day 19 post challenge, two 
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Table 3.2. Recovery of Infectious TBEV From Mice Immunized 
with RAd51 Prior to TBEV Challenge: 
Days Post Mice Immunized with 
Challenge RAd51 Prior to Challenge 
With 1CD 50 'IEEV 
SERA Brains 
NV V NV V 
1++++ 
2++++++ 
3++++++ 
4++++++ 
5++++++ 
6++++++ 
7++++++ 
8++++++ 
9++++++ 
10 +++ +++ 
11 ++++++ 
12 ++++++ 
13 ++++++ 
14 ++++++ 
15 ++++++ 
16 ++++++ 
17 ++++++ 
18 +++ + 
19 ++++++ 
KEY 
V Infectious virus recovered. 
NV No infectious virus recovered. 
++ Two mice samples. 
++ Two mice samples pooled. 
Mice Immunized with 
RAd35/PBS Prior to 
Challenge with 
10LD50 TBEV 
Sera Brains 
NV V NV V 
++ ++ 
++ ++ 
++ ++ 
++ ++ 
++ ++ 
++ ++ 
++ ++ 
++ ++ 
++ ++ 
++ ++ 
All mice had died or 
been sacrificed on or 
before day 10 
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mice were sacrificed from the RAd51-im a-mized mice group. Between day 
two and 13, three mice inoculated with RAd51 were sacrificed. Serum 
and brain samples were obtained from the RAd51-immunized mice as for 
the RAd35 mice, however, the sample were not pooled, but labelled so 
that the serum and brains from individual mice could be identified. 
The samples collected were used to infect PS cells and a productive 
infection in the cells assessed by imnr fluorescence using the anti-E 
monoclonal antibody pool (Table 3.2). The spread of virus in the 
i 135-im=ized mice mirrored that in the PBS immunized mice, with an 
apparent viremia lasting from day two to day five post challenge and 
infectious TBEV appearing in the brain on day five and persisting 
until death. Again similar results were obtained with the PBS 
immunized group and the RM35-immunized group in that all the mice had 
all been either sacrificed or had died by day 11. 
The mice treated with RAd51, with the exceptions described below, 
had neither an apparent viremia or infection of the brain following 
challenge with ZBEV. The exceptions included a mouse taken on day six 
which in both a viremia and virus in the brain were detected; and two 
mice, one taken at 11 and one 13 which had an apparent 'IBEV infection 
of the brain. These infected RAd51-vaccinated mice would probably 
have succumbed to the TBEV infection and died. In addition to the 
three infected mice, two RAd51 vaccinated animals died on day 13 post 
challenge. Statistically, the group of 54 mice it Mated with RAd51- 
infected cell lysates in this experiment had an apparent survival rate 
of approximately 90%, a slightly higher level of protection than seen 
in the previous experiment. 
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3.3.5. Emamination of T'BVV Reovvered Fran Mice immunized With RAd51: 
The possibility that TBEV mutants capable of evading the anti-NS1 
immune surveillance were responsible for the death of the mice not 
protected when immunized with RAd51 was examined. Sera and blood 
samples collected on day 6,11 and 13 post challenge (section 3.17) 
that contain TBEV E antigen were detected by the anti-NS1 monoclonal 
antibodies (T12,33/1,33/3) in immunofluorescence assays (data not 
shown). 'These data suggests that the death of the mice was not due to 
RAd51 immune selection of a NS1 mutant TBEV capable of evading the 
immune response raised to the recombinant NS1. 
3.3.6. Protection E icited Against Lethal -nL; i ChaUkup in O' pleýerit 
Deficient Mice to TBEV: 
The mechanism by which NS1 elicits protection of mice is unknown. 
Antibody dependent complement mediated lysis of infected cells is 
currently accepted as the most satisfactory explanation. This model 
is based primarily on an ohservaticn that caplement-fixing monoclonal 
antibodies to YFV could partially protect mice against virus challenge 
(Schlesinger et al 1985., 1986 & 1987). In other flavivirus animal 
models (including TBEV), however, a correlation between the ability of 
an anti-NS1 monoclonal antibody to mediate cytolysis of infected cell 
and to protect mice against virus challenge has not been shown 
(Despres et al., 1991a; Henchal, et al., 1988; Phillpotts et al., 1987; 
putnak and Schlesinger, 1990). In order to study the importance of 
complement mediated lysis directed by anti-NS1 antibodies in the 
protection of mice against TBEV, a congenic strain of B10 D2 mice 
unable to express the cxmplement C5 receptor on the cell surface was 
employed in a protection study. 
124 
It was necessary to perform a preliminary experiment to establish 
the W50 of TBEV for both the C5 deficient (OSN) and sufficient (NSN) 
B10 D2 mice. This was established using the protocol described in 
section 2.37. Groups of 10 OSN and 10 NSN mice were challenged with 
2004 virus 10-3,10-4,10-5,10-6 and 10-7 in PBS and observed. 
Mice fron both strains began to died on day eight post challenge, and 
all of the mice which sued to virus challenge had died by day 18. 
All NSN mice inoculated with virus diluted to 10-4 and 10-5 died, and 
of the 10 mice NSN mice which survived TBEV challenge, one had been 
inoculated with virus diluted at 10-3, three inoculated with virus at 
10-6 and six mice with virus diluted to 10-7. Nine OSN mice survived 
challenge with TBEV. Two OSN mice challenged with virus diluted to 
10-3 survived as did one mouse challenged with virus diluted to 10-6 
and six mice challenged with virus diluted to 10-7. All the OSN mice 
inoculated with TBEV diluted to 10-4 or 10-5 died. Since both strains 
of mice appeared to be equally susceptible to the virus challenge 
permitting a similar amo mt of virus to be used as the challenge doses 
in the actual experiment. 
For the experiment 36 OSN mice and 34 NSN mice were im sized with 
RAd51 as in the prescribed schedule (Table 3.3). In addition 11 OSN 
and 11 NSN mice were imrnmized with RAd35 and eight OSN and eight NSN 
mice inoculated with PBS. 30 mice from each group immunized with 
RAd51 were challenged with 10 LD50 of Neud8rfl strain of TBEV as were 
eight RAd35 immunized mice and four PBS inutnized mice. The remaining 
mice in each group were challenged with PBS. 
No mouse died from the effect of immunization with RAd51, RAd35 or 
pBs. All mice immunized with the control virus RAd35 succumbed to 
TBEV challenge, while one mouse immunized with PBS survived TBEV 
challenge. The survival of the PBS-immunized mouse is not unexpected 
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Table 3.3. Protection Afforded by RPd51 Against TBEV Challen ge in Mice 
Deficient in the Terminal Lytic Pathway of the Complement Cascade: 
Immunization TBEV Challenge 
Dose (LD50) 
Mice Survived/ 
Total No (%) 
NSN RAd51 10 15/30 (50) 
OSN RAd51 10 18/32 (56) 
NSN RAd51 0 (PBS) 3/3 (100) 
OSN RAd51 0 4/4 (100) 
NSN RAd35 10 0/7 (0) 
OSN RAd35 10 0/8 (0) 
NSN RAd35 0 3/3 (100) 
OSN RAd35 0 4/4 (100) 
NSN PBS 10 0/4 (0) 
OSN PBS 10 1/4 (25) 
NSN PBS 0 4/4 (100) 
OSN PBS 0 4/4 (100) 
KEY 
NSN B10 D2 mice sufficient in the complement C5 receptor. 
OSN B10 D2 mice deficient in the complement CS receptor. 
t 
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since not all mice receiving TBEV challenge in the LD50 analysis died. 
with the exception of the OSN mouse which survived TBEV challenge 
following immunization with PBS, results obtained from the OSN and NSN 
ccntrol groups were identical. Although 56% of the OSN mice immunized 
with RAd51 survived TBEV challenge, compared to 50% of the NSN mice, 
using the Exact Fisher Test significant protection was found to have 
been obtained in both groups when compared with the mice immunized 
with Rad35 (P<0.1). The terminal lytic pathway of the complement 
cascade does not appear to be necessary for the protection elicited by 
NS1. 
3.3.7. Pr tection Elicited by RAd51 Treated With UV irradiated and/or 
Gradient Purified: 
rib determine whether the protection observed in mice was elicited by 
the NS1 antigen contaminating the RAd51 inoculum or by de novo 
synthesised RAd51-encoded NS1, mice were inru nized with RAd51 that had 
been p rified cri C,, -Cl gradients and/or irradiated. By either removing 
contaminating NS1 or inactivating recombinant adenovirus expressing 
NS1 in the inoculum the role of each canponent in the protection of 
mice against lethal challenge with TBEV could be assessed. Virus was 
extracted with Arklone-p from monolayers of 293 cell infected with 
pAd51 at 1 pfu/cell. The virus extracts were divided into two, one 
portion being stored at -7000 while the remainder was purified from 
NS1 through two CsCl gradients as described in section 2.8. Following 
dialysis the 'purified' virus was stored at -700C. Both the purified 
and unpurified virus stocks were titrated in 293 cells. 
Virus was Arklone-P extracted from n nolayers of 293 cell infected 
with RAd51 at 1 pfu/cell. The virus extracts were divided into two, 
one portion being stored at -700C while the remainder was purified 
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Table 3.4. The Titre of RAd51 Following Shortwave UV Irradiation: 
Source of RAd51 W Exposure (mJ/mm 2) Titre of RAd51 
pfu/ml 
Infected cell 0 107 
lysates 0.9 4x104 
1.8 2x102 
4.5 0 
9.0 0 
13.5 0 
CsC1 purified 
infected cell 0 107 
lysates 0.9 2x106 
1.8 1x102 
4.5 0 
9.0 0 
13.5 0 
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Table 3.5. The ability of the CMV IE Promoter to Drive Expression 
Following Shortwave UV Irradiation 
Source of RAd51 
Infected cell 
lysates 
CsCl purified 
infected cell 
lysates 
UV Exposure % of Cell 
(mJ/mm2) Mrxx layer Infected 
0 
1.062 
3.124 
5.31 
10.62 
21.24 
100 
25 
5 
0 
0 
0 
0 
1.062 
3.124 
5.31 
10.62 
21.24 
100 
75 
25 
0 
0 
0 
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from NS1 through two CsC1 gradients as described in section 2.8. 
Following dialysis the `purified' virus was stored at -700C. Both the 
purified and unpurified virus stocks were titrated in 293 cells. 
As described in section 2.32,5 ml aliquots of the purified and 
unpurified virus stocks diluted to 107 pfu/ml were treated in parallel 
with UV light at 1.5 mW/cm2 for 0 sec, 60 sec (0.9 mJ/rrm2), 120 sec 
(1.8 mJ/mn 2) ,5 min (4.5 m i/mn2) , 10 min (9.0 m7/mm2) and 15 min (13.5 
mJ/mm2). The irradiated virus was then stored at -70oC. Virus 
samples not exposed to irradiation were titrated and shown to have 
maintained an infectivity of 107 pfu/ml. Each irradiated sample was 
assayed for adenovirus infectivity by titration in 293 cells and for 
expression from the CMV IE promoter by inmunofluorescence staining. 
Virus samples receiving 4.5 mJ/mm2 or more were unable to induce 
plaque formation (Table 3.4). Expression of NS1 was assayed 24 hpi by 
immunofluorescence using the anti-NS1 antibody T12. In no cell 
monolayer infected with virus exposed to 4.5 mJ/mm2 of UV light or 
more could NS1 expression be detected (Table 3.5). Virus stock in 
which expression from the CMV IE promoter and plaque formation had 
been inhibited by the minimum annxmt to irradiation (4.5 m7/mm 2) in an 
attempt to minimise any denaturing effect on the inoculum of prolonged 
UV treatment. 
Balb/C mice were divided into three groups of 12 mice, one of 11 
mice and a group of 6 mice. Fach mouse was iamunized according to the 
prescribed schedule (section 2.38). The mice in one of the groups of 
12 receive CsCl purified RAD51, while a second group of 12 mice 
received the irradiated infected cell lysate and the third group UV 
irradiated? CsCl purified RAd51. The mice in the group of 11 received 
untreated RM51-infected cell lysate and the mice in the group of six 
were inoculated with PBS (Table 3.6). One week following the third 
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Table 3.6. Capability of Treated RAd51 to Protect Mice Against Lethal 
TBEV Challenge: 
Immunization TBEV Challenge Mice Survived/ Average Survival 
(treatment) Dose (LD50) Total NO (%) Time (days) 
RAd51 10 5/8 (62.5) 17 
0 (PBS) 3/3 (100) - 
RAd51 # 10 7/8 (82.5) 17 
0 4/4 (100) - 
RAd51 * 10 0/8 (0) 13 
0 4/4 (100) - 
RAd51 #* 10 0/8 (0) 11 
0 4/4 (100) - 
PBS 10 0/4 (0) 12 
0 2/2 (100) - 
KEY 
# Virus had been purified on a CsC1 gradient prior to inoculation 
t Virus had been subjected to 5.31 m7/mm 2W radiation prior to 
inoculation. 
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inoculation of the immunization schedule, eight mice from each of the 
RAd51 groups and six from the PBS inoculated group were challenged 
subcutaneously with 10 LD50 of the TBEV Neudörf1 strain. The 
remaining mice were challenged with PBS. 
In addition to those mice given' PBS prior to challenge, the mice 
given UV-treated RAd51, whether CsCl purified or not, failed to 
survive the virus challenge (Table 3.6). The average survival time of 
the mice in the 'unprotected' groups was 12 days. The majority of 
mice receiving non-irradiated RAd51, CsCi purified or not, survived 
the lethal challenge. The average survival rate of the mice receiving 
non-irradiated RAd51 prior to challenge (17 days) was not 
significantly different from those mice challenged with either 100 
LD50 or 1000 W50 (16 days) in the original protection study imtnmized 
with RAd51. It is notable that while 62.5 % of the mice receiving 
RAd51-infected lysates were protected against TBEV challenge, 82.5% 
were protected when the virus had been purified on a CsCl gradient 
prior to inoculation, the significance of this result, however, is 
unclear as the number of mice used in this study was too small to be 
of statistical value. 
The presence of contaminating NS1 in the RAd51 virus lysate injected 
into mice is not responsible for the protection of the mice against 
lethal TBEV challenge. In the defective adenovirus expression system 
used throughout this work, protection of mice from a lethal virus 
infection appears to be afforded by de novo synthesis of NS1. 
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CHAPTER 4. DISCUSSION. 
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4.1. Discussion. 
Expression of TBEV NS1 was dependent on correctly identifying its 
gene sequence and associated processing signals within the long ORF. 
A cDNA fragment, encoding the NS1 gene with additional sequence from 
the upstream E gene and downstream NS2a gene, was originally generated 
by PCR using reverse transcripts of the TBEV genome as templates. 
Initially, these reactions generated a truncated cDNA fragment with a 
p. 9kb deletion which map to a region with potential to encode 
secondary structure in the corresponding RNA molecule. In order to 
efficiently generate full-size cDNA fragments it was necessary to 
denature this structure by treating the RNA molecule with DMSO prior 
to reverse transcription. Since TBEV gencmic RNA contained a 24 bp 
inverted repeat with the potential to form a hairpin structure it was 
assumed that this structure was preventing primer binding in that 
region. This structure may play a role in either RNA synthesis or 
transcription of the TEEV genaue. Its location at the beginning of 
the non-structural proteins is intriguing since in this position the 
structure has the potential to downregulate expression of the TBEV 
non-structural proteins. 
Except for a translationally silent change firm T to A at base 3265, 
the sequence of the cloned Neudörfl NS1 gene was found to be in 
agreement with published results (Mandl et al., 1989a). The amino 
acid sequence of K23 encoded NS1, as derived from its nucleotide 
sequence, showed a high degree of homology with the Neudörfl strain. 
Furthermore, the position of the three potential N-linked 
glycosylation motifs and all 12 cysteines residues identified in the 
NS1 sequence of TBEV strain K23 were absolutely conserved with those 
of the Neudörfl strain, 11 of the cysteine residues being further 
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conserved with those in NS1 of all flaviviruses so far sequenced. 
Since cysteine residues are involved in the formation of di-sulphide 
bonds their extensive spatial conservation implies a ccnmon tertiary 
structure which may be important in the functioning of NS1. 
With a view to determining the NS1 coding region, 5 additional cDNA 
fragments (Fig. 3.4) were generated by PCR using the original TBEV 
clone as a template. Each TBEV cDNA fragment was cloned under the 
control of the CMV IE promoter and their ability to encode NS1 tested 
in DNA transfecticn experiments. Of the plasmfäs tested, only the to 
were found to synthesise NS1. Since these two cDNA were the only 
ones to contain just the putative translocation signal sequence 
upstream of the NS1 gene it was concluded the expression of 
recombinant NS1 is dependent on this signal. What could not be 
determined by this work, however, was whether the arginine proposed to 
act as a translocatia-i stop signal, interrupts translocaticn of E into 
the ER and therefore necessitate the use of this translocation signal 
in the TBEV translation product. 
In the absence of a translocation signal, expression of NS1 could 
not be detected. If NS1 is not translocated it is possible that the 
protein was degraded in the cytosol by proteases or not recognised by 
anti-NS1 antibodies. Why NS1 could not be detected in cells 
transfected with the NS1 gene preceded by translocation signal 
sequence and additional sequence from E, was not clear. Since 
translocation of NS1 within the primary translocation product is 
directed by an internal signal sequence and it has been reported that 
internalisation of a signal sequence does not interfere with its 
functioning, this result was unexpected (Bangs et al., 1986; Rottier 
et al., 1987). It has been reported however that for the signal to 
function an alpha helix fanned by the signal's central and hydraphobic 
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domains must be maintained (Emr and Silhavy, 1983). It may be 
therefore, that the additional amino acids from E had a destabilizing 
effect on this structure, inactivating the signal. Alternatively, the 
E: NS1 cleavage site may have been masked by the additional E sequence. 
Inhibition of this cleavage could, therefore , have generated an 
inappropriately processed NS1 fusion protein which was not detected. 
Each of the two cDNA fragment capable of inducing the synthesis of 
NS1 had a translational stop colon specifically inserted. In pMV45 
(from which RAd51 was derived) the stop colon had been placed at the 
proposed C-terminal of NS1, while in the pMV54, the stop codon 
followed 79% of the coding sequence for NS2a. With pMV54 recombinant 
TBEV NS1 was expressed with 79% of NS2a, ' for which it appeared 
that appropriate cleavage of the NS1: NS2a junction had occurred. 
Although this result does not implicate NS2a in this cleavage, it is 
consistent with reports that NS1: NS2a cleavage is inhibited when NS1 
is expressed in the presence of less than 75% of NS2a (Falgout et al., 
1989; Falgout and Lai, 1990). Since there was no apparent difference 
in the level of expression of NS1 or the distribution of NS1 specific 
immunofluorescence when co-expressed with part of NS2a, the 
requirement for NS1: NS2a cleavage was assumed to have been 
circumvented in the shorter fragment by the stop signal. This 
strategy therefore permitted the expression of NS1 without NS2a and 
has also been used in the expression of JEV and YEV NS1 (Despres et al 
1991; Fan and Mason, 1990). It was decided to use the cDNA fragment 
containing just the NS1 coding region rather than that with additional 
NS2a sequence for insertion into a recombinant adenovirus, since to 
express NS2a may have interfered with the interpretation of data 
obtained from in vitro and in vivo experiment. 
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A detailed comparison between NS1 encoded by TBEV and by the 
recombinant adenovirus RAd51 demonstrated that both NS1 antigens were 
indistinguishable in (i) apparent molecular weight by SDS PAGE, (ii) 
ability to recognise a number of anti-NS1 monoclonal antibodies, 
(iii) glycosylation pattern, (iv) ability to form high molecular 
weight complexes and (v) ability to be secreted from the cell. 
Furthermore, as both the intra- and extra- cellular NS1 antigens 
encoded by RAd51 co-migrated with their TBEV encoded counterparts, the 
ends of the NS1 gene were assumed be either identical or extremely 
close to the coding sequence of the wild type TBEV NS1. 
Endoglycosidase treatment demonstrated the presence of N-linked 
mannose rich (or hybrid) oligosaccharide side chains on both the 
recombinant and TBEV encoded infra-cellular forms of NS1. Whether all 
three potential glycosylaticn sites identified in the primary sequence 
of TBEV NS1 were glycosylated is not yet known. For the mosquito- 
borne flaviviruses dengue, 3EV and YFV only two N-linked glycosylation 
motifs have been identified in the primary sequence of NS1 both of 
which are known to be used (Despres et al., 1991; Falgout et al., 
1989; Mason, 1989; Post et al., 1990; Winkler et al 1988). 
The larger extra-cellular forms of NS1 (both TBEV and RAd51 encoded) 
were found to contain at least one mannose rich (or hybrid) and one 
complex side chain. Modification of a mannose rich oligosaccharide 
side chain to a complex type is consistent with maturation of intra- 
cellular NS1 to the extra-cellular form occuring in the median Golgi 
prior to secretion (Dunphy 1985 cell 40 463-72). This proposal was 
further supported by evidence which shoed the ea-migration of the de- 
glycosylated backbone of intra- and extra-cellular NS1 (both 
recombinant and authentic). 
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A pattern of glycosylation similar to that of extra-cellular TBEV 
NS1 has been reported for dengue virus and JEV NS1, although both side 
chains of the YFV NS1 appear to be modified. The difference in the 
glycosylation patterns of the extra-cellular forms of NS1 encoded by 
yFV compared to the other flaviviruses so far investigated probably 
reflects divergent amino acid sequences rather than the cell type in 
which they were propagated since both the JEV and dengue virus studies 
were performed in Vero cells (Despres et al., 1991; Mason, 1989; Post 
et al., 1990). 
The significance of the TBEV NS1 oligosaccharide side chains is 
unknown. The presence of side chains is not thought, however, to 
influence processing or transportation of NS1 through the cell as it 
has been reported that YFV, JEV and dengue virus encoded NS1 is 
processed by, and secreted from, tunicamycin treated cells (Despres et 
al., 1991; Mason, 1989; Winkler et al., 1989). The apparent absence 
of a role for NS1 glycosylation in the transportation of NS1 is 
consistent with a more general proposal that in tissue culture, at 
least, oligosaccharide side chains do not signal processing or 
transportation of proteins (Keller and Swank, 1978; Olden et al., 
1978; Weiland et al., 1987). 
The study reported here clearly demonstrated that the infra-cellular 
and extra-cellular forms of NS1, from both TBEV- and RAd51-infected 
cells, participated in the formation of higher molecular weicht 
ocr plexes which survived n n-reducing SDS-PAGE but not boiling in SDS. 
In view of the fact that the high level of expression from the 
recombinant NS1 may be expected to saturate an interaction with a 
specific cellular component, it is proposed that these higher- 
molecular-weight complexes represent NS1 homodimers. TBEV NS1 
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horodimers have also been identified in Fbwassan virus infected cells, 
although, like TBEV NS1 dieters, characterisation of these dimers is 
awaited (Winkle et al., 1988). 
The apparent absence of moncmeric NS1 in RAd51-infected cells was 
unexpected. If, however, dimerisation is a concentration dependent 
process then dimerisaticn of NS1 in RAd51 infected cells is probably 
rapid. Alternatively it is possible that dimerisation of NS1 in TBEV 
infected cells is delayed by some requirement of virion maturation. 
The significance of TBEV NS1 dimers, and whether they are mature 
functional complexes in themselves or are, precursor of a harodimers, 
has also to be determined. 
The ease with which intra-cellular TBEV NS1 was identified in cells 
suggests that it is allowed to accumulate in the cell. While 
mechanisms exist for the retention of specific proteins within cells, 
it unlikely than NS1 is actively retained as no known signal 
sequences, such as the KDEL signal, could be identified in the primary 
sequence of either the Neudorfl or K23 strains of TBEV (Munro and 
pelham, 1986). Specific retention of NS1 prior to the median Golgi 
can not, however, be ruled out. Alternatively, accumulation of NS1 
within the cell may be determined by sane aspect of its own assembly 
or role. Acanulaticn of NS1 prior to the median Golgi is consistent 
with the proposal that NS1 has a role in viricn assembly within the ER 
or early Golgi ccmplex(Hase et al., 1987 & 1990; Ishak et al., 1988; 
Leary and Blair, 1980; Ng, 1987). 
After leaving the ER, NS1 is assigned to be transported to the Golgi 
complex. Proteins move sequentially through the Golgi complex to the 
trans-Golgi network (TGN) where they are sorted into either the 
membrane, secretory or lyscsome traffic (Griffiths and Simons, 1986). 
As in mammalian cells, the oligosaccharide side chains of NS1 are 
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trimmed in the Golgi complex of insect and probably arthropod cells. 
In insect/arthropod cell, however, the final stages of glycan 
modification associated with mammalian cells, are not completed 
(Jarvis and Summers 1899). While this altered processing appeared to 
have little effect on the cellular transportation and properties of 
yFV NS1, NS1 secretion from insect /arthropod cells was inhibited 
(Depres et al., 1991; Mason, 1989). Whether this inhibition of 
secretion resulted from glycan modification or not remains unclear 
Differences in the way proteins are processed by insect/arthropod cell 
compared to mammalian cell are important and of particular relevance 
to arboviruses. The ability of an arbovirus to encode a protein which 
is processed differently in the arthropod vector compared to the 
mammalian host has implications in aspects of arbovirology including 
the etiology of arbovirus disease. 
An undefined screening event within the TGN determines whether 
proteins destined for the cell surface are constitutively delivered or 
enter the regulated exocytic pathway (reviewed Burgess and Kelly, 
1987; Griffiths and Simons, 1986; Gumbiner and Kelly, 1982). While 
passage along the constitutive secretory pathway is non-specific, the 
passage of proteins via regulated pathway is receptor mediated' 
(clathrin coated vesicles) and involves the concentration of proteins 
in acidified secretory vesicle. Since the larger, extra-cellular form 
of NS1 does not appear to accumlate in either TBEV or RAd51-infected 
cells it is unlikely that NS1 is secreted via the regulatory pathway. 
The presence of NS1 in the regulated pathway could be determined by 
demonstrating a build up of recombinant NS1 in exocytotic vesicles 
using immuno-electronmicroscopy or by studying the effect of 
acidotropic drugs on NS1 secretion. A demonstration of NS1 egress via 
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the constitutive pathway would be intriguing since it would suggest 
that NS1 plays no role in those-stages of virion maturation occurring 
in acidified vesicles. 
It is unclear whether, on reaching the cell surface, NS1 associates 
with the membrane directly or reattaches following secretion. Since 
NS1 expressed in insect cells appears not to be secreted but remains 
located at the cell surface, surface expression of NS1 appears not to 
require reattachment (Despres et al., 1991). By using two different 
fluorochrcmes one conjugated to anti-'IBEV E monoclonal antibodies and 
the other to anti-TBEV NS1 monoclonal antibodies in immuno- 
fluroescence studies it could be shown whether cells not infected with 
TBEV display NS1 on their surface. 
If NS1 was found on the surface of uninfected cells, it would 
implicate the involvement of constitutively expressed cellular ligands 
in this association. This would be an interesting result as a 
mechanism by which NS1 associates with the cell surface has yet to be 
determined. Several potential mechanisms for NS1: cell association were 
considered briefly in this study. Sequence analysis of the NS1 gene 
from the Neudörfl and K23 TBEV strains revealed neither regions of 
hydrophobicity or homology with phophatidylinostol (PI) anchors 
(Furguson and Williams, 1988). It has recently been demonstrated 
directly that PI linkers are not involved in YFV NS1: cell surface 
interaction since YFV NS1 was found to be insensitive to phospholipase 
C (Post et al., 1990). The potential for NS1 oligosaccharide chains 
to direct cell association also appears unlikely since baculovirus 
expressed YFV NS1 was located to the cell surface (Despres et al., 
1991). One positive note in the ongoing investigations into NS1: cel1 
surface interaction is work which has suggested that the dimeric form 
of NS1 is less hydrophilic than the monomeric form, and thus the 
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process of dimerisation may lead NS1 to become membrane associated 
(Winkler et al., 1989). Consistent with this proposals is the 
demonstration that NS1 dimers are present on the cell surface 
(Schlesinger et al 1990). 
Since recombinant NS1 was found to be indistinguishable from the 
authentic protein in glycosylation, folding, assembly, transportation 
and secretion, it is proposed that all the signals required for these 
processes are contained within the NS1 gene identified in this study. 
Moreover, it was assumed that cellular processing of the authentic and 
recombinant proteins were fundamentally the same. It should be noted 
however, that appropriate processing and functioning of NS1 during 
TBEV infections may have requirements additional to those of the 
recombinant protein. 
In addition to investigations into the TBEV NS1 gene and its encoded 
product, this study has demonstrated the potential of a novel 
adenovirus vector/CNN IE promoter expression vector. This vector is 
based on a mammalian system and therefore was expected to process NS1 
in a manner similar to that seen in a clinical TBEV infection. 
Expression of TBEV NS1 was not undertaken using an insect based vector 
as it was felt that altered processing of glycoproteins associated 
with baculovirus may affect protection elicited by NS1. This concern 
appears to have been borne-out recently when it was reported that 
immunization with recombinant baculovirus encoded YFV NS1 failed to 
protect mice against a lethal virus challenge (Despres et al., 1991a). 
The major advantage of a baculovirus system over available manvolian 
expression system is its potential to express high levels of the 
recombinant protein. During the course of this study, however, it 
became apparent that recombinant NS1 encoded by RAd51 constituted the 
major protein in infected cells. This unexpectedly high level of NS1 
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expression appears to be a property of the adenovirus vector system 
since similar high levels of expression of ß-gal have recently been 
achieved with this vector (Wilkinson and Akrigg, 1992). 
A significant advantage that the adenovirus system presented here 
has over comparable viral vectors, is the absence of vector-encoded 
proteins expression in non-permissive cells. The absence of 
adenovirus encoded proteins not only enabled the identification and 
purification of NS1 to be undertaken easily and efficiently but also 
allowed for a more accurate interpretation of data, particularly that 
generated in immunological studies. Of particular importance to the 
animal studies was that infection with El- recombinant adenovirus 
induced no discernable effects in the mice. The inability of the 
defective adenovirus to replicate in non-permissive cells also 
provides a degree of biological containment. In summary, therefore, 
the data presented here has indicated that the novel defective 
adenovirus vector system used in this study has distinct advantages 
over both mammalian and baculovirus expression systems. 
The data presented in this thesis also demonstrated for the first 
time that the NS1 antigen could elicit an immune response sufficient 
to protect mice against either a tick-borne flavivirus or an 
encephalitic flavivirus. Furthermore, this is the first report of 
protection being elicited using a cloned cDN7 fragment containing only 
the NS1 gene sequence, thereby providing definitive evidence that 
flavivirus NS1 free of other virus encoded proteins is able to elicit 
a protective immune response. 
Since immunization of RAd51 appeared to protect mice against death 
it was assumed the infection of the target organ (brain) had been 
inhibited. In addition to demonstrating that infectious virus could 
not be recovered from brains of mice challenged with TBEV following 
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RAd51 immunization, this study further deitnstrated protection against 
viremia. Similar results have been reported for mice challenged with 
the Hypr strain of TBEV following immunization with formalin 
inactivated virus (Malkova, 1960a; Malkova and Kolman 1964). The 
capacity of NS1 to inhibit disease seems therefore to be similar to 
the capacity of the whole virus. 
Although not tested, it was expected that RAd51 immunization would 
not inhibit replication of TBEV immediately following immunization. 
This prediction was based on reports in which the sera from mice 
protected against lethal challenge, following immunization with YFV 
and dengue virus NS1 antigens, contained antibodies capable of 
neutralizing the challenge virus Schlesinger et al., 1985,1986 & 
1987). The prediction is further supported by reports of infectious 
virus being recovered from regional lymph nodes (only) close to the 
site of virus injection in mice immunized against the Hypr strain of 
TBEV (Malkova, 1960; Malkova and Frankova, 1959). Although, 
im nization with RAd51 protects mice against a viremia and death, one 
would not expect protection against infection since it is unlikely 
that any vaccine totally protects against infection. Although a non- 
specific immune response based on natural killer T cells and cytokines 
is elicited at the time of infection, the activation of a B- and 
memory based T-cell immunity is not so immediate. 
Since protection against death has been observed following 
immunization with YFV or dengue virus purified NS1 or anti-NS1 
monoclonal antibodies, it is presumed that the anti-NS1 humoral 
response (in association with MHC class II restricted T cells) is 
sufficient to protect mice and monkeys against lethal virus challenge 
(Cane and Gould, 1988; Gould et al., 1986; Henchal et al., 1986; 
Schlesinger at al., 1985,1986 & 1987), although the importance of a 
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humoral based immunity in protection elicited with RAd51 was not 
defined a strong antibody response to NS1 was clearly elicited. The 
Importance of a humeral response to RAd51 in protect mice could be 
assessed by investigating whether anti-seru n from RAd51-immunized mice 
could protedct non-immune mice against virus challenge. Although 
protection of mice by the passive transfer of anti-serum raised to a 
vaccinia virus vector expressing dengue virus NS1 and NS2a has been 
reported, the precise role of NS1 was unclear since either NS2a or 
vaccinia virus encoded protein may have accounted for the protective 
response (Falgout et al., 1990). This result does, however, 
demonstrate the importance of the adenovirus expression system used 
here, in immunological studies, as the absence of vector encoded 
proteins ensured that protection is afforded solely by antibodies 
raised to recombinant protein. 
If anti-NS1 antibodies were responsible for protection obtained in 
RAd51 immunized mice, the mechanism by which virus is cleared may be 
similar to that activated in mice protected following immunization 
with YFV or dengue virus NS1 antigens. Neutralization of a TBEV 
infection in vivo by anti-NS1 antibodies is not generally considered a 
mechanism of protection, since NS1 appears not to form part of the 
TBEV virion. The absence of antibodies in serum raised to RAd51 
capable of neutralizing TBEV, was confirmed in this study by plaque 
reduction neutralisation assay. C1 has been suggested as a mechanism 
by which N51 antibodies are able to elicit protection (Schlesinger et 
al., 1985,1986 & 1987). This study reports, however, that CMC 
appears to play, at the most, only a minor role in the protection of 
mice. The implication that mechanism/s other that CMC are important 
in the NS1 induced imr inity, is crnsistent with reports of anti- TBEV, 
YFV and JEV NS1 antibodies capable of protecting mice against lethal 
145 
virus challenge but unable to direct CMC in vitro (Despres et al., 
1991a; Henchal et al., 1988; Phillpotts et al., 1987; Putnak and 
Schlesinger, 1990). It is possible, however, that CMC could have 
played a minor role in the protection against TBEV challenge since a 
correlation between the ability of individual YFV and dengue virus 
antibodies to protect mice against lethal virus challenge and to 
direct CMC when assayed in vitro has been reported (Schlesinger et 
al ., 1985,1986 
& 1987). To determine the precise extent to which QVC 
is involved in the humoral based protective response elicited 
following NS1 immunization, the protection experiment using C5 
deficient mice could be repeated but instead of monitoring death, the 
ability of the challenge virus to disseminated throught complement 
deficient animals could be assessed. 
A third potential mechanism of virus clearance is by antibody 
dependent cell cytolysis (ADOC). ADOC occurs when antibodies capable 
of directed phagocytic cells against cells expressing the NS1 antigen, 
are elicited. While it is possible to assay for the ability of 
antibodies to direct complement mediated cytolysis of infected cells, 
the ability of antibodies to direct ADCC could be assayed in vitro, 
it should be noted however that activity in vitro is not necessary an 
indication as to its role in vitro. 
Although a humeral based imrame response does appear to be essential 
for the clearence of same viral infections, such as measles and Herpes 
simplex, it is possible that protection elicited by NS1 could involve 
a cm response. Evidence for an anti-NS1 CM response is consistent 
with reports of an anti-NS1 CI'L epitope having been mapped in dengue 
virus immune individuals and least one murine T cell epitope which 
maps to NS1 (Kurane et al., 1990; Rothman et al., 1990). Since the 
raising of an MUC class I CIL response requires a de novo synthesised 
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antigens (reviewed Braciale and Braciale, 1991), it was presuned that 
immunization with RAd51 would elicit an MHC class I restricted CIL 
resprnse as RAd51 and de novo synthesis of NS1 had been demonstrated. 
Activation of a CIL response could be demonstrated by the transfer of 
MHC, class I restricted CI'Ls from mice immunzed with RAd51 into non- 
iimnme mice prior to challenge (adoptive treanfer). Since survival of 
mice into which cell has been transfered would implicate a CTL 
response in the protection. 
It is not known whether TBEV NS1 is an essential gene for virus 
replication. If non-essential then incomplete protection following 
vaccination with RAd51 may have resulted from immunization positively 
selecting for TBEV NS1 deletion mutants capable of evading immune 
surveillance. Virus recovered from mice immunized with NS1 but 
had succumbed to TBEV challenge was therefore tested and shown to be 
recognised by several anti-NS1 monoclonal antibodies, discrediting 
this hypothesis. 
Since the potential of the recombinant adenovirus vector used in 
this study to elicit an HiC class I restricted CM response has not 
been investigated,. the possibility that it is inappropriate for use in 
this type of study must be considered. Both the El and E3 gene 
products of adenovirus are able to downregulate an MHC class I CTL 
response (reviewed Wold and Gooding, 1991). It might be, therefore, 
that breakthrough expression of these gene products has caused a 
downregulation of the CI'L response. This is unlikely, however, as the 
adenovirus vector reported here has deletions in both genes. 
Alternatively, the protective immunity elicited may have been 
downregulated as a result of the associated CTL lysis, which, unlike 
CMC lysis that permeablized the plasma membranes allowing osmotic 
swelling and release of the cytoplasm, fragments DNA in the nucleus of 
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the cell under attack prior to apoptosis (Martz and Howell, 1989). 
This is of importance, probably to adenovirus based vector as the 
adenovirus genaue consists of a DNA molecule which functions in the 
nucleus. Evidence fron Reovirus type 3 infections on the other hand 
suggests that the CM DNA fragmentation mechanism does not affect 
RNA molecules in the cytoplasm and would therefore spare the TBEV 
genome (Martz and Howell, 1987; Martz and Howell, 1989). This 
highlight a more general point which must be considered in the used 
of recombinant virus vector when trying to elicit an MHC class I 
restricted CIL response. In order to ensure an appropriate MHC class 
i restricted CTL response, the mechanism of infection used by the 
virus from which the recombinant protein originated should wherever 
possible be reflected in the mechanisms used by the vector (reviewed 
Long and Jacobson, 1989). 
This study was able to demrnstrate that de novo synthesised NS1 fron 
RAd51 whether by a humoral or cellular response (or both) provided 
protection against viral challenge. The novel combination of 
defective adenovirus and strong constitutive CMV IE promoter has not 
only proved to be an excellent high level expression system for the 
investigation of proteins in vitro, it has also proved a significant 
potential for used in vaccine development where a non-replicative 
system has a distinct advantage over currently available vectors. 
Although the NS1 gene sequence has been identified and its product 
characterised many question remain to be answered before the 
processing and function of NS1 is fully understood. The recombinant 
adenovirus RAd51 will facilitate future studies into these question 
and can be used to investigate more thoroughly the immunological. basis 
for the protection elicited by TBEV NS1. The protection provided by 
the reocmbinant TBEN NS1 protein has clear implications for flavivirus 
148 
vaccine development programs, since it demonstrates that NS1 can 
elicit protection without inducing antibodies capable of enhancing 
subsequent infections. 
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